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CHAPTER 1 INTRODUCTION AND SIGNIFICANCE 
1a: Need for HDACs-Specific PET Imaging Agents 
Over the past two decades, epigenetic regulation has become a rapidly growing, highly 
innovative and influential field of biology and medicine. One of the key epigenetic regulatory 
mechanisms involves the acetylation and deacetylation of lysine residues on histone core proteins 
and other critical proteins involved regulation of gene expression and protein function. Protein 
acetylation and deacetylation is mediated by histone acetylase transferases (HATs) and histone 
deacetylases (HDACs), respectively. The important roles of some of the HDACs in normal cellular 
physiology and the pathophysiology of different diseases have been recognized for more than a 
decade. Several HDAC inhibitors have been developed by the pharmaceutical industry and 
academia and some of them have been approved by the FDA for treatment of certain diseases (i.e., 
Vorinostat® for treatment of cutaneous T-cell lymphoma). However, many of the existing HDACs 
inhibitors lack enzyme isoform specificity and/or are unable to pass through the BBB (Hendricks 
et al., 2011a; Hooker et al., 2009) and are unsuitable for treatment of many CNS diseases. 
The vast majority of studies on epigenetic regulation were conducted in cell cultures and 
tissue samples using conventional methodologies of molecular and cellular biology. However, 
these methods have several limitations for monitoring the efficacy of HDACs-targeted inhibitory 
therapies, because they require invasive biopsies of tissues, which, except for cancer, are 
prohibitive in most types of diseases involving vital organs (i.e., diseases of heart and brain). 
Therefore, there is a growing need for novel, advanced methodologies that allow for non-invasive 
detection and monitoring of HDAC–mediated epigenetic regulatory processes in different organs 
and tissues, to improve our understanding of their roles in epigenetic pathophysiology of different 
diseases and to aid the development and clinical translation of novel inhibitors of HDACs. One 
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such methodology is molecular imaging with positron emission tomography (PET), which allows 
for non-invasive visualization and quantification of spatial and temporal dynamics of expression-
activity of various receptors and enzymes in different organs and tissues in norm and disease. 
The availability of selective substrates to individual classes and isoforms of HDACs would 
enable the development of radiolabeled imaging agents for non-invasive in vivo PET imaging. The 
advantages of enzyme substrate based vs. inhibitor based imaging agents include the ability to 
measure enzyme expression-activity product rather than the presence and level of expression in 
tissues, and provide the means for non-invasive monitoring of pharmacodynamics of HDACs 
inhibitors at the target level. Therefore, the aim of this work was to develop class- and/or isoform-
selective radiolabeled substrates of HDACs, with particular emphasis on class III (sirtuins, SIRTs), 
as will be discussed further.   
1b: Overview of HDACs 
The modification of DNA and corresponding histone core proteins to alter the transcriptional 
availability of chromatin is referred to as epigenetic regulation. The primary methods of epigenetic 
regulation include DNA methylation, nucleosomal remodeling and covalent histone modifications. 
These epigenetic modifications, carried out by a variety of enzymes, act as either activators or 
repressors of DNA transcription through alteration of surface charges on DNA or histone protein 
and subsequent changes in interactions between the two. One of the primary epigenetic regulations, 
includes the addition or subsequent removal of an acetyl moiety to a lysine residue in the tail of a 
histone core protein (Wolffe, 1996).  The addition of an acetyl moiety to a lysine amino acid on a 
histone tail causes the tail to “loosen” its coil of the DNA thereby opening the core nucleosome 
structure and allowing RNA polymerase to bind, thus forming the open reading frame structure. 
The enzymes responsible for the transfer of an acetyl moiety to the lysine residue, and subsequent 
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transcriptional activation, are so called histone acetyl transferases (HATs) (Nishina et al.) 
(Brownell and Allis, 1996).  Consequently, the enzymes responsible for the removal of the acetyl 
groups from these lysine residues, and subsequent transcriptional silencing, are referred to as 
histone deacetylases (HDACs) (Fig. 1). While, the processes of acetylation and deacetylation were 
first discovered in 1968 , the first HAT and HDAC enzymes were not known until the mid-1990’s 
(Yang and Seto, 2007).  
Since the 1990’s the number and 
type of distinct HDACs has grown 
considerably. To date, 18 HDAC 
enzymes have been identified in humans 
and are typically divided into four major 
classes (Haberland et al., 2009). To date, 
18 HDAC enzymes have been identified 
in humans and are typically divided into 
four major classes (Haberland et al., 
2009). Class I HDACs includes: HDAC1, 
HDAC2, HDAC3, and HDAC8, which 
have significant domain and sequence similarity. HDAC’s in this class have typically a nuclear 
localization (Park et al., 2004) and are involved in the regulation of cellular proliferative activity 
(de Ruijter et al., 2003; Khochbin et al., 2001). Class II HDACs, including HDAC4, HDAC5, 
HDAC6, HDAC7, HDAC9, and HDAC10, shuttle between the cytoplasm and nucleus. Class II is 
divided further into Class IIa (HDACs 4, 5, 7, 9) and Class IIb (HDACs 6, 10), with the primary 
difference in the central domain of class IIb, containing a zinc finger motif, while class IIa contains 
Figure 1. Histone acetylation and deacetylation causing 
transcriptional activation and repression of associated 
DNA. Figure from (Chuang et al., 2009) 
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a structural regulatory zinc-binding domain (Bottomley et al., 2008; Yang and Grégoire, 2005). 
Class IIa is able to shuttle more readily between the nucleus and the cytoplasm, whereas class IIb 
is primarily localized in the cytoplasm. In studying brain activity and pathophysiology, class IIa 
HDACs are more relevant over class IIb due to their increased expression in certain structures of 
the brain. HDAC enzymes in classes I, II, and IV are dependent on Zn2+ for enzymatic activity. 
Class III is comprised of HDAC enzymes termed “silent information regulators” or “sirtuins” 
(SIRTs), which represent a family of closely related deacetylases that are Zn2+-independent but 
are dependent on NAD+.  Seven sub-types of SIRTs (SIRT 1-7) have been identified in humans 
(Haberland et al., 2009). SIRT enzymes are becoming increasingly scrutinized for their 
involvement in cancer, mental illness, and lifespan regulation. Class IV HDACs is comprised of a 
single HDAC protein, HDAC11, which is considered separate from classes I and II due to its 
biological actions (Gao et al., 2002; Gregoretti et al., 2004). The mechanisms of catalytic activity 
amongst different HDAC classes and unique structures of individual isoforms correspond to 
peptide sequence-specificity and types of post-translational modifications of their client proteins 
(i.e., acetylation, succinylation, myristoylation, etc.) (Yao and Yang, 2011). This allows for the 
development of class and isoform-specific inhibitors for treatment of various pathological 
conditions and diseases (Thomas, 2009). 
HDACs class III is comprised of HDAC enzymes termed “silent information regulators” 
(sirtuins, SIRTs), representing a family of closely related deacetylases that are Zn2+-independent 
but NAD+-dependent.  This family was first discovered as SIR2 (silent information regulator) gene 
in the murine mode (Michan and Sinclair, 2007) and thus far seven sub-types of SIRTs (SIRT 1-
7) have been identified in humans (Haberland et al., 2009). Sirtuins are implicated in a variety of 
cellular processes including gene silencing, cell cycle regulation, metabolism, apoptosis, lifespan 
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extension and the effects of calorie restriction, as well as circadian rhythms (Pan et al., 2011a). 
Each of the SIRT isoforms plays a unique role in the regulation of cellular processes through SIRT-
mediated epigenetics. Accordingly, the SIRT isoforms vary in their cellular localization, with 
SIRTs 1, 6, and 7 being primarily located in the nucleus, SIRTs 3, 4, and 5 located in mitochondria. 
While SIRT enzymes cleave the acetyl moiety from a lysine residue, much like their other 
HDAC counterparts, it has recently been recognized that the SIRT isoforms are capable of cleaving 
many larger leaving groups than the acetyl (i.e., acetylation, succinylation, myristoylation, etc.) 
(Yao and Yang, 2011). Furthermore, these enzymes are reported to act on other client proteins 
outside of histone core proteins including TNF-a, FOXO, p53, a-tubulin and others (Jiang et al., 
2013; Solomon et al., 2006). 
The HDAC enzymes are implicated in an increasing number of pathologies including cancers 
and neurodegenerative disorders. A review on HDAC class IIa has been done very recently by 
Volmar and Wahlestedt describing the expression of HDAC Class IIa enzymes in the brain and 
their involvement with Alzheimer’s, stress related disorders, Autism and addiction (Volmar and 
Wahlestedt, 2015). But these findings have not yet resulted in a substantial improvement to 
treatment due to the complexity of these interactions.  Likewise, HDAC1 was originally linked to 
mSin3A expression in human cancers and a great rush ensued to produce inhibitors of HDAC1 for 
cancer treatment (Dhordain et al., 1998; Laherty et al., 1997). However, as more research has 
amassed and much data has been produced; the resulting evidence for either activating or inhibiting 
HDACs in disease has been inconclusive and conflicting (Lakshmaiah et al., 2014; Taunton, 1996).  
To confound this problem, many of the existing HDAC inhibitors lack selectivity to a single 
isoform or class thereby limiting the understanding of the true biological effects of these enzymes.  
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1C. HDAC Class III Biological Implications 
Sirtuins play a variety of roles in the regulation of cellular metabolism and survival. Within 
the cell, the SIRT enzymes are tagged for nuclear, cytoplasmic, or mitochondrial localization in 
accordance with the primary function of the enzyme. SIRTs 1, 6 and 7 are primarily localized in 
the nucleus while SIRT2 retains the ability to shuttle between the nucleus and the cytoplasm and 
are believed to regulate histone core protein acetylation (North and Verdin, 2004).  SIRTs 3, 4, 
and 5 are located in the mitochondria and primarily regulate metabolic processes (North and 
Verdin, 2004).  
In particular, SIRT1  has been recognized for involvement in diabetes, cardiovascular disease 
and neurodegeneration (Haigis, 2010) through cleavage of an acetyl moiety from lysine residues 
of various proteins including PPARƔ, and NF-Kβ, and members of the p53 family. Through 
regulation of these client proteins, SIRT1 acts as both a suppressor and activator of disease in 
cancer and neurodegeneration.  
Through deacetylation of lysine residues on histones H1, H3 and H4, namely H1K26, H3K9, 
H4K16, H4K56, (Vaquero et al., 2004b) SIRT1 induces hypoacetylation thus causing the 
formation of heterochromatin, which is generally associated with gene repression (Blander and 
Guarente, 2004; Michan and Sinclair, 2007; Taylor et al., 2008) (Imai et al., 2000; Vaquero et al., 
2004a). Additionally, non-histone protein substrates, such as components of the core RNA 
polymerase I transcriptional machinery and the HAT p300/CBP (Bouras et al., 2005), are 
deacetylated by SIRT1 also contribute to the role of SIRT1 in reducing gene expression (Muth et 
al., 2001). Through this gene regulation, SIRT1 may play a anti-apoptotic function and thus 
promote cancer growth (Michan and Sinclair, 2007). SIRT1 can further promote cancer cell 
survival by deacetylating the DNA repair protein Ku70 thereby blocking mitochondrial 
7 
 
translocation of BAX to prevent apoptosis (Cohen et al., 2004). Additional key client proteins of 
SIRT1 include tumor suppressors p53 and p73, as well as other enzymes of the p53 family, PPARγ, 
and NF-Kβ (Rahman and Islam, 2011). SIRT1-mediated p53 deacetylation prevents p53 
transcriptional activity preventing the usual apoptotic triggers in response to oxidative stress and 
DNA damage (Dai et al., 2007; Di Giovanni et al., 2006; Luo et al., 2001; Vaziri et al., 2001).  
SIRT1-mediated deacetylation of FOXO family transcription factors may also contribute a role to 
the anti-apoptotic nature of SIRT1 pathways (Michan and Sinclair, 2007; Wang et al., 2007; Wang 
and Tong, 2009).  
However, SIRT1 has also been reported in some cases to act as a tumor suppressor through 
indirect regulation of cell cycle progression (Brooks and Gu, 2009). For example, SIRT1 
deficiency in mice actually impairs the DNA damage response and leads to genomic instability 
(Wang et al., 2008). Whereas under in wild-type SIRT1 models, the introduction of double-
stranded breaks causes SIRT1 to relocate as part of the transcription complex from more 
housekeeping gene promoters to the site of DNA damage and begin facilitating repair 
(Oberdoerffer et al., 2008).  
SIRT1 catalytic activity is regulated by phosphorylation of key functional site residues (i.e. 
threonine, serine, tyrosine residues) on the enzyme surface. In SIRT1, the primary sites of 
regulation include S27, S47, T530, T540, T522, S434 and S682 (Protein Data Bank). One example 
of this regulation begins with the JNK1 mediated pathway. JNK1 phosphorylates S47 on hSIRT1 
to increase SIRT1 activity upon increase in cellular glucose levels, which subsequently targets 
SIRT1 for ubiquination and degradation in response to increase in insulin levels (Gao et al., 2011). 
JNK2 also phosphorylates SIRT1 at S27 to stabilize SIRT1 and allow the enzyme to activate 
apoptotic pathways in cancer cells under damaged DNA conditions (Ford et al., 2008). Similarly, 
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DYRK1A and DYRK3 phosphorylate SIRT1 at T522 to prevent apoptotic pathways from 
occurring under conditions of damaged DNA, thereby acting as pro-survival enzymes through 
direct SIRT1 modulation (Guo et al., 2010). Other factors influencing the activity of SIRT1 include 
AMPK and cAMP/PKA. These enzymes primarily regulate SIRT1 activity in response to cellular 
glucose levels, especially in the liver. For example, cAMP regulates PKA which in turn 
phosphorylates S434 of SIRT1 to enhance deacetylase activity and promote fatty acid oxidation 
under conditions of glucagon receptor stimulation in the liver (Gerhart-Hines et al., 2011). The 
same pathway is also stimulated by oleic acid to activate SIRT1-PGC1α complex in skeletal 
muscles to increase rates of fatty acid oxidation (Lim et al., 2013).  
Other measurements of cellular energy stores may influence SIRT1 catalytic activity. 
Because SIRT1 is dependent on NAD+ for catalytic activity, the ratio of NAD+ to NADH within 
a cell plays a part in the ability of SIRT1 to effectively deacetylate client proteins. Under energy 
depravation conditions, the ratio of NAD+ to NADH will increase, thus increasing the ability of 
SIRT1 to be active. This theory is supported by studies demonstrating activation of a C. elegans 
SIRT1 homologue as a result of calorie restriction, which may contribute to an increase in lifespan 
and longevity (Bordone and Guarente, 2005). This pathway is of particular interest for the 
treatment of obesity and Diabetes Type II resulting in exploratory clinical trials with SIRT1 
activators for therapy (NCT01677611, NCT01031108, NCT01938521). Other hypotheses have 
included the use of Resveratrol (a small molecule SIRT1-activator) for therapeutic use in humans 
to increase lifespan (NCT01150955). Other clinical trials ongoing involve EX-527 (Selisistat, 
SEN0014196) a SIRT1 selective inhibitor, for tolerability and treatment of Huntington ’s disease 
(NCT01521585, NCT01485965). While these hold great promise for pharmacologic intervention 
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of these diseases through SIRT1-targeted therapies, conclusive results have not yet been 
determined.  
Other indirect pathways for metabolic regulation include the SIRT1-mediated deacetylation 
of PPARGC1α and forkhead box o1 (FoXo1) to increase gluconeogenesis in low energy states 
under stimulation from glucagon and epinephrine (Schwer and Verdin, 2008). To promote fat 
mobilization from white adipocytes in the fasted state, SIRT1 interacts with SMRT to inhibit the 
transcription of PPARγ target genes (Picard et al., 2004). Additionally, SIRT1 is involved in 
regulation of cholesterol metabolism in the liver through deacetylation and activation of liver X 
receptor (LXR) causing the LXR to regulate the ATP-binding cassette transporter A1 (aBCa1) 
promoter (Li et al., 2007) dictating cholesterol efflux rate from peripheral tissues and subsequent 
formation of high-density lipoprotein particles (HDL).  
In addition to the role SIRT1 plays in cancers and all of cellular metabolism on a larger scale, 
SIRT1 is implicated in the outcome of many neurodegenerative diseases. Both SIRT1 and SIRT2 
have been implicated in many types of neuronal degeneration including amyotrophic lateral 
sclerosis (ALS), Parkinson's, Huntington's and Alzheimer's disease and models of induced axonal 
degeneration (i.e. Wallerian degeneration) (Dillin and Kelly, 2007; Outeiro et al., 2008; Tang and 
Chua, 2008; Taylor et al., 2008). Through SIRT1 interactions with p53 and p73, SIRT1 may 
indirectly influence neuronal cell migration, nerve fiber outgrowth, growth cone motility and 
axonal regeneration (Di Giovanni et al., 2006; Tedeschi and Di Giovanni, 2009; Zhang and Chen, 
2007). For this reason, SIRT1 has generally been assigned neuroprotective functions, while SIRT2 
has been implicated in more neurodegenerative functions. For instance, blocking SIRT2 function 
resulted in rescue of alpha synuclein toxicity in Parkinson's disease models (Outeiro et al., 2007) 
while the overexpression of SIRT2 prevented resistance of Wallerian axonal degeneration in a 
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mouse model (Suzuki and Koike, 2007). Other studies demonstrate that elevated SIRT2 level 
down-regulates neuronal motility (Pandithage et al., 2008).  
The role of SIRT2 in the cell is primarily centered on cell cycle regulation through 
deacetylation of H4K16 and α-tubulin (Inoue et al., 2007a; Inoue et al., 2007c; Inoue et al., 2009). 
Through regulation of α-tubulin, SIRT2 is considered a primary mitotic exit regulator for the cell 
(Dryden et al., 2003) and relative expression of SIRT2 can be correlated with cell cycle 
progression. Therefore, the catalytic activity and expression of SIRT2 during cell cycle is also 
highly regulated. SIRT2 is regulated by phosphorylation at different site-specific residues on the 
surface of the enzyme. One example is inhibition of SIRT2 by CDK1-mediated phosphorylation 
on S368 to delay cell cycle progression during G1/M phase transition (North and Verdin, 2007b) 
(Pandithage et al., 2008). Similarly, phosphorylation of SIRT2 by CDC14B late in M/G2 transition 
(Dryden et al., 2003) may provoke mitotic exit through increasing SIRT2 targeted ubiquination 
and degradation. E-Cdk2 is another member of the cyclin family that may target SIRT2 for 
phosphorylation on S331 to inhibit SIRT2 function (Pandithage et al., 2008). 
The role of SIRT2 in various cancers been explored in limited detail. Thus far, SIRT2 has 
been reported to act as to suppress glioma growth and colony formation in culture through 
inhibiting mitotic exit (Hiratsuka et al., 2003). The mitotic exit regulatory mechanisms of SIRT2 
through deacetylation of α-tubulin may be particularly dependent on stress-induction within the 
cell, i.e. under normal, non-stressed conditions SIRT2 plays a much less significant role in cell 
cycle control (Pandithage et al., 2008). Whereas, under imposed stress conditions in vitro due to a 
microtubule poison, such as nocodazole, SIRT2 is overexpressed and delays mitotic exit (Dryden 
et al., 2003; Inoue et al., 2007c; Inoue et al., 2009).  
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Due to the pivotal role SIRT2 plays in cell cycle progression through its regulation of α-
tubulin and ability to shuttle between the nucleus and cytoplasm, it follows that SIRT2 would be 
a key regulator cancer cell growth. In vitro studies have indicated an inverse relationship between 
colony colony growth in glioma (Claes et al., 2007) cell lines and SIRT2 expression, indicating 
that a decrease in SIRT2 expression may lead to a more severe grade of glioma . Furthermore, 
genomic analysis has confirmed that mutations causing deletion of the SIRT2 gene arise in many 
glioma cells as the cancer advances (Hiratsuka et al., 2003).  
However, in some cases, the overexpression of SIRT2 is associated with an increase in cancer 
growth and progression. Through immunohistological staining, it has been demonstrated that 
SIRT2 is highly up regulated in breast cancer tissue (McGlynn et al., 2014). Previous studies 
demonstrated downregulation of SIRT2 expression in about 70% of gliomas (Hiratsuka et al., 
2003; Inoue et al., 2007b). In contrast, studies that are more recent demonstrated that the labeling 
index of nuclear-localized SIRT2 is significantly higher in glioblastomas (grade IV), as compared 
to astrocytomas (grade II) and normal brain tissue and strongly correlated with malignant 
progression and the overall survival of patients with glioblastomas (Imaoka et al., 2012). Higher 
levels of expression and higher labeling index for SIRT2 is also associated with progression and 
poor prognosis in patients with non-small cell lung cancer (NSCLC) (Grbesa et al., 2015) and 
cervical carcinoma (Singh et al., 2015). Some tumors (i.e., melanomas), may harbor mutations in 
SIRT2 gene resulting in reduction of enzymatic activity by 80–90% compared to the wild-type 
protein, however consequences to tumor progression and overall prognosis are yet unknown 
(Lennerz et al., 2005).  
The role of SIRT2 in tumor progression is attributed to the stabilization and lack of 
degradation of the Myc proteins, namely, C-Myc and N-Myc in pancreatic cancer and 
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neuroblastoma cells, respectively (Liu et al., 2013). Therefore, the use of SIRT2-selective 
inhibitors may provide therapy for Myc-induced malignancies. But, for most cancer strains it 
remains yet unknown, whether a patient’s treatment would benefit most from inhibition or 
activation of SIRT2. 
Unlike SIRTs 1 and 2, SIRT3 is localized in the mitochondria and acts primarily as a 
metabolic protein deacetylase rather than a true histone core protein deacetylase. SIRT3 is directly 
involved in regulation of TCA cycle and fatty acid synthesis through increasing pools of acetyl-
coA molecules by deacetylation and subsequent activation of acetyl-CoA synthetase Lys-642 
(ACS) (Jin et al., 2009). It is interesting to note that ACS may (has only been reported in yeast 
thus far) also facilitate the transfer of acetyl groups to the lysine residues of histone core protein 
tails, activating DNA transcription in a similar to the manner to HATs. Additionally, SIRT3 
influences fatty acid oxidation and breakdown through regulation of the long-chain acyl-coA 
dehydrogenase (Bharathi et al., 2013). Due to the metabolic implications of SIRT3, clinical trials 
on undergoing intermittent fasting to affect aging and oxidative stress, as well as studies of 
vitamins C and E on SIRT activity are currently in progress with specific focus on SIRT3 and 
interactions with SIRT5 (NCT02132091, NCT02011906). 
SIRT3 further plays a part in control of the TCA cycle through for deacetylation of alpha 
subunit of E1 on pyruvate dehydrogenase (PDH) and ICDH2 K75 and K241 (Mathias et al., 2014; 
Ozden et al., 2014; Schlicker et al., 2008b); while working in conjunction with SIRT4 to regulate 
the activity of PDH complex.  In most cases, deacetylation of E1 by SIRT3 activates PDH and 
may contribute to the increase in metabolic activity of cancer cells.  This may contribute to some 
of the metabolic reprogramming that occurs during the cancer cell transition phase, often referred 
to as the Warburg effect. SIRT3’s integral role in cellular metabolism and glycolysis-
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gluconeogenesis transition are still widely unknown and require further research to better 
understand the consequences of this enzyme in pathological conditions.  
SIRT4 is also located in the mitochondria and functions primarily as a lipoamidase rather 
than a deacetylase (Mathias et al., 2014) and retains very little deacetylase activity.  Primarily 
SIRT4 is responsible for catalyzing the removal of lipoyl and biotinyl moieties from lysine 
residues on metabolic client proteins (Mathias et al., 2014). Through delipoylation of pyruvate 
dehydrogenase E2 subunit, SIRT4 works in conjunction with SIRT3 to regulate PDH activity 
(Mathias et al., 2014) suggesting that PDH is regulated by other cofactors outside of E1 
phosphorylation, as previously understood. Additionally, SIRT4 aids in cellular metabolism 
regulation by decreasing reactive oxygen production and increasing ATP production (Haigis et al., 
2006). In cases of a SIRT4 knockout, the concentration of free fatty acids in the blood go to 
unhealthy levels indicating a direct link between SIRT4 regulation and regulation of FFA. 
Furthermore, circulating levels of SIRT4 may act as a biomarker for coronary artery disease due 
to its role of FFA regulation (Tarantino et al., 2014). SIRT4 may play pivotal roles in mitochondrial 
disease and aging though more research is currently needed to understand the cellular mechanisms 
at play.  
SIRT5 is the third of the mitochondrial localized sirtuins and regulates proteins involved in 
oxidation/reduction reactions, fatty acid metabolism, aerobic respiration and TCA cycle (Tan et 
al., 2014). Similar to SIRT4, SIRT5 contains very little deacetylase activity and primarily cleaves 
succinyl and glutaryl moieties from lysine residues (Du et al., 2011).  The cleavage of succinyl 
moiety from a lysine residue of client proteins by SIRT5 may play a role in directly regulating the 
succinyl-coA pool available for TCA cycle. SIRT5 also plays a critical role in mitochondrial and 
cellular health by controlling reactive oxygen species (ROS) through desuccinylation and 
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activation of superoxide disumutase 1 (SOD1) (Lin et al., 2013). Additionally, SIRT5 may work 
synergistically with SIRT1 to increase lifespan under conditions of calorie restriction (Geng et al., 
2011). SIRT5 regulates the activity of carbamoyl phosphate synthetase I (CPSI) by desuccinylating 
specific lysine substrates (Du et al., 2011; Peng et al., 2011).   
Through regulation of ROS, apoptosis and cellular metabolism, SIRT5 may alter the 
neuronal growth neuropathologies. In the rat model, immunohistochemical staining indicates 
SIRT5 is present in the neurons of the cerebral cortex and the cerebral medullary substance (Geng 
et al., 2011). Reportedly, SIRT5 knockout mice (KO) have minimal phenotypic differences from 
the WT under normal, non-pathological conditions, however when they are given a Parkinson’s 
Disease-like state the KO become more severely affected than the WT with PD. Through this study 
the researchers believe that SIRT5 may be an important player in the protection of motor neurons 
in the brain after pathological state sets in (Lei Liu, 2015). These findings support the 
understanding that SIRT5 is a major player in the ROS pathway and neuronal mitochondria.   
SIRT5 may also play a role in apoptosis and electron transport chain function through 
regulation of other mitochondrial client proteins, such as cytochrome C (Schlicker et al., 2008a).  
Reports have indicated that SIRT5 may be responsible for regulation, possible activation, of 
cytochrome C through deacetylation in the inner mitochondrial space (IMS) (Schlicker et al., 
2008b).  While the role of SIRT5 in many diseases has not been fully elucidated, the SIRT5-
mediated regulation of many critical client proteins indicate that targeting SIRT5 for treatment of 
various pathologies may be beneficial. This work will need to be aided by the development of a 
non-invasive imaging agent that is specific for SIRT5.  Development of this agent will allow for 
study of neuronal degenerative diseases such as ALS, Parkinson’s, and Alzheimer’s diseases to be 
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investigated further under the lens of SIRT5 activity. These findings will be important for the 
further discovery of treatments for these diseases.  
SIRT6 is recognized for regulating cell cycle and cellular functions through control of client 
proteins, such as NF-KB, HIF-1α, and other genes involved in metabolism and ageing 
(Beauharnois et al., 2013). While SIRT6 does act as a deacetylase in vivo on endogenous client 
proteins, reports have demonstrated that this enzyme may contain demyristoylase activity as well.  
Though experimentally the ability of SIRT6 to cleave a myristoyl lysine from H3K9 or TNF-α 
K19-20 it has not been validated that these activities occur in vivo (Kokkonen et al., 2012).  
Pathologically, SIRT6 has been implicated in diseases such as type II diabetes (Huhtiniemi et al., 
2011).  SIRT6 has also demonstrated a protective role for the cell during ageing.  It follows then, 
that using SIRT-6 targeted inhibitors or activators may be therapeutic for various pathological 
conditions (Kokkonen et al., 2014). 
SIRT7, the most recently discovered sirtuin, is implicated in the cellular transformation from 
benign to malignant within cancer cells. SIRT7 localized to the nucleus and deacetylates both 
histones and other non-histone client proteins, though the primary target for SIRT7-mediated 
deacetylation is H3K18 (Paredes et al., 2014).  SIRT7 plays a vital role to DNA transcription and 
protein translation through deacetylation of H3K18 and interactions with non-coding RNA’s to 
regulate rRNA and tRNA synthesis. Additionally, SIRT7 has been found to deacetylate and play 
a role in regulation of p53 to aid in cellular regulation of DNA damage from oxidative stress 
(Paredes et al., 2014).  Another role SIRT7 plays in cells under stress includes regulating MYC 
protein to facilitate the unfolded protein response (Paredes et al., 2014). 
In cancer, the role of SIRT7 is likely both cancer suppressive and cancer supportive as its 
functionality may change with the phenotype of the cell. Reports have indicated inactivation of 
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SIRT7 in progressive cancers may halt the progression of cancer and even reverse the phenotype 
of the cancer cells to reduce tumor expression, in vivo (Barber et al., 2012; Paredes et al., 2014).  
However, it is also noted that SIRT7 plays a tumor suppressive and cellular protective role in pre-
malignant, early stage cancer cells. One hypothesis for the change in cellular roles of SIRT7 is that 
enzyme regulation may come from free fatty acids in the cell, indicating a link between SIRT7 and 
cellular metabolic status (Paredes et al., 2014). While SIRT7 remains a promising target for 
therapy of cancers, more work is needed to understand the correct pharmacomodulation (i.e. 
activation or inhibition) most beneficial for a patient.  
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CHAPTER 2 HDAC CLASS III SUBSTRATE SPECIFICITY  
The catalytic mechanism and active site structure varies slightly between each class of 
HDAC’s.  HDAC classes I and IV are very similar in both structure and function and have only 
very slight variations in the amino acid residues within their catalytic sites (Lombardi et al., 2011). 
These two classes vary more in their biological activity than their catalytic activity. HDAC class 
IIa has differences in the primary residues needed for catalysis within the active site, thereby 
altering the mechanism of action, which will be discussed further in chapter three.   
Lastly, class III HDACs, the sirtuins, have the most unique catalytic structure and mechanism 
among the HDACs. These enzymes bind NAD+, (generally prior to binding the substrate) which 
alters the state of the enzyme active site. Ultimately, the NAD+ will be cleaved into two parts, the 
ADP-ribose ring and the nicotinamide during the catalyzed cleavage of a leaving group from a 
lysine residue on a client protein. During this cleavage reaction, the leaving group moiety will be 
transiently attached to the ADP-ribose ring (Sauve, 2010). Within the SIRT class, there are 
subclasses based on the mechanistic differences within this group. There are two primary catalytic 
functions among the sirtuins, which are defined as mono-ADP ribosyl transferase (ART) and 
NAD+ dependent deacetylase (DAC) (Michan and Sinclair, 2007).  Sirtuins can be subdivided into 
four classes, class I includes sirtuins 1, 2, and 3, which are able to do both ART and DAC and bind 
the substrate prior to the NAD+ (Pan et al., 2011a). Classes II and III encompass sirtuins 4 and 5. 
While class IV includes sirtuins 6 and 7, which act as NAD+ dependent allosteric activator 
enzymes, and act only as a DAC; this indicates that they rely on the binding of NAD+ prior to the 
the substrate binding and are unable to act as an ART alone (Pan et al., 2011a).  Unlike the rest of 
the HDACs, which primarily localize to the nucleus or cytoplasm, the sirtuins can also localize to 
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the mitochondria. Sirtuins, even more-so than other HDACs, deacetylate not only histone proteins 
but also many other client proteins with acetylated lysines. SIRTs also have the unique ability to 
cleave lysine moieties other than the typical acetyl susbtrate.  
SIRT enzymes vary in cellular localization and core catalytic domain (Michan and Sinclair, 
2007).  As research continues, it becomes increasingly evident that sirtuins are capable of cleaving 
much larger leaving groups from lysine residues than the acetyl moiety. Recently, reports have 
indicated SIRT enzymes are responsible for acting as a desuccinylase, deglutarylase, 
delipoamidase or demirostoylase within the cell (Du et al., 2011; He et al., 2014; Hu et al., 2013; 
Tan et al., 2014). The SIRT substrates are wide ranging across many proteins outside of the histone 
core proteins and the even the nucleus. Due to this great variation in enzyme activity the catalytic 
residues and active site differ greatly in size and hydrophobicity within class III enzymes. HDAC 
class III is the most unique among the 18 HDAC proteins and has wide ranging impacts on norm 
and pathological states in the cell.  
The primary mechanism for SIRT-mediated cleavage of lysine residue moieties using NAD+ 
was published (Sauve, 2010) and is represented in Fig. 2, though there are distinct differences 
between the seven active sites allowing substrate specificity to be achieved. Towards an 
understanding of substrate specificity for each sirtuin enzyme and structure activity relationships 
(SAR) for these enzymes, an evaluation and comparison of the active site residues for each of the 
Figure 2. An illustration for deacetylation by SIRT of a lysine residue on a client protein using 
NAD+ as a cofactor. 
 
19 
 
seven sirtuins was performed. Another review of sirtuin substrate specificity has recently been 
published demonstrating some of the differences in pocket structure by molecular modeling 
(Bheda et al., 2016). All sirtuins contain a large Rossman fold (7 mostly parallel beta sheets 
connected by an alpha helix) encompassing the NAD+ binding domain and a smaller, more 
variable, zinc ion binding domain. While SIRT enzymes have retained the Zn2+ binding domain 
from the other classes of HDACs this domain is not utilized as the primary coordination site for 
catalytic cleavage as it is in the other HDAC classes. 
Activation of an acetylated lysine residue for SIRT-mediated amide bond cleavage occurs 
through interactions with water molecule and NAD+. First, the acetylated lysine chain enters the 
active site from a channel opposite to the NAD+, allowing for correct interaction between the two 
substrates at the active site. The overall mechanism for sirtuin deacetylation relies on the 
attachment of the lysine-leaving group to the adenine (Sauve et al., 2006).  The nicotinamide leaves 
when the oxygen of the carbonyl carbon from the lysine acetyl group attacks the adenine sugar at 
the 1’ position and this position has been activated by a histidine or tyrosine residue (Zhao et al., 
2004).  The 2’OH group is deprotonated by the histidine or tyrosine residue that is correctly 
positioned for this reaction to occur (Sauve, 2010).  As the nicotinamide leaves, the lysine-acetyl 
moiety is transiently connected to the 1’ position through an ester linkage. An oxocarbenium ring 
forms when the 2’ hydroxyl oxygen attacks the double nitrogen amide bond. This oxocarbenium 
intermediate is stabilized by the presence of a highly conserved asparagine residue in all sirtuins 
(Zhao et al., 2004). As the oxocarbenium is opened the lysine leaves as –NH2 while the acetyl (or 
other leaving group) moiety is transferred to the 2’ position of adenine dinucleotide and connected 
via ester linkage. Two histidine residues facilitate this leaving group transition from the 1’ position 
to the 2’ position on the adenine ribose ring (Zhao et al., 2004).  Therefore, the proof of a successful 
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synthetic sirtuin substrate composition comes through evidence of the leaving group attached to 
the adenine sugar ring.  
This attachment of the leaving group to the 2’ O-ADPR portion of NAD is instrumental in 
developing an imaging agent (Fig. 3), because the entire molecule will be trapped inside the cell 
as it is too polar and large to be 
transferred back across the cell 
membrane. The ester linkage 
of the leaving group to the 
ADPR has been observed in 
cases of the long acyl chain 
leaving group as well as the 
small acetyl moiety (Feldman 
et al., 2013).  The hydrophobic 
binding pocket containing the 
nicotinamide end of NAD+ and the substrate leaving group is comprised of different residues in 
each of the sirtuins, thereby altering the substrate specificity.  
Among sirtuins 1,2, and 5 there are a considerable number of conserved and semi-conserved 
residues surrounding the active site region (Cosgrove et al., 2006).  Sirtuins have 4 active site loops 
within the large and small domains of the protein (Finnin et al., 2001). Finnin et al. gives an 
excellent description of each of the loops in the sirtuin enzyme structure and their functions for the 
enzymatic activity (Finnin et al., 2001). Due to such similarity, the ability to develop specific 
substrates for each sirtuin becomes increasingly difficult. The large groove residues, which include 
the NAD+ binding site, remain identical across Sirt1, 2, 3, 4, 5, and 6 (Finnin et al., 2001). The 
 
 Figure 3. The entrapment mechanism of a sample sirtuin 
substrate leaving group within a cell through attachment of the 
leaving group to the adenine dinucleotide. From Gelovani et al. 
21 
 
small domain, including alpha helices 5, 6, and 9, and loops 3 and 4 have some variations among 
the sirtuins.  These helicies consist of primarily hydrophobic residues, containing both zinc binding 
sites and the substrate-binding site (Finnin et al., 2001).  A number of these residues also 
encompass the catalytic site for the sirtuin, and in many cases amino acid mutations in this region 
will result in a complete loss of deacetylation activity. 
To construct an isoform specific substrate, it is necessary to look closely at the residues 
within the two primary loops, L3 and L4, which contain the substrate binding and activating 
pocket. L3 is the active site containing the deprotonating residue for all sirtuins. This residue, 
generally a histidine, is responsible for activating the substrate allowing deacetylation to occur.   
SIRT1 contains regions distinct from other sirtuins at both amino and carboxyl terminals; 
however, the catalytic core is highly conserved in all of the class III sirtuins.  SIRT1 is an unordered 
protein due to a flexible loop involved in the active, C site, residues and forming about half of the 
total sequence (Autiero et al., 2009). While the core in all sirtuins is made from a Rossman fold, 
containing a channel terminating near the NAD+ ribose ring; SIRT1 active site contains five 
aromatic residues, Trp176, Tyr185, Phe187, Trp221 and Trp624 which contribute to pi-stacking 
interactions (Autiero et al., 2009).  These aromatic residues line the hydrophobic pocket where the 
acetylated (or other moiety) lysine binds and could indicate that aromatic ring leaving groups with 
hydrophobic features would bind well in the pocket and contribute to the pi-pi stacking (Autiero 
et al., 2009).  Therefore, it is understandable that an aromatic ring would work well as a leaving 
group on a substrate type radiotracer.  Interesting to note, SIRT1 is unable to effectively cleave 
propionyl or butyryl groups, and functions at only ~28% and ~2%, respectively, of its deacetylase 
efficacy in these cases (Heltweg et al., 2004; Hirsch and Zheng, 2011). However, this study showed 
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that dephenylacetylation by SIRT1 had a catalytic reaction rate of about 56% of the deacetylation 
rate.  
The distance between the alpha carbon and the side chain acetamido group plays a large role 
in the catalytic efficiency of SIRT1, thus the full lysine chain is necessary for activity (Hirsch and 
Zheng, 2011).  The orientation of the lysine’s center carbon (L-conformation) is also extremely 
important, as all catalytic activity is lost from the enzyme with the D-lysine isomer (Jamonnak et 
al., 2010).  
Multiple X-ray crystal structures have been identified for SIRT2, allowing analysis of its 
substrates and catalytic site interaction (Finnin et al., 2001; Moniot et al., 2013). SIRT2 primarily 
regulate lysine residues on the tails of H3 (H3K9) and H4 (H4K16) (Imai et al., 2000). In contrast 
to Sir2-Af1 (the murine homologue of SIRT1) SIRT2 has a lower degree of flexibility in the 
binding loop leading to a very high level of substrate specificity even though it has a much wider 
channel than some of the other sirtuin homologues in other species (Finnin et al., 2001).  
Specifically, there are two residues that are necessary for deacetylase activity, Asn168 and 
Asp170, which activate the ribose ring to allow for a quicker enzymatic transfer (Finnin et al., 
2001).  It has also been proposed that it is Ser88 in SIRT2 performing the initial glycosidic attack 
on the NAD+, thereby allowing the nucleophilic attack on the carbonyl (Finnin et al., 2001).  
SIRT2 has a deeper catalytic pocket, though not wide enough to accommodate a benzene ring like 
SIRT1, SIRT2 has the ability to fit much longer chains. He et al. provide proof of SIRT2 cleaving 
the myristoyl moiety on a lysine chain of H3K9 and TNF-αK19-20 (He et al., 2014). 
SIRT2 and SIRT3 share multiple residues in key positions, many of which are generally not 
conserved between all sirtuins. For example, the amino acid at the -2 position from the protonating 
residue is not conserved across all sirtuins, but both SIRT2 and SIRT3 share a tyrosine here. 
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Similarly, the two key residues in the L4 active site loop are shared between SIRT 2 and SIRT3 as 
they contain a valine at the +7 position from their respective FGEXL loops.  Notably, the -1, -3 
and -4 positions from this loop are also conserved between these two enzymes, yet not between 
any of the other sirtuins. This information is important to understand how to construct a substrate 
specific to one or the other.  
Examining the surface residues for SIRT3 through in silico modeling demonstrates the cap 
residues more preferred by SIRT3. Investigation of many of the natural client proteins for SIRT3, 
the side chain and cap residues will provide valuable information for unique substrate synthesis 
for SIRT3 (Smith et al., 2011). According to this model study, SIRT3 prefers the positively 
charged and aromatic residues on both sides of the modulated lysine, namely, tyrosine, 
phenylalanine and tryptophan (Smith et al., 2011).  This will explain why so many of the positive 
SIRT3 synthetic substrates are successful with the fluorescent compound amino-methylcoumarin 
(AMC) on one side of the lysine.  Much of SIRT3’s activity relies on the substrate’s cap and its 
ability to fit well into SIRT3. Di-lysine cap groups also enhance SIRT3 catalytic activity regardless 
of changes in leaving group. However, the most selective leaving group for SIRT3 is the crotonyl 
moiety, as this sirtuin is the only one capable of successfully cleaving a crotonylated lysine moiety. 
SIRT5 uses a histidine as the deprotonating residue, His158, which is common amongst the 
sirtuins, however SIRT5 has a unique arginine in the catalytic pocket (Du et al., 2011). The Tyr102 
and Arg105 in the active site allow SIRT5 to cleave succinylated substrates (Du et al., 2011). 
SIRT5 has a further differentiated substrate-docking site due to its two arginine residues in the 
bottom of the binding pocket. Du et al., demonstrated effectively that these two arginine residues 
form hydrogen bonding with the carboxylic acid present on the end of the succinyl moiety (Du et 
al., 2011).  Because of this alteration in the active site, the substrate specification for SIRT5 is very 
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straightforward; this is the only enzyme that will easily cleave these terminal carboxylic acid 
chains. Tan et al. have also observed that SIRT5 is able to act as a deglutarylase on specific proteins 
with lysine-glutarylated residues (Tan et al., 2014).  Literature reports have suggested that SIRT5 
is the only sirtuin with the ability to act as a deglutarylase (Tan et al., 2014).  
An interesting study demonstrated the corresponding changes in SIRT5 Km and Kcat after the 
addition of various groups at the beta carbon of the succinyl and glutaryl substituents. The 
conclusion that the large changes in km did not necessarily reflect changes in kcat demonstrates a 
fundamental difference in kinetic measurements of enzymatic activity (Roessler et al., 2014). It 
appears that for SIRT5 a lowered affinity to a substrate is not necessarily reflected in a decreased 
catalytic activity. In the development of synthetic substrates it is necessary to identify both strong 
Km and Kcat values, but the Kcat is more indicative of the effectiveness for a particular substrate to 
be cleaved.  Furthermore, they identified multiple different dicarbonic acyl groups, which are 
likely used as covalent lysine modifications for carbamoyl phosphate synthetase 1 (CPSI). Thus, 
it has been found that SIRT5 acts on many dicarbonic acyl chains of lengh 2 carbons to 8 carbons 
(Roessler et al., 2014). This finding was supported by the identification that Arg105 in SIRT5 is 
able to adopt different conformations allowing larger acyl residues to interact with the Tyr102 and 
Arg105 residues. This study also confirms the previous findings that SIRT5 is not an active 
deacetylase, as the Kcat and Km for the deacetylase activity is extremely low. These findings are 
instrumental in our design of radiolabeled substrates for imaging of SIRT5 in vivo.  
While all other sirtuins contain the FGE loop, named for the conserved FGEXL residues, 
SIRT6 contains instead a loop with WEDSL residues.  Along with this, SIRT6 lacks the salt bridge 
that normally constrains the two loops used in binding NAD and substrate, in the Rossman fold.  
It has been documented in most sirtuins that the conserved FGEXL loop forms the hydrogen 
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bonding interactions with the substrate in the pocket (Jin et al., 2009). However, SIRT6 is the only 
enzyme without these conserved residues; instead it has a large gap in the protein sequence and 
corresponding cleft in the quaternary structure, followed by a WEDSL loop.  These changes make 
the selectivity of the cap in SIRT6 much more important.  This gives the enzyme more flexibility 
in its binding mechanism.  It is implied in Hu et al. that the cap of the substrate plays a large role 
in the ability of an enzyme to cleave the lysine substrate (Hu et al., 2013).  In their study they have 
tested three compounds with a myristoyl-lysine contained within.  The H3K9 (myr)-AMC did not 
work at all while the TNF-alpha shortened analog works very well and SIRT6 is able to cleave the 
myristoylated lysine.  Furthermore, the full chain length TNF-alpha protein with K20 
myristoylated cuts the shortened peptide’s Km in half (Hu et al., 2013).  It has been shown that 
SIRT6 can catalyze demyristoylation in vitro for the TNF-α but it does not effectively cleave this 
moiety from the myristoylated lysine 9 in H3K9 (Hu et al., 2013).  However, the same group has 
also published findings that SIRT2 can also cleave the myristoyl leaving group, but on H3K9, not 
TNF-α (He et al., 2014). Looking at the structures of the two amino acid sequences in the TNF 
protein and the histone protein there is one major difference.  The TNF protein contains lysine-
lysine moiety where the lysine is myristoylated, however the H3 protein contains only one lysine 
in the peptidic sequence. This leads us to believe that SIRT6 needs to have the Lys-Lys structure 
for cleavage to occur, which may be the reason for SIRT6’s higher activity with a Lys-Lys 
substrate. These studies are important for differentiation of possibly substrates between SIRT2 and 
SIRT6 as they both fit many of the same leaving groups.  
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CHAPTER 3 DEVELOPMENT OF NOVEL HDAC CLASS IIa 
IMAGING AGENTS  
Histone deacetylases (HDAC’s) became increasingly important targets for therapy of various 
diseases, resulting in a pressing need to develop HDAC class- and isoform-selective inhibitors. 
Class IIa deacetylases possess only minimal deacetylase activity against acetylated histones, but 
have several other client proteins as substrates through which they participate in epigenetic 
regulation. Herein, we report the radiosyntheses of the second generation of HDAC class IIa–
specific radiotracers: 6-(di-fluoroacetamido)-1-hexanoicanilide (DFAHA) and 6-(tri-
fluoroacetamido)-1-hexanoicanilide ([18F]-TFAHA). The selectivity of these radiotracer substrates 
to HDAC class IIa enzymes was assessed in vitro, in a panel of recombinant HDACs, and in vivo 
using PET/CT imaging in rats. [18F]TFAHA showed significantly higher selectivity for HDAC 
class IIa enzymes, as compared to [18F]DFAHA and previously reported [18F]FAHA. PET imaging 
with [18F]TFAHA can be used to visualize and quantify spatial distribution and magnitude of 
HDAC class IIa expression-activity in different organs and tissues in vivo. Furthermore, PET 
imaging with [18F]TFAHA may advance the understanding of HDACs class IIa mediated 
epigenetic regulation of normal and pathophysiological processes, and facilitate the development 
of novel HDAC class IIa-specific inhibitors for therapy of different diseases. 
3a: Novel Histone Deacetylase Class IIa Selective Substrate Radiotracer 
for PET Imaging of Epigenetic Regulation in the Brain 
Portions of this chapter have been published by PLOS One (Bonomi et al., 2015) 
Authors: Robin Bonomi, Uday Mukhopadhyay, Aleksander Shavrin, Hsien-Hsien Yeh, 
Anjoy Majhi, Sajeewa W. Dewage, Amer Najjar, Xin Lu, G. Andrés Cisneros, William P. Tong, 
Mian M. Alauddin, Ren-Shuan Liu, Thomas J. Mangner, Nashaat Turkman, Juri G. Gelovani, 
Introduction:  
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There is an increasing demand for understanding the molecular pathophysiology of 
epigenetic regulation by histone deacetylases (HDACs). Longitudinal studies in experimental 
animal models and in humans, aimed to investigate different HDACs-mediated epigenetic 
mechanisms, could be greatly facilitated by the availability of agents for non-invasive, repetitive, 
and quantitative imaging of enzyme expression-activity in vivo. Previously, we demonstrated that 
Boc-Lys-trifluoroacetate (BLT) could be used for 19F-NMR spectroscopic monitoring of HDAC 
activity in vivo (Sankaranarayanapillai et al., 2006; Sankaranarayanapillai et al., 2008). Also, our 
group developed the first radiotracer for PET imaging of HDAC expression and activity, the 6-
([18F]fluoroacetamido)-1-hexanoicanilide, termed [18F]FAHA (Mukhopadhyay U, 2006a). We 
demonstrated that after intravenous injection, [18F]FAHA rapidly accumulates in the brain in rats 
and in rhesus macaques, and that the rate of [18F]FAHA accumulation in the brain is inhibited in a 
dose-dependent manner by HDAC inhibitor SAHA (vorinostat) (Nishii R, 2007; Sanabria S, 2008; 
Yeh et al., 2013a). Other investigators confirmed the results of our initial studies using PET 
imaging with [18F]FAHA in mice (Tang et al., 2014) and baboons (Reid et al., 2009b; Seo et al., 
2013) . These studies reproducibly demonstrated accumulation of [18F]FAHA-derived 
radioactivity in the n. accumbens, amygdala, hippocampus, periaqueductal grey matter and in the 
cerebellum. These structures of the brain have selective upregulation of HDACs class IIa 
expression, as demonstrated by immunohistochemical staining methods in rhesus macaque (Nishii 
R, 2007; Sanabria S, 2008; Yeh et al., 2013a) and human brain (Yeh et al., 2013b). Furthermore, 
the importance of HDAC IIa enzymes in n. accumbens, such as HDAC4 and HDAC5, has been 
demonstrated in addiction, specifically in the development of drug-seeking behavior (Renthal et 
al., 2007) . Evidence from different laboratories using cell culture and in vivo model systems 
indicates that HDAC4 plays an essential role in the development of central nervous system (Morris 
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and Monteggia, 2013) and in maintenance of neuronal survival (Chen and Cepko, 2009; 
Majdzadeh et al., 2008). The HDAC4 null knockout mice, which die within 2 weeks of birth, 
display cerebellar degeneration (Price et al., 2013). Also, selective deletion of HDAC4 in the brain 
resulted in loss of learning and memory function (Kim, 2012), and haploinsufficiency 
of HDAC4 in humans is associated with brachydactyly mental retardation syndrome  (Williams, 
2010). 
Considering the importance of HDAC class IIa in epigenetic regulatory mechanisms 
involved in brain development and function, we developed the second generation of HDAC class 
IIa–specific radiotracers: 6-(di-fluoroacetamido)-1-hexanoicanilide (DFAHA) and 6-(tri-
fluoroacetamido)-1-hexanoicanilide ([18F]-TFAHA) with improved selectivity and substrate 
efficiency to HDACs class IIa. The rationale for development of these radiotracers was based on 
previous reports that HDACs class IIa enzymes exhibit higher catalytic efficiency for Boc-L-
Lys(ɛ-trifluoroacetyl)-AMC, as compared to Boc-L-Lys(ɛ-acetyl)- AMC. This is attributed to 
much higher electrophilicity of carbonyl carbon atom of the trifluoroacetyl moiety, as compared 
to acetyl moiety, despite the similarities in Van der Waals radii of acetyl and trifuloroacetyl 
moieties (28-30). However, Boc-L-Lys(ɛ-trifluoroacetyl)- AMC has demonstrated high substrate 
affinity also to HDAC8 (class I), which was discouraging in terms of its selectivity to HDACs 
class IIa. It is well established that the rim region in the active site of individual HDACs mediates 
the contact with capping groups of substrates (or inhibitors) and influences their affinity to 
individual HDACs (Riester et al., 2007). Therefore, in this study we tested the hypothesis that a 
smaller sized capping group, such as an aniline moiety, may preserve high substrate affinity of 6-
(trifluoroacetamido)-1-hexanoicanilide to HDACs class IIa, while reducing its substrate affinity to 
HDAC8 and other HDACs class I enzymes. Also, we assessed whether the number of fluorine 
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atom substitutions in the acetyl moiety influences the substrate affinity and selectivity of mono-, 
di-, and tri- fluoroacetyl-hexanoicanilides to different HDACs. 
Herein, we report the synthesis of DFAHA and TFAHA, as well as the radiosynthesis of 
[18F]DFAHA and [18F]TFAHA. We demonstrate that TFAHA exhibits significantly higher 
substrate affinity and selectivity to HDACs class IIa, especially to HDACs 4 and 5, as compared 
to FAHA and DFAHA. Although we have previously reported the results of 18F-FAHA PET/MRI 
imaging studies in rhesus macaques (Yeh et al., 2013a), the results of PET imaging studies in rats 
comparing [18F]FAHA, [18F]DFAHA, and [18F]TFAHA head-to-head are reported here for the first 
time.  
Results and Discussion:  
Several previously studied radiolabeled hydroxamite HDAC inhibitors, including [125/131I]-SAHA 
(Haberkorn U, 2007), [11C]MS-275 (Hooker et al., 2009),  [18F]SAHA (Zeglis et al., 2011), 
[18F]FESAHA (Hendricks et al., 2011b), and [64Cu]CUDC-101 (Meng et al., 2013) demonstrated 
poor accumulation in the brain due to inability to efficiently cross the BBB. Other hydroxamite-
based HDAC inhibitors containing more lipophilic capping groups, such as the adamantyl in 
[11C]martinostat, demonstrated efficient cellular membrane and BBB penetration of this 
radiotracer, as well as efficient visualization and quantification of HDACs class I expression levels 
in the brain and other organs in non-human primates (Wang et al., 2014). Thus, PET imaging has 
been proven as an effective tool for image-guided optimization of potent BBB-permeable HDAC 
inhibitors (19, 35-37). 
Figure 4. Synthesis of DFAHA and TFAHA. Reaction conditions are as follows: a) RT overnight; 
b) 2mL DCM, stirred overnight. 
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We focused on the development of class- and isoform- selective radiolabeled substrates 
instead of radiolabeled inhibitors, because of their ability to visualize not only the localization and 
magnitude of HDACs expression, but more importantly, their expression-activity product. In this 
paper, we report two novel radiolabeled substrate-based radiotracers [18F]DFAHA and 
[18F]TFAHA with enhanced enzyme selectivity for HDAC Class IIa, as compared to [18F]FAHA 
(Nishii R, 2007; Yeh et al., 2013a). We demonstrate that increasing the number of fluorine atoms 
in the acetyl moiety from [18F]FAHA to [18F]DFAHA to [18F]TFAHA increases not only the 
selectivity and catalytic 
efficiency of these 
substrates for HDACs 
class IIa, but also 
improves the metabolic 
entrapment of 
radiolabeled leaving 
groups 
([18F]difluoroacetate 
and [18F]trifluoroacetate) in the brain. In contrast, previously reported studies with [11C]6-
acetamido-1-hexanoicanilide (11C-AHA) demonstrated significantly lower uptake and more 
uniform distribution in the brain, as compared to 18F-FAHA (Seo et al., 2013).  
The syntheses of DFAHA (3a) and TFAHA (3b) are shown in Fig. 4. Compound 1 was 
synthesized following a previously published method in 80% yield (Mukhopadhyay U, 2006b). 
Compound 1 was the key intermediate for the synthesis of the precursor compounds for both 
DFAHA (3a) and TFAHA (3b). Reaction of 1 with bromofluoro acetyl chloride (freshly prepared 
Figure 5. Synthesis of DFAHA and TFAHA precursors. Reaction 
conditions are as follows: c) pyridine, acetyl chloride added drop-
wise at 0°C, stirred overnight at RT d) 0.9 eq. SOCl2, 12 hr. stirred 
under argon at 40°C, catalytic DMF; e) DCM, triethylamine added 
drop-wise at 0°C, stirred 24 hr. under argon at RT. 
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by reacting 
bromofluoro acetic acid 
with thionyl chloride), 
and triethylamine in 
DCM at 0°C, produced 
compound 2a in 15% 
yield. Due to the low boiling point of bromofluoro acetyl chloride, it was not possible to evaporate 
excess thionyl chloride prior to adding the compound 1; for this reason, less than 1 equivalent of 
thionyl chloride was used in the reaction. Compound 2a was obtained as a diastereoisomeric 
mixture and characterized by 1H, 13C and 19F NMR spectroscopy and high-resolution mass 
spectroscopy. The 1H NMR spectrum of compound 2a showed 2 doublets corresponding to the 
fluorobromomethyl proton at 7.03 and 6.74 ppm with coupling constants of 49.45 Hz (typical for 
F-H coupling). Based on the relative integration of these two doublets the, diasteromeric mixture 
was obtained in an 80:20 ratio. The corresponding 19F-NMR spectrum showed 2 doublet peaks at 
-147.34 and -143.52 ppm with coupling constants 50.35 Hz and 48.83 Hz respectively, and the 
same diasteromeric ratio of 80:20. Resolving the diastereomeric mixture was unnecessary, because 
the subsequent reaction (radio-fluorination) led to the formation of difluroacetyl amide, which is 
optically inactive. The yield of this reaction is quite low, only 15%. As an alternative, we 
performed this reaction using the isobutyl chloroformate as intermediary step to aid the coupling. 
Also, we tested N,N'-dicyclohexylcarbodiimide (DCC) as an alternative coupling agent with 4-
dimethylaminopyridine (DMAP) as a catalyst. Although not yet tested, other alternative coupling 
agents such as hydroxybenzotriazole (HOBT) or (1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) (HATU) can be explored with N,N-
Figure 6. Synthesis of [18F]DFAHA and [18F]TFAHA. Reaction 
conditions are as follows: f) [18F]KF, K2,2,2; 0.4mL ACN, 105°C 25 
min.; g)[18F]KF, K2,2,2; 0.4mL ACN, 105°C 25 min. 
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diisopropylethylamine (DIPEA) as catalyst. One possible reason for the consistently low yield is 
the bromine atoms ability to couple with the amine of compound 1. The competition for coupling 
site between the bromine and the chlorine will inherently lower the correct product formation. 
Reaction of compound 1 with difluorobromo acetyl chloride in DCM in the presence of 
triethylamine (Mathias et al.) produced the precursor, compound 2b, in 50% yield. Consistent with 
the structure of 2b, a singlet at -60.07 ppm was observed in the 19F NMR spectrum.  
Compound 3a was synthesized from 1 by reacting with difluoroacetic anhydride with no 
additional solvents in 42% yield. The 1H NMR spectrum of 3a in DMSO-d6 was consistent with 
the structure and the geminal proton observed at 6.16 ppm as a doublet with a coupling constant 
of 53.8 Hz. The 19F NMR spectrum showed a doublet at -125.65 ppm with coupling constant 54.93 
Hz, matching the coupling seen in the 1H NMR spectrum. Compound 3b was obtained in 51% 
yield by reacting compound 1 with trifluoroacetic anhydride with only a small amount of DCM 
(~2 ml). A singlet fluorine peak was observed at -74.32 ppm in the 19F NMR spectrum of 3b, which 
is consistent with the structure of three fluorines in the trifluoroacetyl moiety.  Compounds 3a and 
3b were used as non-radioactive standards for HPLC analysis and biochemical assays (Fig. 5). 
Compounds 4a and 4b were synthesized in radiochemical yields of 25% and 22%, respectively 
(Fig. 6). The identity of the radioactive product was confirmed by co-elution with nonradioactive 
standard as it is not possible to test the purity of radiochemical compounds by NMR.  The purity 
of the compounds was greater than 95%, as assessed by analytical radio-HPLC, and specific 
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activities ranging between 60 and 80 GBq/µmole. The quality control HPLC chromatograms taken 
for compounds 3a and 3b are shown in Figs. 7a and 7b respectively.  
Evaluation of substrate affinity of FAHA, DFAHA, and TFAHA in a panel of recombinant 
HDACs demonstrated the selectivity of these compounds for HDACs class IIa (HDACs 4, 5, 7, 
and 9), especially for HDACs 4 and 5. The kcat values in HDACs class IIa were two orders of 
magnitude higher than those for other classes of HDACs (Fig. 8a). The higher kcat values of 
TFAHA, as compared to DFAHA and FAHA demonstrates the increasing ability of HDACs class 
IIa to cleave the trifluoro acetyl moiety, as compared to both difluoroacetyl and fluoroacetyl 
moieties. The HDAC class IIa enzymes also have lower km values and higher vmax values for 
TFAHA than the other HDACs enzymes (Fig. 8b, 8c). There is a significant change in the vmax 
value of TFAHA from those of FAHA or DFAHA for HDAC8, demonstrating the decreased 
Figure 7. Quality control chromatograms for 4a and 4b. A) Shows Compound 4a in 
blue co-injected with compound 3a, the cold standard, in red. B) Compound 4b shown 
in blue with compound 3b, the cold standard, shown in red. The blue shows the clean 
radioactive spectrum, of the pure compound. UV detection was done at 254nm. 
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cleavage efficiency of HDAC class I with the addition of fluorine atoms (Fig. 8b).  Also, these 
results are consistent with previous reports demonstrating that HDACs class IIa enzymes exhibit 
higher catalytic efficiency for Boc-L-Lys(ɛ-trifluoroacetyl)- AMC, as compared to Boc-L-Lys(ɛ-
acetyl)- AMC, which is not an efficient substrate to class IIa HDACs (Lahm et al., 2007). This 
explains, at least in part, why [11C]6-acetamido-1-hexanoicanilide (11C-AHA) demonstrated 
Figure 8. A) Substrate affinity of FAHA, DFAHA, and TFAHA to different recombinant 
HDACs in vitro. The substrate affinity is expressed as Kcat. B) Maximum catalytic rate of 
FAHA, DFAHA, and TFAHA for different recombinant HDACs in vitro, expressed as vmax. 
C) The concentration required for half of the maximal catalytic activity for all recombinant 
HDACs expressed as km. 
A B 
C 
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significantly lower uptake and more uniform distribution in the brain in the regions of high 
accumulation of 18F-FAHA (Seo et al., 2013). 
It is important to 
note, that the entire 
structure of the substrate 
molecule plays a role in 
the selectivity for HDACs 
class IIa. The structure of 
HDAC substrates can be subdivided into three regions, which individually contribute to HDAC 
class and isoform selectivity: 1) the leaving group; 2) the linker; and 3) the capping moiety (Fig. 
9). Previous studies demonstrated that trifluoroacetyl group can be cleaved by HDAC 8 when it is 
attached to a lysine residue flanked by Boc and AMC (Boc-Lys(TFA)- AMC) (Riester et al., 2004). 
In contrast, the phenyl capping group and lysine linker in DFAHA and TFAHA confer selectivity 
of these compounds only to HDAC Class IIa, with no significant affinity to HDAC8.  
Fig 9. The three parts of a HDAC substrate, the cap (red), the linker 
(green), and the leaving group (blue). 
Figure 10. The structures of compounds and docking scores with HDAC8, a 
HDAC Class I enzyme. A lower docking score indicates higher affinity. 
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Structural comparison of active sites of HDACs class I and IIa enzymes may explain the 
mechanism of selectivity of FAHA, DFAHA and TFAHA for HDACs class IIa. The major 
differences between HDACs class I (1, 2, 3 and 8) and HDACs class IIa (4, 5, 7 and 9) is the 
substitution of His976 (class IIa) for Tyr306 (class I) in the catalytic site. This change in amino 
acid residues in the catalytic site results in negligible intrinsic deacetylase activity but has two 
important structural consequences: the change in size of the active site, and the removal of a 
hydrogen bond donor site. Class I HDACs have a smaller catalytic cavity than class IIa enzymes, 
which explains why larger leaving groups do not fit in the catalytic site and are not cleaved by 
these enzymes. The docking results for HDAC 8 (class I) shown in Fig. 10, demonstrate that 
increasing the size of the leaving group (acetyl < trifluoroacetyl) increases the docking score, 
reflecting reduced ability of a molecule to fit inside the catalytic site of an enzyme. Indeed, 
previous studies 
have reported that 
larger leaving 
groups, such as 
propionyl, 
butyryl, (Z)-but-
2-enyl, 
isobutyryl, 3-
hydroxypropanyl, 
3-methylbutanyl, 
4-amino-4-
  
Figure 11. Mechanism of deactylation of AHA by HDAC8. In HDAC8 
and other HDACs class I enzymes, the hydrogen bond forming between 
Tyr306 and the carbonyl oxygen of the acetyl moiety increases the 
electrophilicity of the carbonyl carbon, rendering it more susceptible to the 
nucleophilic attack by the activated water molecule, bound to His142 and 
His143. This leads to the formation of a tetrahedral oxyanion intermediate 
stabilized by Zn2+ ion and the hydroxyl group of Tyr306. Subsequently, 
the amide bond is cleaved and the acetyl moiety is released. 
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oxobutanyl, and several other similar compounds are poor substrates for class I HDACs (Jones et 
al., 2008).  
HDAC class 
IIa enzymes lack a 
hydrogen bond 
donor that can 
bind to the 
carbonyl oxygen 
of the leaving 
acetyl group as a 
result of the 
substitution 
His976 (class IIa) 
for Tyr306 (class I), which renders the acetyl group inactive (Figs. 11, 12). In HDAC class I, this 
hydrogen bond increases the electrophilicity of the carbonyl carbon in the acetyl group, which 
renders it more susceptible to the nucleophilic attack by the activated water molecule, bound to 
His142 and His143. This leads to the formation of a tetrahedral oxyanion intermediate stabilized 
by the Zn2+ ion and by the hydroxyl group of Tyr306 of HDAC8. Consecutive replacement of the 
hydrogen atoms in the methyl moiety of the leaving acetyl group by fluorine atoms reduces the 
enzymatic activity in HDACs class I. This suggests that increasing the electronegativity of the 
leaving group is not sufficient to overcome the size increase, which may force the carbonyl carbon 
to rotate away from the activated water molecule, adding additional distortion to the hydrogen 
bonding with Tyr306. Increasing the electronegativity should increase the reactivity of carbonyl 
  
Figure 12. The mechanism of action of HDAC4. As compared to HDAC 
class I, HDAC class IIa enzymes exhibit significantly reduced ability to 
deacetylate. In class IIa enzymes the His976 located in the same position 
in the catalytic site as Tyr306 in class I HDACs does not serve as a 
hydrogen bond donor to bind to the carbonyl oxygen of the leaving acetyl 
group and thus reduces the susceptibility of carbonyl carbon to 
nucleophilic attack by the water, as in HDAC class I. 
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carbon, but since this is not the case, it is reasonable to assume that the relative increase in the 
effective size of the leaving group in TFAHA > DFAHA > FAHA may be a determining factor in 
the decreasing enzymatic activity. In contrast, increasing the number of fluorine atom substitutions 
in the methyl moiety of the acetyl leaving group increases the electrophilicity of the carbonyl 
carbon and restores the catalytic activity of HDACs class IIa by facilitating the nucleophilic attack 
on the carbonyl carbon of the acetyl moiety by activated water molecule bound to His802 and 
His803. As a result, the formation of the tetrahedral oxyanion is irreversible and releases 
trifluoroacetate as shown in Fig. 13. 
The uptake, accumulation, and clearance of [18F]FAHA, [18F]DFAHA, and [18F]TFAHA in 
various regions of the rat brain were studied using dynamic PET/CT imaging. Higher levels of 
accumulation of all three radiotracers were observed primarily in n. accumbens, hippocampus, 
amygdala, periaqueductal grey, and cerebellum (Fig. 14), where the HDACs 4 and 5 are 
abundantly 
expressed (Yeh et 
al., 2013a). The 
alignment of the 
PET/CT images 
with the digital rat 
brain atlas 
(Paxinos, 2006) 
was used to 
identify regions of 
interest (Fig. 15). 
 
 
Figure 13. Proposed mechanism of de-trifluoroacetylation by HDAC4. 
Increased electronegativity of trifluoromethyl moiety of the trifluoroacetyl 
leaving group increases the susceptibility of the carbonyl carbon to the 
nucleophilic attack by the water molecule bound to His802 and His803 and 
enables the catalytic activity of HDACs class IIa. This results in formation of the 
tetrahedral oxyanion, which is irreversible, thereby releasing the trifluoroacetate. 
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Highly selective accumulation of [18F]TFAHA-derived radioactivity was observed in the 
cerebellum, n. accumbens, periaqueductal gray, and hippocampus (dentate gyrus-CA1, CA3 
region). The levels of [18F]TFAHA-derived radioactivity accumulation in these brain structures 
were higher than those from either [18F]DFAHA or [18F]FAHA. While [18F]FAHA exhibited 
moderate levels of radioactivity accumulation throughout the brain, including brain cortex, which 
is consistent with its higher substrate affinity to other HDAC classes, both [18F]DFAHA and, 
especially [18F]TFAHA, exhibited much lower accumulation in the cortex (Fig. 16). Logan  
graphical analysis of [18F]FAHA, [18F]DFAHA and [18F]TFAHA accumulation in cerebellum 
using cortex as the reference tissue demonstrated that [18F]TFAHA was more actively accumulated  
(had a steeper slope of the Logan plot) in the cerebellar nuclei than either [18F]FAHA or 
[18F]DFAHA (Fig. 17). Following PET/CT in vivo imaging with [18F]TFAHA, quantitative 
autoradiography (QAR) was performed in selected animals to verify the results at higher resolution 
of images. Fig. 18 demonstrates a high degree of correlation between the areas of 18F-TFAHA-
derived accumulation displayed by autoradiography and the PET images shown in Fig. 18. Higher 
levels of accumulation of [18F]TFAHA were observed using QAR in n. accumbens, hippocampus, 
periaqueductal grey, and in cerebellar nuclei. 
Furthermore, our preliminary imaging studies demonstrated the feasibility of PET/CT with 
[18F]TFAHA for monitoring pharmacologic inhibition of HDACs class IIa with SAHA. A 
significant inhibition of [18F]TFAHA-derived radioactivity accumulation in the brain was 
observed when SAHA (100 mg/kg) was administered i.p. 30 min prior to i.v. administration of 
[18F]TFAHA (Fig. 19). These results demonstrate that [18F]TFAHA is a much more selective and 
more efficient radiotracer for imaging expression-activity of HDAC class IIa enzymes in the brain, 
as compared to either [18F]DFAHA or [18F]FAHA.  
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In summary, current studies demonstrated that that [18F]TFAHA is a more selective and 
effective substrate-based radiotracer for non-invasive PET imaging of class IIa HDACs 
expression-activity in the brain. This novel PET imaging radiotracer can be readily translated into 
the clinic and may aid in the fundamental understanding of epigenetic regulation by HDACs class 
IIa involved in brain development and function, as well as in the mechanisms of different diseases, 
including traumatic brain injury and post-traumatic stress disorders, depression, drug addiction, 
Alzheimer’s, Huntington’s, brain tumors and other diseases of the brain. Furthermore, PET 
imaging with [18F]TFAHA should facilitate the development and clinical translation of novel 
HDACs class IIa selective inhibitors by enabling non-invasive quantification of their 
pharmacodynamics at the drug target level.  
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Figure 14. PET/CT images (A) of the spatial and temporal dynamics of influx, distribution, clearance and 
retention of each of the three radiotracers at different time intervals after intravenous administration: 
[18F]FAHA (top panel), [18F]DFAHA (middle panel), and [18F]TFAHA (bottom panel). In each panel, 
PET/CT images are provided in three different planes: top row - axial images through the middle of the 
brain; middle row – coronal images through the middle of the brain; bottom row – coronal images through 
the cerebellum area. Images are color-coded to range of standard uptake values (SUV) shown in the color 
bar and cross-normalized to facilitate direct comparison of radioactivity distribution. Corresponding time-
activity plots (B) of each radiotracer are provided on the right hand side for: cerebellum (blue diamonds), 
muscle (green triangles), cortex (red squares), and heart (grey crosshairs). 
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Materials and Methods: 
All reagents and solvents were purchased from Aldrich Chemical Co. (Milwaukee, WI), and 
used without further purification. Preparation of 6-amino-1-hexanoicanilide (Mukhopadhyay et 
al., 2006) was done following a previously published method (Mukhopadhyay U, 2006b). Thin layer 
chromatography (TLC) was performed on pre-coated Dynamic Absorbance F-254 (Norcross, 
Georgia) silica gel, aluminum backed, plates. 1H, 13C and 19F NMR spectra were recorded on 
Mercury and Varian 400 MHz spectrometers at Wayne State University.  High-resolution mass 
spectra (HRMS) were obtained from a Waters LCT Premier/XE mass spectrometer at the Lumigen 
Imaging Center in the Department of Chemistry at Wayne State University using electrospray 
ionization (ESI) technique.  High performance liquid chromatography (HPLC) was performed 
with an 1100 series pump from Agilent Technologies (Stuttgart, Germany), with a built-in UV 
detector operated at 254 nm and a radioactivity detector with a single channel analyzer model 
FC3200 (NaI/PMT) detector from Eckert and Ziegler Radiopharma, Inc. (Germany) with an 
Ascentis RP-Amide column (Supelco, 4.4x150mm) for analytical and quality control 
chromatography.  Semi-preparative HPLC was conducted on a Knauer  P4.1S pump 10ml/Ti, with 
a Azura UVD 2.1S Detector using Clarity Software (Berlin, Germany) pump with an Alltima C18 
(Fisher Scientific, 250x10mm) column with a UV detector at 254 nm and a radio detector model 
FC-3500 from Eckert and Ziegler AG (Berlin, Germany). 
Preparation of 6-(bromofluoroacetamido)-1-hexanoicanilide (2a): Bromofluoro acetic 
acid (530mg, 3.3 mmol) was added to a reaction flask with 0.9 equivalents of thionyl chloride (210 
μl, 2.9 mmol). The reaction was stirred for 4 hours at 60°C.  Subsequently, the reaction mixture 
was cooled to room temperature and a solution of compound 1 (280 mg, 1.37 mmol) in 12 mL of 
anhydrous dichloromethane was added and followed by trimethylamine (2 ml, 15 mmol). The 
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reaction was stirred under argon for 24 hours, after which, all of the solvent was evaporated and 
the compound was re-dissolved in dichloromethane and washed with aqueous saturated sodium 
bicarbonate solution. The organic layer was dried over sodium sulfate and evaporated.  Flash 
column chromatography was used for purification of the compound with a gradient of solvent from 
10% ethyl acetate in hexane to 50% ethyl acetate in hexane. Product 2a (25 mg) was obtained in a 
15% yield as an off-white solid.  
Diastereomer 1: 1H NMR (DMSO-d6) : 9.83 (s, 1H, NH), 8.62 (s, 1H, NH), 7.56 (d, 2H, 
aromatic, J = 8.11 Hz), 7.26 (t, 2H, aromatic, J = 7.30 Hz), 6.99 (t, 1H, aromatic, J = 7.30 Hz),   
7.03 (d, 1H, -CHFBr, Jgem = 49.45 Hz) 3.12 (q, 2H, CH2, J = 6.49 Hz), 2.27 (t, 2H, CH2, J = 7.34 
Hz), 1.57 (m, 2H, CH2), 1.46 (m, 2H, CH2), 1.28 (m, 2H, CH2). 
13C NMR (DMSO-d6) δ: 189.88, 
171.63, 164.66 (d, -C=O-CF, J = 22.13 Hz), 139.70, 128.97, 123.34, 119.58, 85.93 (d, -CHFBr, J 
= 262.46 Hz), 36.67, 28.89, 26.21, 25.13 ppm.  19F NMR (DMSO-d6) : -147.34 (d, J = 50.35 Hz), 
-143.52 (d, J = 48.83). HRMS (m / z): [M + H]+ calculated for C14H20FBrN2O2, 367.0445; found 
367.0433 (M+H).  
Diastereomer 2: 1H NMR (DMSO-d6) : 9.83 (s, 1H, NH), 8.62 (s, 1H, NH), 7.56 (d, 2H, 
aromatic, J = 8.11 Hz), 7.26 (t, 2H, aromatic, J = 7.30 Hz), 6.99 (t, 1H, aromatic, J = 7.30 Hz),   
7.03 6.74 (d, 1H, -CHFBr, Jgem = 49.45 Hz), 3.12 (q, 2H, CH2, J = 6.49 Hz), 2.27 (t, 2H, CH2, J = 
7.34 Hz), 1.57 (m, 2H, CH2), 1.46 (m, 2H, CH2), 1.28 (m, 2H, CH2). 
13C NMR (DMSO-d6) δ: 
189.88, 171.63, 164.66 (d, -C=O-CF, J = 22.13 Hz), 139.70, 128.97, 123.34, 119.58, 85.93 (d, -
CHFBr, J = 262.46 Hz), 36.67, 28.89, 26.21, 25.13 ppm.  19F NMR (DMSO-d6) : -147.34 (d, J = 
50.35 Hz), -143.52 (d, J = 48.83). HRMS (m / z): [M + H]+ calculated for C14H19FBrN2O2, 
367.0445; found 367.0433 (M+H).  
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Preparation of 6-(bromodifluoroacetamido)-1-hexanoicanilide (2b): Comound 1 (200 
mg, 0.97 mmol) was dissolved in dimethylformamide (7.0 mL) with two equivalents of 
diisopropylethylamine and stirred at 0 °C.  2-bromodifluoro acetyl chloride (0.2 mL, 2.2 mmol) 
was added drop-wise to the mixture. The mixture was subsequently stirred at 0 °C for 1 hour then 
warmed to room temperature and stirred for an additional 3 hours under argon. After evaporation 
of solvent, the compound was purified using flash column chromatography with a gradient of 10-
50% ethyl acetate/hexane as the eluent. Product 2b (150 mg) was obtained after evaporation as a 
white solid with 50% yield. 1H NMR (DMSO-d6) δ: 9.83 (s, 1H, NH), 9.17 (s, 1H, NH), 7.54 (d, 
2H, aromatic, J = 7.34 Hz), 7.34 (t, 2H, aromatic, J = 7.34 Hz), 6.99 (t, 1H, aromatic, J = 7.83 Hz), 
3.15 (q, 2H, CH2, J = 6.36 Hz), 2.27 (t, 2H, CH2, J = 7.34 Hz), 1.58 (m, 2H, CH2), 1.49 (m, 2H, 
CH2), 1.28 (m, 2H, CH2). 
13C NMR (DMSO-d6) δ: 171.42, 159.95 (t, -CO-CF2Br, J = 27.47 Hz), 
139.71, 129.03, 123.21, 119.33, 112.21 (t, -CF2Br, J = 315.10 Hz), 36.70, 28.58, 26.40, 25.21 ppm. 
19F NMR (DMSO-d6) δ: -60.07 (s). HRMS (m/z): [M +H]+ calculated for C14H17N2O2F2Br 
363.0520, found 363.0515. 
Preparation of 6-(difluoroacetamido)-1-hexanoicanilide (DFAHA 3a): Compound 1 
(200 mg, 0.97mmol) was stirred in difluoroacetic anhydride at room temperature until fully 
dissolved.  And then triethylamine (1 mL, 7.2 mmol) was added gradually until the pH of the 
solution reached a value close to 8. The reaction mixture stirred at room temperature overnight.  
The anhydride was removed under reduced pressure and the residue was purified by flash 
chromatography using 50% ethyl acetate in hexane.  Product 3a was obtained as a white powder 
in a 42% yield. 1H NMR (DMSO-d6) : 9.82 (s, 1H, NH), 8.75 (s, 1H, NH), 7.56 (d, 2H, aromatic, 
J = 7.83 Hz), 7.26 (t, 2H, aromatic, J = 7.34 Hz), 6.99 (t, 1H, aromatic, J = 7.34 Hz),   6.16 (t, 1H, 
-CHF2, Jgem = 53.8 Hz), 3.12 (q, 2H, CH2, J = 13.1, 6.7 Hz), 2.28 (t, 2H, CH2, J = 7.34 Hz), 1.57 
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(m, 2H, CH2), 1.46 (m, 2H, CH2), 1.27 (m, 2H, CH2). 
13C NMR (DMSO-d6) δ: 171.42, 162.48 (t, 
-CO-CF2, J = 24.41 Hz), 139.71, 129.03, 123.21, 119.33, 108.98 (t, -CHF2, J = 246.44 Hz), 36.83, 
28.74, 26.47, 25.18 ppm.  19F NMR (DMSO-d6) : -125.65 (d, J = 54.93 Hz). HRMS (m / z): [M 
+ H]+ calculated for C14H19F2N2O2, 307.1234; found 307.1226 (M+H).  
Preparation of 6-(trifluoroacetamido)-1-hexanoicanilide (TFAHA 3b): Compound 1 
(100 mg, 0.48 mmol) was dissolved in trifluoacetic anhydride (1.0 g, 4.76 mmol) and 2mL of 
dichloromethane at 0°C. The reaction mixture was stirred under argon for 20 min and then 2 hours 
at room temperature overnight. The solvent was evaporated and the crude compound was purified 
by flash column chromatography using 30% ethyl acetate in hexane. After evaporation of the 
solvent, the product 3b was obtained as white solid in 51 % yield. 1H NMR (DMSO-d6) : 9.83 (s, 
1H, NH), 9.4 (s, 1H, NH), 7.57 (d, 2H, aromatic, J = 8.8 Hz),   7.25 (t, 2H, aromatic, J = 7.83 Hz), 
6.99 (t, 1H, aromatic, J = 6.85 Hz ), 3.16 (q, 2H, CH2, J = 13.1 Hz, J = 6.7), 2.28 (t, 2H, CH2, J = 
7.5 Hz), 1.57 (m, 2H, CH2), 1.49 (m, 2H, CH2), 1.27 (m, 2H, CH2). 
13C NMR (DMSO-d6) δ: 
171.61, 156.51(q, -CO-CF3, J = 71.6, 35.86 Hz), 139.83, 129.18, 123.52, 119.42, 116.45 (q, -CF3, 
J = 576.6, 288.40 Hz), 36.69, 28.47, 26.30, 25.09 ppm. 19F NMR (DMSO-d6) : -74.32 (s). HRMS 
(m / z): [M + H]+ calculated for C14H18F3N2O2 , 303.1320; found 303.1312 (M+H). 
Radiosynthesis of 6-([18F]difluoroacetamido)-1-hexanoicanilide ([18F]DFAHA 4a): A 
solution of K[18F]/kryptofix in acetonitrile (1 ml) was received and transferred into a crimped V-
vial. The acetonitrile removed under a stream of argon at 105°C. A solution of 2a (6-7 mg) in dry 
acetonitrile (0.4 mL) was added to previously dried K18F/kryptofix and the mixture was heated at 
100°C for 20 minutes. The reaction was cooled and the mixture was passed through a silica gel 
cartridge (Alltech, 900 mg) and eluted with 30% methanol in dichloromethane (2.5 mL). After 
evaporation of the solvent under a stream of argon at 80°C, the mixture was re-dissolved in HPLC 
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solvent and purified by semi-preparative HPLC using 40% ACN/buffer solution. The compound 
eluted at 9.7 minutes. The solvent was evaporated under reduced pressure and the final product 
was re-dissolved in saline for animal injection.  The product purity and identity was confirmed by 
co-injection with an authentic non-radiolabeled (4a) using an analytical HPLC. The compound 
was obtained in 25% decay corrected yield, with > 95% purity, and specific activity of 60-70 
GBq/µmole. 
Radiosynthesis of 6-([18F]trifluoroacetamido)-1-hexanoicanilide ([18F]TFAHA 4b): A 
solution of kryptofix/ K[18F] in acetonitrile (1 ml) was received and transferred into a crimped V-
vial.  The acetonitrile removed under a stream of argon at 105°C. A solution of 2b (6-7 mg) in dry 
acetonitrile (0.4 mL) was added to previously dried K18F/kryptofix and the mixture was heated at 
100°C for 20 minutes. The mixture was heated and stirred at 110°C for 25 minutes.  The reaction 
was cooled and the mixture was passed through a silica gel cartridge (Alltech, 900 mg) and eluted 
with 30% methanol in dichloromethane (2.5 mL).  After evaporation of the solvent under a stream 
of argon at 80°C, the mixture was re-dissolved in HPLC solvent and purified by semi-preparative 
HPLC using 40% ACN/buffer solution. The compound was eluted at 20 minutes. The solvent was 
evaporated on a high vacuum pump and the desired product was re-dissolved in saline for animal 
injection. The solvent was evaporated under reduced pressure and the final product was re-
dissolved in saline for animal injection.  The product purity and identity was confirmed by co-
injection with an authentic non-radiolabeled (4b) using an analytical HPLC.  The product was 
obtained in a 22% decay corrected yield, with > 95% purity, and specific activity of 70-80 
GBq/µmole. 
In vitro HDAC enzyme affinity assay: In vitro enzyme assays were performed for a panel 
of Class I, II, III, and IV HDACs. 10 nmol solution of each test compound or 2 nmol of control 
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substrate 2A (BPS Bioscience, San Diego, CA) was incubated in 100 μl of the HDAC assay buffer 
(25 mM Tris-HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) in the presence or absence 
of 1μg/ 100 μl of different HDAC enzymes (BPS Bioscience, San Diego, CA) at 37°C for 60 min.  
The reaction was quenched by heating the assay at 95°C for 3 min. Subsequently, 25 ul of the 
reaction mixture was analyzed by analytical HPLC (Agilent, Santa Clara, CA) equipped with 
Econosil C18 column (Altech Associates, Deefield, IL) using a mobile phase: 50% acetonitrile / 
20 mM ammonium acetate, pH=8.5. Detection of reaction products was detected via UV detection 
at 240 nm. The area under the peak corresponding to hexanoic anilide reaction product were 
integrated and expressed as percent of the area under the peak of the parent compound and 
converted into mass (moles). The Kcat parameters were determined as described elsewhere 
(Leskovac, 2003) using software GraphPad Prism 4 (GraphPad Software, La Jolla, CA).  
In silico modeling: The crystal structures 1T69 and 2VQJ were used for the docking studies 
of HDAC8 and HDAC4 respectively. For HDAC8 the missing residues 1-13 and 85-90 were added 
using MODELLER (UCSF, San Francisco, CA) (Sali and Blundell, 1993). The residues 85-90 are 
involved in the formation of a loop that is in close proximity to the inhibitor binding region of 
HDAC8. Due to this potential importance, the loop formed by these MODELLER-added residues 
was further refined using Chimera (UCSF, San Francisco, CA) (Pettersen et al., 2004). The two 
crystal structures were hydrogenated using MolProbity software (Duke University, Durham, NC) 
(Chen et al., 2009). Docking calculations were performed using the FlexX algorithm (Rarey et al., 
1996) as implemented in the LeadIT software package (BioSolveIT GmbH, Germany) 
(BioSolveIT et al.). For both HDAC8 and HDAC4, native ligands in the crystal structure (namely 
SHH for HDAC8 and TFG for HDAC4) were used as reference ligands for the docking 
calculations. A grid volume that covered amino acids within 20Å from each reference ligand was 
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used. All the waters within the grid volume were taken as freely rotatable and displaceable. 
Pharmacophore rules based on the knowledge of ligand-receptor binding were used to guide the 
ligands towards the binding site. For both HDAC8 and HDAC4 docking was performed with the 
ligands AHA, FAHA, DFAHA, and TFAHA. Top 20 poses based on the docking score of each 
docking run were saved and the top 10 poses were used for binding affinity calculations using 
Hyde software (BioSolveIT GmbH, Germany) (Lange, 2010; Schneider et al., 2013).  
PET Imaging Procedures in Animals: All studies involving animals were performed under 
a protocol (A 6-13-13) approved by the Institutional Animal Care and Use Committee of Wayne 
State University. Sprague-Dawley rats (200-250 g, N=3) were anesthetized with 3% isoflurane in 
oxygen and maintained at 2% isoflurane in oxygen throughout the imaging studies. The body 
temperature was maintained using electronically-controlled heating pad (M2M Imaging, 
Cleveland, OH) set at 37oC. Anesthetized rats were placed in the microPET R4 scanner (Siemens, 
Knoxville, TN) in the supine position with the long axis of the animal parallel to the long axis of 
the scanner with the brain positioned in the center of the field of view. Each radiotracer (300-500 
µCi/animal) was administered in saline via the tail-vein injection in a total volume ≤1.25 ml.  
Dynamic PET images were obtained over 60 minutes, followed by 2 overlapping frames (5 min 
each) acquired to obtain a whole body images of radiotracer biodistribution in other organs and 
tissues. After PET imaging, the positioning bed with the affixed anesthetized animal was 
transferred to the Inveon SPECT/CT scanner (Siemens, Knoxville, TN) and CT images and 4 
overlapping frames (2 min each) were acquired covering the whole body using X-ray tube settings 
of 80 kV and 500  uA.  
Quantitative Autoradiography: After PET imaging (or at certain time point after 300-500 
µCi radiotracer injection i.v.), the animals were sacrificed, the brain was rapidly extracted, frozen, 
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and embedded in the mounting medium M1 (Shandon-Lipshaw, Pittsburg, PA). Serial 20 µm thick 
coronal sections of frozen brain tissue were obtained at -13°C using a cryomicrotome CM3050S 
(Leica, Germany). Tissue sections were thaw-mounted on poly-A lysine coated glass slides and 
heat-fixed for 5 min at 65°C on a slide warmer (Fischer Scientific, PA). For QAR, tissue sections 
were exposed to the phosphor plate (Fujifilm Life Science, Woodbridge, CT) along with set of 20 
µm autoradiographic standards of known 18F radioactivity concentration, freshly prepared using 
calf liver homogenate. Knowing the radioactivity concentration in standards, the injected dose, 
and optical densities of each reference standard, a standard curve was developed, based on which 
the autoradiographic images were converted to color-coded parametric images of percent injected 
dose/g tissue (%ID/g) and/or standard uptake values (SUV) using software MCID 7.0 (Interfocus 
Imaging Ltd., Cambridge, UK). 
Image Analysis and Quantification: PET images were reconstructed using ordered subset 
expectation–maximization (Guo et al.) method. PET image analysis was accomplished using the 
AMIDE software. Digital Rat Brain Atlas was used for alignment and identification of specific 
anatomical markers in the brain (Watson, 2006).  GraphPad Prism 6 (Graph Pad Software La Jolla, 
CA) and Excel 2010 (Microsoft, Redmond, WA) were used for image data analysis. Levels of 
accumulation of individual radiotracers in tissues were expressed as standard uptake values (SUV) 
that were calculated for the regions of interest (Ron S. Broide and Floyd E. Bloom) using the 
AMIDE software. The SUV is defined as the ratio of the tissue radioactivity concentration C (e.g. 
expressed as Bq/g tissue) at given time point post injection T, and the injected dose (e.g. in Bq, 
decay-corrected to the same time T), and normalized by the body weight in grams. Formulas for 
calculations for Logan plot analysis are provided in the supplemental materials (Logan J, 1996). 
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Supporting Information 
Quantification of dynamic PET imaging by multi-graphical analysis   
To locate the exact ROI’s the Rat Brain Atlas was referenced and the corresponding maps to 
PET images are shown in Fig. 15. While exact co-localization was difficult because the animal 
was not perfectly planar, these images show a very close representation of the sites for metabolite 
accumulation of the radiotracer.  While the primary ROI of this paper is the cerebellum, the other 
regions of specific uptake are quantified and shown in Fig. 16.  
We used the heart-derived blood time-activity curve 
(TAC) as an input function between 0 and 30 min, 
because a previous study showed that blood radioactivity 
 
BP=DVR-1
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during the first 30 min 
post-i.v. injection of 
[18F]FAHA is 
predominantly caused by 
the parent un-metabolized 
compound.  
The dynamic PET 
imaging data were 
analyzed using Logan 
graphical analysis (25) to 
determine whether 
[18F]TFAHA PET/CT 
imaging could have 
highest substrate affinity 
for HDAC 4 and 5. The 
ratio of integrated 
radioactivity 
concentration in ROIs 
over time normalized by 
the radioactivity concentration at a given time point in tumor radioactivity concentration was set 
as the y-axis. The ratio of integrated reference tissue radioactivity concentration over time 
normalized by tumor radioactivity concentration was set as the x-axis of a Logan plot. The cortex 
was used as reference tissue, because relatively it has low HDAC4 and 5 activity or expression in 
 
 
Figure 15. The corresponding map and brain image for co-
localization and ROI identification. 
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the brain. The slope of the 
linear portion of the Logan 
plot is the distribution 
volume ratio (DVR). The 
slope of the linear portion of 
the lot is calculated as (Eq. 
2). The binging potential 
(BP) can be calculated as Eq. 
3. For these calculations the 
target ROI used is the 
cerebellum. The y-intercept 
is denoted as C’ and used to 
accommodate for differences in the immediate tracer uptake by tissue. 
18F-FAHA has non-specific interactions to many other HDAC enzymes in the brain. 
Therefore, it shows a higher level of accumulation.  The specific interaction, however, is actually 
much higher for TFAHA and DFAHA because these have a very similar uptake but act on far 
fewer enzymes.  These conclusions are supported by the biochemical results showing that FAHA 
is a substrate for many of the HDAC enzymes in all four classes. The plot in Fig. 17 is the Logan 
plot given by Eq. 2 show the uptake for [18F]FAHA is very similar to that of [18F]DFAHA, while 
[18F]TFAHA uptake has a steeper slope and therefore higher levels of metabolite accumulation in 
the cerebellum. 
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Figure 16. The average calculated SUV quantification for each 
of the ROI’s and reference tissues for all three compounds. The 
error bars represent the standard deviation of the data. The stars 
indicate statistical significance obtained by two-way ANOVA 
with P < 0.01. 
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Following PET/CT in 
vivo imaging with 
[18F]TFAHA, quantitative 
autoradiography (QAR) was 
performed to verify the 
results at higher resolution. 
Fig. 18 demonstrates a high 
degree of correlation 
between the areas of 18F-
TFAHA-derived 
accumulation displayed by autoradiography and the PET images in Fig. 15. Higher levels of 
accumulation of [18F]TFAHA were observed in n. accumbens, hippocampus, periaqueductal grey, 
and cerebellar nuclei. 
Figure 18. Quantitative autoradiagraphy for 18F-TFAHA in the rat brain following in vivo i.v. 
injection of the radiotracer and PET imaging.  The rat brain atlas maps are shown with the images 
for co-registration. 
 
 
 
Figure 17. The Logan plot for the primary ROI, cerebellum, with 
the cortex used as a reference tissue. The stars represent statistical 
significance as determined by comparison of linear regression fit 
with a P < 0.01. 
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Furthermore, our preliminary imaging studies in a 
rat demonstrated the feasibility of PET/CT with 
[18F]TFAHA for monitoring pharmacologic inhibition of 
HDACs class IIa with SAHA. Significant inhibition of 
[18F]TFAHA-derived radioactivity accumulation in the 
brain was observed when SAHA (100 mg/kg) was 
administered i.p. 30 min prior to i.v. administration of 
[18F]TFAHA (Fig. 19). Additionally, we are currently 
conducting expanded studies in rats to determine the IC50 
values for SAHA for different regions of the brain. 
3b. Continuing work 
Due to the prevalence of HDACs 4 and 5 in the n. accumbens, hippocampus, amygdala, 
periaqueductal grey, and cerebellum in the brain and immunohistochemistry data suggesting that 
HDACs class IIa enzymes are overexpressed in cases of brain trauma and stress, the disease model 
proposed for study is post-traumatic stress disorder (PTSD) (Kwapis and Wood, 2014; Zovkic et 
al., 2013).  The rat model for PTSD has been well established by Dr. Perrine’s group using a 
method termed single-prolonged stress (SPS) (Eagle et al., 2013a; Eagle et al., 2013b; Knox et al., 
2010). In conjunction with Dr. Perrine’s group, the efficacy of 18F-TFAHA as an imaging agent 
for PTSD will be studied in rats. The aim is to understand the changes in relative expression of 
HDAC class IIa enzymes in the brain at varying time points after a traumatic event. Quantification 
of 18F-TFAHA-derived radioactivity accumulation in areas of the brain known to express high 
levels of HDAC class IIa (primarily HDACs 4, 5 and 9) will be used as a method for a non-
invasively monitoring changes enzymatic activity.  These PET/CT images will also be compared 
Figure 19. A normal rat imaged 
with 18F-TFAHA before (left) and 
after (right) 100mg/kg injection of 
HDAC inhibitor, SAHA.  
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against IHC stained sections from sacrificed animals at each time point (24hrs, 7d, 14d post SPS) 
to verify imaging results. Furthermore, autoradiography will be done on some of these animals to 
gain higher resolution images of the radioactivity distribution within the brain. These may also be 
done with dual labeling to allow for comparison between C14-C6H12O6 and 
18F-TFAHA 
distribution. Preliminary work in this project has demonstrated significant differences as compared 
to baseline in 18F-TFAHA-derived accumulation in areas of the brain known to have high HDAC 
class IIa expression-activity, especially at 24h post SPS. As this has evolved into a very large 
project due to promising results, the majority of the work will be presented in a separate PhD thesis 
of another student in BME.  
Additionally, HDACs class IIa has demonstrated promise for treatment of cancers, There are 
many HDAC targeted drugs (HDACs class I and II) currently in clinical or pre-clinical use for 
treatment of lymphomas and leukemias, in particular.  Recently, HDACs class IIa targeted 
inhibitors have also arisen and shown promise in preclinical work for inhibiting melanoma cell 
growth and proliferation (Venza et al., 2013). Furthermore, in identifying HDAC regulatory 
enzymes with upregulation in a very aggressive form of brain cancer, gliomas, HDACs 4 and 5 
demonstrated significant increase in expression via immunohistochemical (IHC) staining in patient 
derived tissues (Protein Data Bank). Therefore, PET imaging of glioma tumor models using 18F-
TFAHA as an HDACs class IIa-selective imaging agent may lead to furthering the understanding 
of HDAC-mediated epigenetic regulation in pathophysiology of disease.  
 18F-TFAHA has shown great promise as an imaging agent for detection of glioma cancer in 
the brain. In studies of both U87 and 9L rat glioma models clear detection of the tumor is 
differentiable from the rest of the brain and demonstrates significantly different uptake between 
structures in the brain and the tumor. This will be expanded upon in chapter 5. An example image 
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for 18F-TFAHA characterization in 9L an U87 tumor models are demonstrated below in Fig. 20-
21. Within the tumor images, large amounts of intratumoral heterogeneity is visible as 
demonstrated by the distribution of 18F-TFAHA-derived radioactivity within the areas of tumor 
tissue, i.e. areas of high and low expression activity of HDACs class IIa. Also, many differences 
in HDACs class IIa expression between 9L and U87 tumors, both in degree of expression as well 
as localization, are visible within these images. The localization and expression-activity of HDACs 
class IIa will be compared and contrasted with SIRT1 heterogeneity in chapter 5. In summary, 
HDACs class IIa are upregulated within tumor tissue as demonstrated by increases in 18F-TFAHA-
derived radioactivity accumulation as observed via in vivo PET/CT imaging. This finding provides 
a promising opportunity for identifying treatments to slow or reverse tumor progression in this 
aggressive form of cancer.  
 
Figure 20.  Dynamic PET/CT images using 18F-TFAHA in a 9L tumor-bearing rat, with 
PET/CT images overlaid on MR. These images demonstrate increased accumulation of 
the radiotracer in areas of the tumor lesions with relatively higher levels of HDAC activity. 
57 
 
  
  
 
Figure 21. Dynamic PET/CT images using 18F-TFAHA in a U87 tumor-bearing rat, with 
PET/CT images overlaid on MR. These images demonstrate increased accumulation of the 
radiotracer in areas of the tumor lesions with relatively higher levels of HDAC activity. 
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CHAPTER 4 DEVELOPMENT OF NOVEL PET IMAGING 
SUBSTRATES FOR SIRT2  
This work has been submitted as a provisional U.S. Patent.  
Towards the development of a novel radiotracer for quantitative imaging of SIRT2 
expression activity with PET, a focused library of potential substrates of SIRT2 has been 
synthesized with tert-butyloxycarbonyl-lysine-aminomethylcoumarin (Boc-Lys-AMC) backbone 
derivatized on the free amino terminus of lysine with a fluoroalkyl chain varying between 3 and 
16 carbons in length. Enzyme kinetic studies with recombinant SIRT2 demonstrated most efficient 
cleavage of the myristoyl group, followed by 12-fluorododecanoic and 10-fluorodecanoic groups 
(kcat/km equals 716.5 ± 72.8, 615.4 ± 50.5, 269.5 ± 52.1 s
-1M-1, respectively). Subsequently, an 
aminohexanoicanilide (AHA) backbone was derivatized with 12-bromo- and 12-iododecanoic 
groups to generate precursors for radiosynthesis of 12-[18F]fluorododecanoic 
aminohexanoicanilide (12-[18F]DDAHA). In vitro uptake studies demonstrated a three-fold higher 
accumulation of 12-[18F]DDAHA in U87 glioma cells with high SIRT2 activity, as compared to 
MiaPaCa, MDA-MB-231, and MCF10A cells with relatively lower SIRT2 activity. Non-invasive 
PET imaging with 12-[18F]DDAHA should enable in vivo studies of SIRT2-mediated epigenetic 
regulation in normal physiology and in different diseases, and to facilitate the development of 
novel SIRT2-targeted therapies. 
4a. A novel substrate radiotracer for molecular imaging of SIRT2 
expression and activity with positron emission tomography 
Robin E. Bonomi, Vadim Popov, Aleksandr Shavrin, Philip Alther, Nashaat Turkman, 
Thomas Mangner, Juri G. Gelovani 
Introduction 
SIRT2 is primarily localized in the cytoplasm, but can translocate into the nucleus (North 
and Verdin, 2007a) and deacetylase of cytoplasmic alpha-tubulin and nuclear H4K16 proteins, 
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thereby acting as a mitotic exit and cell cycle regulator (Hiratsuka et al., 2003; Inoue et al., 2007a; 
Inoue et al., 2007c; Inoue et al., 2009; North and Verdin, 2007a; North and Verdin, 2007b). Several 
studies have revealed important roles of SIRT2 in the pathogenesis of various diseases. SIRT2 can 
play a neuroprotective role in neuorodegenerative diseases, such as Parkinson’s, Alzheimer’s 
(Wang et al., 2013), and Huntington’s (Donmez and Outeiro, 2013). SIRT2 has been identified as 
having both cancer-promoting functions (i.e., through stabilization of Myc oncoproteins in breast 
cancer (Liu et al., 2013),(McGlynn et al., 2014)), as well as cancer suppressing functions (i.e., 
through tubulin regulation (Hiratsuka et al., 2003)). Therefore, SIRT2 has been identified as a 
potential drug target for treatment of various neurodengenerative and inflammatory diseases, and 
cancer. However, it is important to assess its activity during pharmacomodulation (i.e., activation 
or inhibition) due to pleiotropic roles of SIRT2 under normal and pathologic conditions. The 
development of non-invasive molecular imaging approaches for monitoring SIRT2 expression and 
activity in vivo using PET with SIRT2-selective substrate radiotracer may aid in the development 
of therapies targeting SIRT2.  
Understanding structure-activity relationships (SAR) of SIRT2 and its endogenous substrates 
is important for the development of SIRT2-specific substrate-type radiotracers. The best studied 
endogenous substrates of SIRT2 are acetyl-α-tubulin and acetyl-H4K16. SIRT2, similar to other 
SIRT isoforms namely 4, 5, and 6, is able to cleave larger moieties outside of the acetyl. In 
particular, it has been demonstrated that SIRT2 can cleave a myristoyl group from the myristoyl-
(K19 and K20)TNFα (Yao and Yang, 2011). 
To explore the efficiency with which SIRT2 cleaves larger leaving groups, a focused library 
of potential substrates was synthesized with tert-butyloxycarbonyl-lysine-aminomethylcoumarin 
(Boc-Lys-AMC) backbone derivatized on the free amino terminus of lysine with a fluoroalkyl 
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chain varying between 3 and 16 carbons in length. Additionally, the influence of fluorine 
substitution on the ω-carbon in the alkyl chain on substrate affinity and specificity for SIRT2 was 
evaluated as well. The library of compounds was studied using a fluorogenic enzyme assay with 
recombinant SIRT2 to determine trends in catalytic efficiency. Furthermore, the SAR of these 
compounds with SIRT2 was investigated using in silico modeling to better understand the 
observed trends (Fig. 22). Based on these studies, the lead compound, the Boc-Lys(12-
fluorododecanoyl)-AMC, was identified and its analogue with an aminohexanoicanilide (AHA) 
backbone was synthesized (12-fluorododecanoic-AHA; 12-FDDAHA). The AHA backbone has 
been used previously to generate effective HDAC class IIa specific radiotracers: [18F]FAHA and 
[18F]TFAHA(Bonomi et al., 2015; Yeh et al., 2013a)a,19b. Additionally, the radiolabeled analogue 
Figure 22. The structure of SIRT2 docked with the Boc-Lys(12F-dodecanoyl)-AMC and NAD+ 
adapted from crystal structure 4RMG. The SIRT2 sites of phosphorylation and binding highlighted 
on the residue chart. The SIRT2 client proteins are also listed in the table and the mechanism for 
NAD-dependent SIRT2 mediated cleavage of long acyl chains is depicted here.  
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of the lead compound, 12-[18F]DDAHA, was synthesized from 12-iodododecanoic and 12-
bromododecanoic precursors. Finally, the uptake of 12-[18F]DDAHA was studied in vitro to 
determine the magnitude of radiotracer accumulation in cells with high versus low SIRT2 
expression.  
Results: 
The library of compounds with terminally fluorinated acyl chains was synthesized through 
traditional coupling methods of the fluorinated carboxylic acid chain with the lysine amino 
derivative via in-situ formation of an acetyl chloride in moderate yields of 20-55%. Synthesis of 
the fluorinated carboxylic acid chains employed a novel approach: diethylaminosulfur trifluoride 
was used for non-selective fluorination of the n-hydroxycarboxylic acid forming the acetyl fluoride 
and fluorination of the terminal carbon. Selective hydrolysis of the acetyl fluoride was achieved 
using flash chromatography over silica gel to form a mono-ω-fluorinated chain due to the abrupt 
change in pH. The 
purity of final 
compounds in the 
Figure 23. The focused library of compounds synthesized with 
fluroalkyl chain derivatized lysines. A) The backbone used tert-
butyloxycarbonyl-L-lysine-7-amino-3-methylcoumarin (Boc-Lys-
AMC) was coupled to fluoroalkyl chains, varying in length from 3 
carbons to 16 carbons using acetyl chloride coupling.  
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library was >95%, as determined by 1H-NMR, 13C-NMR, 19F-NMR, and HRMS (Fig. 23).  
Compound 11 was synthesized from Cbz-Lys-OH (Bachem) and Boc-Lys-AMC (Bachem), 
which was derivatized to Boc-Lys(myr)-AMC. Following myristoylation, the Boc protecting 
group was removed and the resulting free lysine amino terminus was coupled with the Cbz-Lys-
OH group. The four-step synthesis yielded 11 in a yield of 12% with >95% purity as determined 
by 1H NMR, 13C NMR, and HRMS (Fig. 24).  
Results from in vitro characterization of this library of compounds using fluorogenic assay 
demonstrated a positive correlation between the substrate efficiency for SIRT2 and the increasing 
length of the leaving alkyl chain. Compound 9 containing the myristoyl group was the most 
efficient substrate of SIRT2 with Kcat/Km = 715.6±72.8 s
-1M-1followed by compound 8 
(fluorododecanoyl) and compound 7 (fluorodecanoyl) with Kcat/Km of 615.4±50.5 s
-1M-1 and 
269.5±52.1 s-1M-1, respectively. In contrast, compound 10 containing the fluoropalmitoyl leaving 
Figure 24. To experimentally determine the effect of the cap on the selectivity of 
a substrate for SIRT2 we developed a di-lysine substrate, with a more peptidic 
backbone, Cbz-lys-lys(myr)-AMC (11). This allows for head to head comparison 
between the Boc-lys(myr)-AMC (9). 
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group exhibited a significant decrease in substrate efficiency for SIRT2 (30.4±7.3 s-1M-1), as 
compared to compounds containing shorter fluoroalkyl chains. The reference substrate, p53(379-
382)K382ac-AMC (BPS1) exhibited Kcat/Km = 275±42 s
-1M-1 (Fig. 25). 
To assess the influence of a “cap” modification on SIRT2 selectivity, compounds 4, 5 and 7 
were evaluated against a panel of recombinant sirtuins (SIRT1-7). 7 was cleaved efficiently by 
 
Fig. 25.  Biochemical assay data from fluorogenic (Fluor de Lys®) assay. A) The catalytic 
efficiency (kcat/km) for SIRT2 against different length fluoroalkyl chain leaving groups to assess 
the structure activity relationship between these compounds and SIRT2.  The error bars represent 
the standard deviation of N=6 experiments. B) The table details the effect on km (amount of 
substrate necessary for half of vmax), vmax (the maximal turnover velocity for a given substrate in 
SIRT2), and kcat (the catalytic efficiency for a given substrate with SIRT2).  
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Boc-Lys(3F-propanoyl)-AMC (5) 53.53 11.44 0.15 0.016 1.41E-03 5.00E-04 26.3 5.07
Boc-Lys(6F-hexanoyl)-AMC  (6) 44.89 4.56 0.28 0.013 2.58E-03 4.11E-04 57.4 5.22
Boc-Lys(10F-decanoyl)-AMC (7) 18.03 4.07 0.52 0.041 4.86E-03 1.29E-03 269.5 52.2
Boc-Lys(12F-dodecanoyl)-AMC (8) 8.07 0.79 0.54 0.014 4.97E-03 4.25E-04 615.4 50.5
Boc-Lys(myristoyl)-AMC (9) 2.36 0.22 0.26 0.010 2.38E-03 3.03E-04 716.5 72.9
Boc-Lys(fluoropalmitoyl)-AMC (10) 51.15 6.91 0.33 0.022 3.09E-03 6.83E-04 60.4 7.31
Cbz-Lys-Lys(myr)-AMC (11) 10.36 1.30 0.60 0.022 5.51E-03 6.88E-04 532.3 56.2
BPS1 31.73 5.57 0.95 0.022 8.78E-03 6.98E-04 275.0 42.6
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SIRT2, SIRT3 and, to a lesser 
extent, by SIRT6. In contrast, 8 
and 9 were cleaved efficiently 
only by SIRT2 (Fig. 26). To 
validate the catalytic efficiency 
of SIRT2 with 8, a competitive 
inhibition assay with AGK2 
was performed, which yielded 
an IC50 of 28.21µM (Fig. 27).    
In silico modeling studies 
demonstrated that positioning 
of compounds 8 and 9 in the SIRT2 active site resulted in a smaller distance between the carbonyl 
carbon and the nicotinamide-ribose ester linkage (Fig. 28). This may contribute to enhanced 
substrate efficiency of these compounds. 
12-fluorododecanoyl-AHA (12-FDDAHA) and 12-[18F]-dodecanoylAHA (12-
[18F]DDAHA) were synthesized as non-
radiolabeled and radiolabeled analogues of 
8 (Fig. 29-30). The initial radio-synthesis 
of 12-[18F]DDAHA (15) was performed 
using a brominated precursor, 12Br-
DDAHA (13), however due to low 
radiochemical yield, the iodinated 
precursor, 12I-DDAHA (14), was used for 
Figure 27. Boc-Lys(12F-dodecanoyl)-AMC (8) 
was used to experimentally determine the IC50 
value for a known inhibitor AGK2.  
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Figure 26. Compound 11 is not selective for SIRT2 whereas 
compounds 8 and 9 are selective for SIRT2. These results 
were taken from 40-minute incubation of substrate with 
enzyme. The error bars represent the standard deviations of 
the means with significance of P<0.05 denoted by *, as 
determined by two-way ANOVA.  
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optimization of the radiolabeling procedure and improve radio-synthetic yield. The iodinated 
precursor (14) was synthesized from the brominated precursor in a high yield of 73% using 
literature procedure(Belanger et al., 2011). The radiochemical yield achieved with precursor 14 
was 5-fold higher than that with precursor 13. The highest radiofluorination yields were achieved 
using precursor 14 in acetonitrile at 85-90°C. 12-[18F]DDAHA was obtained with purity of >95% 
 
 
Figure 28. A) The 2D representation of the interactions between SIRT2 and the substrate, Boc-
Lys(12F-dodecanyl)-AMC. The 12-fluoro dodecanyl leaving group has similar interactions to 
those in literature, evidence that the leaving group is fitting in the correct position. B) The table 
of results from our compound docking study. The compound name, MW, docking score (where 
more negative is a better fit), and most importantly, the distance between the 1’ postion of the 
ADP ring and the carbonyl of the leaving group. This distance is also shown after the 1.7Å 
correction for catalytic conformational change.  
 
A 
 
B 
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(Fig. 30) and a decay corrected radiochemical 
yield of 12% (total preparation time: 66 min) 
with specific activity of 259 Gbq/mmol.  
The level of uptake of 12-[18F]DDAHA 
in cell cultures after 30 minutes of incubation 
in vitro was significantly above the cells-to-
culture medium equilibrium and was 3-fold 
higher in U87-NesTG cells, expressing higher 
levels of SIRT2, as compared to MiaPaCa, 
MDA231, MCF10A, expressing relatively lower levels of SIRT2 (Fig. 31).  
Discussion 
 
Figure 29. A)  The backbone used for 
enzymatic in vitro biochemical assays- Boc-
Lys-AMC.  B) The backbone developed for 
improved systemic viability of a small 
molecule radiotracer. 
 
 
Figure 30. A) The synthesis of both the cold (non-radiolabeled) analogue (13) and B) 
precursors for 12-[18F]DDAHA, 12-BrDDAHA (13) and 12-IDDAHA (14). The 12-
[18F]DDAHA (15) radiotracer was synthesized from the iodinated precursor and the in dry 
acetonitrile in 85°C for 15 minutes. 
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Understanding structure-activity relationships of SIRT2 with various natural and synthetic 
substrates to develop novel 
18F-labeled radiotracers for 
quantitative molecular 
imaging of SIRT2 expression 
and activity, it is important to. 
Previously it has been reported 
that in addition to an acetyl 
group, SIRT2 can also cleave 
long acyl chains from lysine 
residues, including a myristoyl 
moiety (He et al., 2014). Other 
HDAC class III enzymes, such 
as SIRT3 and SIRT6, have also been reported to cleave a myristoylated lysines of the H3K9 
peptide (Feldman et al., 2013; Feldman et al., 2015) and K19-20TNF-α (He et al., 2014). However, 
there are no data on the effects of fluorine substitution on the ω-carbon in alkyl chains on different 
lengths on SIRT2 catalytic efficiency.  
Our current studies demonstrated that the catalytic efficiency of SIRT2 gradually increases 
with the elongation of fluoroalkyl chain from 3 to 12 carbons. The catalytic efficiency of SIRT2 
for fluorododecanoyl chain (Kcat/Km = 615.4±50.5 s
-1M-1) is comparable (difference is not 
statistically significant) with that of the non-fluorinated myristoyl chain (reference compound), 
which is cleaved most efficiently (Kcat/Km = 716.5±72.8 s
-1M-1). In contrast, the catalytic efficiency 
of SIRT2 was significantly lower for the fluoropalmitoyl group (Kcat/Km = 60.4±7.3 s
-1M-1) (Fig. 
 
Figure 31. The quality control chromatogram of the 12-
[18F]DDAHA (15) radiotracer as analyzed by HPLC 
demonstrates high radiochemical purity and very small 
amount of UV impurities. A) The UV non-radiolabeled 
standard chromatogram (12) B) The radio-HPLC 
chromatogram for the labeled 12-[18F]DDAHA, (15). 
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25). These observations are in agreement with previous reports, demonstrating a similar trend in 
SIRT2 catalytic efficiency for the H3K9 peptide backbone derivatized with hexanoyl, octanoyl, 
decanoyl, dodecanoyl, and myristoyl groups, but significantly less efficiently the palmitoyl and 
lipoyl-derivatized H3K9 peptide (Feldman et al., 2013; Feldman et al., 2015). Similarly, using 
TNF-α peptide backbone with varying chain lengths to a fluorophore or quencher moiety the 
longer chain length (11 carbons) resulted in much improved catalytic efficiency over the shorter 
(6 or 8 carbons) or very long (13 carbons) chain lengths(Schuster et al., 2016).  However, despite 
the similarities in trends, the absolute Kcat/Km values obtained in the current study for different 
alkyl chains with Boc-Lys-AMC backbone 
are significantly lower than those reported 
previously using a H3K9 or TNF-α peptide 
(Feldman et al., 2013; Feldman et al., 2015; 
Schuster et al., 2016), which can be 
explained, at least in part, by the higher 
efficiency of a peptide “cap” group, as 
compared to Boc-Lys-AMC. Similarly, 
reports of a “cap” group containing either 
p53 or TNF-α peptide residues on one side 
and an AMC group on the other 
demonstrate reduced Kcat/Km as compared 
to compounds with a full peptide cap (Chiang and Lin, 2016; Feldman et al., 2015; Schuster et al., 
2016). Also, the observed differences may be due to the presence of electronegative ω–terminal 
fluorine. In the current study, the Kcat/Km values were determined by measuring the rate of the 
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Figure 32. The radiotracer 12-[18F]DDAHA (15) 
was used in cellular uptake studies for four tumor 
cell lines. The error bars represent the standard 
deviation for N=4 for each cell line. Where **** 
represents P<0.05 as determined by One-Way 
ANOVA and Tukey’s multiple comparisons test 
this value is significantly larger than the other 
three values. 
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AMC cleavage product formation, whereas in some of the previously reported data Kcat/Km values 
were determined by measuring the rate of NAD+ consumption, which may also explain the 
differences in absolute Kcat/Km values between studies. 
Furthermore, results of current in silico modeling studies demonstrate that the distance 
between the carbonyl-carbon to the ADPR-nicotinamide ester linkage is smaller for longer chain 
leaving groups, such as the fluorododecanoyl derivatized Boc-Lys-AMC and AHA backbones 
(Fig. 29). These in silico docking studies were conducted using currently available crystal 
structures of SIRT2, which depict the enzyme in either the “closed” or “open” confirmation (i.e. 
before or after enzymatic reaction with a substrate). Because there are no crystal structures 
available for SIRT2 in the transition state with bound NAD+, we chose the structure of SIRT2 co-
crystallized with SirReal2 (SIRT2 inhibitor) and NAD+(Rumpf et al., 2015) (PDB: 4RMG). This 
crystal structure with full NAD+ intact, rather than post cleavage with only ADPR present (Moniot 
et al., 2013), is indicative of an enzyme in the open confirmation when a substrate initially docks 
inside the enzyme active site. This step is especially important for the SIRT enzymes, as the close 
proximity and accurate positioning between nicotinamide and the substrate carbonyl moiety is 
crucial for the reaction to occur. The root mean square deviation (r.m.s.d) for the central carbon 
during the transition from the “open” to “closed” conformation has been characterized in the 
literature (Rumpf et al., 2015), allowing estimation of the changes in key interaction distances. 
The r.m.s.d of the open versus closed configuration is about 1.7Å in PDB 4RMG. Using this 
correction factor, the distances between a leaving group carbonyl and a nicotinamide of NAD+ 
ring fall into an acceptable range for reaction to occur. Other studies have explored the structural 
activity in 5 ns molecular dynamic simulations and noted similar findings for the structural changes 
in the SIRT2 active site (Sakkiah et al., 2013). Therefore, we hypothesize that the distance between 
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the amide bond carbonyl carbon and the nicotinamide cleavage site of NAD+ plays an important 
role in substrate catalytic efficiency of SIRT enzymes. The mechanism of SIRT2 mediated 
cleavage of acylated lysine moieties involves simultaneous cleavage of nicotinamide and 
activation and subsequent cleavage of the acyl carbonyl carbon amide bond. Therefore, the 
selection of site for with substitution fluorine atom (strongly electronegative and electron 
withdrawing) is crucial for preservation of catalytic activity of SIRT2. For example, if a fluorine 
atom (or another electron withdrawing group) were to be placed in close proximity to the α-carbon, 
catalytic efficiency would decrease, as reported by us previously for fluro- and trifluoro-
acetamidohexanoicanilide (Bonomi et al., 2015; Yeh et al., 2013a).  
To examine the selectivity of compounds for SIRT2 among all SIRT enzymes, three of the 
most efficient substrates, 8, 9, and 11 were screened against a panel of recombinant SIRT enzymes 
(SIRT 1-7). The aim was to elucidate the differences in SIRT selectivity that may occur as a result 
of altering the cap (mono- vs. di-lysine cap), the leaving group (12- vs 14-carbon chain) and last 
the terminal fluorine atom (12F-carbon vs 14-carbon). Our results indicate that compound 11, with 
a di-lysine cap, was cleaved more effectively by SIRT3 and SIRT6 than compound 5, with a mono-
lysine cap. Therefore, 9 is more selective to SIRT2 as it shows very little cleavage by other SIRT 
enzymes. Both 8 (12F-carbon chain) and 9 (14-carbon chain) are cleaved effectively by SIRT2 
and not by any other SIRT enzymes, indicating that both leaving groups are selective for SIRT2. 
These findings are consistent with other reports in the literature (Feldman et al., 2013; He et al., 
2014; Pan et al., 2011b) and demonstrate that leaving group specificity may not entirely define the 
selectivity of a substrate to a certain SIRT enzyme. Altering the cap group can have a significant 
impact on the efficiency with which the SIRT enzyme cleaves a substrate.  
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Also, we assessed the effectiveness of the lead substrate 8 against a potent selective SIRT2 
inhibitor AGK2 (Cui et al., 2014). A competitive inhibition study (Cui et al., 2014) was performed 
using increasing concentrations of AGK2 with 8 at its apparent km concentration (8 µM) for SIRT2. 
The observed inhibition of SIRT2 by AGK2 at IC50 of 28.21 μM (Fig. 27) using 8 as substrate was 
comparable to previously reported IC50 values of 3-5 µM obtained with myristoylated or acetylated 
substrates of SIRT2(Hoffmann et al., 2014; Lain et al., 2008). As demonstrated by the comparable 
catalytic efficiencies of 8 and BPS1 (p53 (379-382)K382ac-AMC) this data further confirm that 8 
is an efficient substrate of SIRT2. 
Based on the results of biochemical and in silico modeling studies, we have chosen the 
dodecanoyl chain fluorinated on the ω-position for coupling to an AHA backbone to generate the 
SIRT2-specific 18F-labeled radiotracer termed 12-[18F]DDAHA. We did not study the 14-
fluoromyristoyl-Boc-Lys-AMC and 14-[18F]fluoromyristoyl-AHA, because Boc-Lys(12-
fluorododecanoyl)-AMC exhibits 2/3 efficiency of Boc-Lys(myristoyl)-AMC as selective 
substrate for SIRT2, and because radiotracers with smaller molecular weight have 
pharmacokinetic advantages over radiotracers with larger molecular weight. Nevertheless, the 
synthesis and evaluation of these compounds are currently underway and will be reported 
separately. For synthesis of 12-[18F]DDAHA, we adapted methods for radiolabeling of ω-
[18F]substituted long chain fatty acids (Belanger et al., 2011), that are used for PET imaging of 
cardiac metabolism (Pandey et al., 2012) (Fig. 30-31). Our studies confirmed previous reports that 
ω-iodinated dodecanoyl precursor provides a 3-fold higher radiosynthetic yield than the ω-
brominated precursor (Belanger et al., 2011). The radiosynthetic yield for 12-[18F]DDAHA could 
be optimized further by using microwave assisted heating (Belanger et al., 2011).  
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The mechanism of substrate cleavage by SIRT enzymes allows for a radioactive leaving 
group to be transiently entrapped in the cell in a similar manner to other radiotracers such as 18F-
FDG and 18F-FLT, by converting or coupling a tracer into a more polar molecule. In this case, an 
ester linkage between a leaving group and O-ADPR (Fig. 22) forms, thereby preventing the 
leaving group from crossing a cell membrane because 18F-fluoroalkyl-O-ADPR is quite large and 
polar. Therefore, SIRT2-mediated cleavage of 18F-fluoroalkyl group from 12-[18F]DDAHA with 
formation of 18F-fluoroalkyl-O-ADPR complex represents the rate-limiting step in the cellular 
entrapment of 12-[18F]DDAHA-derived radioactivity. The removal of the acetyl or longer acyl 
chain moieties from O-ADPR group has been hypothesized to occur by way of ARH3 cleavage or 
possible methanolysis to form 1’O-methyl’ADPR (Fahie et al., 2009; Mashimo et al., 2014). 
Additionally, a nucleophilic attack from lysine side chains of other proteins in close proximity may 
also de-acetylate the O-AADPR. Further studies are needed to fully characterize the half-life of O-
12-[18F]DD-ADPR and residence time for the 12-[18F]dodecanoyl moiety within the cell. Although 
this entrapment may be transient, it should provide a long enough residence time within the cell 
for adequate PET imaging and quantification of SIRT2 expression-activity product.  
In vitro radiotracer uptake studies in cell lines with varying degrees of SIRT2 expression 
provided initial evidence for the efficacy of 12-[18F]DDAHA as a radiotracer for quantification of 
SIRT2 expression-activity. The level of 12-[18F]DDAHA derived radioactivity accumulation was 
increased three fold in U87 glioma cells over other cells with relatively lower SIRT2 expression 
(i.e. MiaPaCa, MDA-MB-231, and MCF10A) (Fig. 32). Previous studies demonstrated 
downregulation of SIRT2 expression in about 70% of gliomas (Hiratsuka et al., 2003; Inoue et al., 
2007b). In contrast, more recent studies demonstrated that the labeling index of nuclear-localized 
SIRT2 is significantly higher in glioblastomas (grade IV), as compared to astrocytomas (grade II) 
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and normal brain tissue and strongly correlated with malignant progression and the overall survival 
of patients with glioblastomas (Imaoka et al., 2012). The immunohistochemical staining of many 
tissues in the Human Protein Atlas displays intense staining of SIRT2 protein in all glioma tissues 
with greater magnitude than in breast or pancreatic cancer patient derived tissue samples 
(http://www.proteinatlas.org/search/sirt2). Higher levels of expression and higher labeling index 
for SIRT2 is also associated with progression and poor prognosis in patients with non-small cell 
lung cancer (NSCLC) (Grbesa et al., 2015) and cervical carcinoma(Singh et al., 2015). Some 
tumors (i.e., melanomas), may harbor mutations in SIRT2 gene resulting in reduction of enzymatic 
activity by 80–90% compared to the wild-type protein, however consequences to tumor 
progression and overall prognosis are yet unknown (Lennerz et al., 2005). Therefore, molecular 
imaging with PET using SIRT2-specific radiotracers should provide information about the location 
and magnitude of SIRT2 expression and activity in tumors non-invasively and in real time. This 
may help to determine the mechanistic, therapeutic, and prognostic roles of SIRT2 in different 
cancers. Also, SIRT2 is an emerging target for therapy of various neurologic diseases, including 
neurodegeneration (Donmez and Outeiro, 2013), as well as cardiac (Matsushima and Sadoshima, 
2015) and metabolic diseases (Houtkooper et al., 2012; Matsushima and Sadoshima, 2015).  
The translation of 12-[18F]DDAHA to in vivo PET imaging may further the field of 
epigenetic regulation in both norm and disease and facilitate development and clinical translation 
of SIRT2-targeted drugs. PET imaging with a substrate type radiotracer such as 12-[18F]DDAHA, 
will allow for in vivo visualization and quantification of the enzyme expression-activity product. 
Accumulation of 12-[18F]DDAHA-derived radioactivity is directly proportional to the amount of 
active enzyme in a tissue. The current approach to imaging SIRT2 activity using substrate-type 
radiotracers complements other methodologies for PET imaging of enzymes, including 
74 
 
radiolabeled inhibitors. PET imaging with radiolabeled enzyme inhibitors is essentially similar to 
a receptor-ligand based imaging approach, where the amount of radiotracer-derived radioactivity 
accumulation is proportional to the amount of free (unoccupied) receptor or enzyme in a given 
tissue (J, 2000). Visualization of receptor or enzyme occupancy is especially important for 
determining the pharmacokinetics and bio-distribution of an inhibitor (i.e. drug or therapeutic 
agent). Successful inhibitor-type radiotracers have been developed specifically for HDAC class I, 
in the form of 11C-Martinostat (Kim et al., 2013; Reid et al., 2009a; Wey et al., 2015). However, 
imaging with an inhibitor does not provide information about the enzyme activity. In contrast, 
substrate-type radiotracers allow for assessment of the enzyme expression-activity and monitoring 
the pharmacodynamics of inhibitor at the target (enzyme) level.  
Although several previous studies have reported significant defluorination of ω-
[18F]substituted fatty acids in rodents following intravenous injection (Pandey et al., 2012), it 
occurs at a much lower magnitude in higher mammals (i.e. pigs and dogs) and in humans, due to 
a decrease in level of expression of defluorinating enzymes (Pandey et al., 2012). The AHA 
backbone was selected based on our previous success with the development of HDAC class IIa 
specific radiotracers 18F-FAHA and 18F-TFAHA(Bonomi et al., 2015; Yeh et al., 2013a) and 
because the use of peptide-based backbones will prevent (or significantly reduce) the ability of 
radiotracers to cross cellular membranes by non-facilitated diffusion. Although it is still possible 
that 12-[18F]DDAHA may exhibit unacceptable levels of defluorination in vivo, an alternative site 
for radiofluorination may be explored in the ω-3 position of dodecanoyl chain. Alternatively, 
carbon-11 labeling of the dodecanoyl chain could be accomplished similar to 11C-palmitate (Mock 
et al., 2011; Runkle et al., 2011).  
Conclusions 
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In summary, guided by the results of biochemical and in silico modeling studies of structure-
activity relationships between SIRT2 and a non-peptide type lysine mimicking substrate backbone 
derivatized with fluoroalkyl chains of different length, we have developed and validated in vitro a 
novel SIRT2-selective substrate-type radiotracer termed 12-[18F]DDAHA.  12-[18F]DDAHA is 
suitable for assessment of SIRT2 expression-activity using in vitro radiotracer uptake assays in 
cell cultures and potentially for in vivo PET imaging of SIRT2 expression-activity in normal and/or 
diseased organs and tissues. Molecular imaging with PET using SIRT2-specific radiotracers, such 
as 12-[18F]DDAHA, should provide information about the location and magnitude of SIRT2 
expression and activity in tumors non-invasively and in real time, which should help to determine 
the mechanistic, therapeutic, and prognostic roles of SIRT2 in different diseases. 
Experimental Methods 
All solvents were purchased from Sigma-Aldrich Chemicals (Milwaukee, WI) and used 
without further purification. Boc-Lys(Ac)-AMC and Cbz-Lys-OH were purchased from Bachem 
(Bubendorf, Switzerland) and used without further purification. Preparation of 6-amino-1-
hexanoicanilide (Mukhopadhyay et al., 2006) was synthesized using a previously published 
procedure (Mukhopadhyay U, 2006b). Thin layer chromatography (TLC) was performed on pre-
coated Dynamic Absorbance F-254 silica gel, aluminum backed plates (Norcross, Georgia); flash 
chromatography was performed using silica gel pore size 60 Å, 230-400 mesh particle size  
(Sigma-Aldrich, Milwaukee, WI). 
NMR spectra including 1H, 13C and 19F were performed on Mercury 400 MHz, Varian 500 
MHz or Agilent 600 MHz spectrometers. High-resolution mass spectra (HRMS) were obtained 
using Waters LCT Premier/XE spectrometer (Milford, MA) with an electrospray ionization (ESI) 
technique. The analytical high performance liquid chromatography (HPLC) system included: 
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Ascentis RP-Amide 4.4x150 mm column (Supelco, Bellefonte, PA) connected to the 1100 series 
pump and UV detector (Agilent Technologies, Stuttgart, Germany), operated at 254 nm, and a 
radioactivity detector FC3200 (Eckert and Ziegler Radiopharma, Inc, Berlin, Germany). The semi-
preparative HPLC system included: the Alltima 250x10mm C18 column (Fisher Scientific, 
Waltham, MA) connected to the P4.1S pump, Azura 2.1S UV detector (Knauer, Berlin, Germany), 
operated at 254 nm, and a radioactivity detector FC-3500 (Eckert and Ziegler Radiopharma, Inc, 
Berlin, Germany).  
SIRT Enzyme Assay: Recombinant SIRT1-7 enzymes and BPS1 reference substrate for 
SIRT2, an oligopeptide corresponding to 379-382 of p53 (Arg-His-Lys-Lys(Ac)-AMC) 
(Huhtiniemi et al., 2011; Marcotte et al., 2004) were purchased from BPS Bioscience (San Diego, 
CA). 10 mM solutions of all newly synthesized compounds were prepared in pure DMSO and then 
diluted to 100 μM aliquots in DMSO for further use. Enzyme assay reactions were performed in 
black, low binding 96-well microtiter plates (Nagle Nunc International, Rochester, NY). End point 
assays were performed by incubation of the appropriate substrate, NAD, a SIRT enzyme, and 
inhibitor (if applicable) in enzyme assay buffer (50 μL final volume). Control wells without 
enzyme were included in each plate. After 40 min at 37 °C, a developer mixture (50 μL) containing 
nicotinamide (2 mM) and trypsin (0.4 mg mL−1) was added, and the mixtures incubated for 30 min 
at 22°C. The intensity of cleaved 7-amino-4-methylcoumarin (AMC) fluorescence was measured 
using Synergy H1 microplate reader (Biotek, Winooski, VT) at 360 nm excitation and 450 nm 
emission wave lengths. Experiments for determination of enzyme kinetic parameters were 
performed by incubation of test compounds or BPS1 reference substrate at different concentrations 
with NAD+ and individual SIRT enzymes in an assay buffer (100 μL final volume) at 37°C for 
different periods of time (5, 10, 20, 30, and 60 min), followed by in situ fluorophore cleavage by 
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addition of a developer mixture (50 μL) containing nicotinamide (2 mM) and trypsin (0.4 mg 
mL−1). Fluorescence was measured as relative fluorescence units (RFU) at 22°C to determine the 
initial linear rate V0 (RFU min
−1) for each concentration. The data were analyzed using GraphPad 
Prism v6.02 (GraphPad, La Jolla, CA) to afford km (μM) and Vmax (RFU min−1) values. The kcat 
values were calculated based on the RFU vs AMC concentration standard curve and the enzyme 
purities and concentrations provided by the manufacturer. 
Computational Docking Studies: Schrodinger Suite (New York, NY) with the Glide(Zhu 
et al., 2014) docking program was used for simulating ligand-protein interactions in silico. The 
ligands were prepared using LigPrep (Sastry et al., 2013) in Maestro v10.3 and the lowest 5 energy 
states were used for covalent docking interactions. Epik was used to generate the tautomeric states 
and choosing the lowest Epic (Shelley et al., 2007) ionization state. The protein, SIRT2 (PDB: 
4RMG) was prepared with the Protein Preparation Wizard (Sastry et al., 2013). A Cartesian 
coordinate receptor grid was generated on SIRT2 by positioning the prereaction form of the ligand 
in the binding site close to the NAD+. The affinity score is given as a Glide score based on the 
binding mode of the ligand with the protein where the optimal interactions are represented by a 
low Glide score (Friesner et al., 2004). The distance between the NAD+ and the carbonyl-carbon 
of the leaving group cleavage site was calculated manually using the Measure Distance 
functionality. 
Cell cultures and in vitro Radiotracer Uptake Studies: The U87MG, MiaPaca, and MDA-
MB-231 cell lines were obtained from the American Type Tissue Culture Collection (ATCC); the 
MCF10A cell line was obtained from the cell culture repository of the Karmanos Cancer Institute 
(Detroit, MI). Tumor cells were propagated in DMEM supplemented with 10% fetal calf serum 
(FCS), penicillin and streptomycin, at 37°C in a humidified atmosphere with 5% CO2. In vitro 
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radiotracer uptake studies were performed as previously described (Yeh et al., 2013c). Briefly, 
prior to in vitro radiotracer uptake experiment, the cells were inspected for confluency and 
viability. Each of the four cell plates for a given cell line had the media removed by pipette 
aspiration, and fresh media (15mL) containing the radiotracer (1-2uCi/mL) was added to cells in 
the culture plates. The tumor cell monolayers were incubated with the radioactivity-containing 
medium for 30 minutes. The cells were then harvested by gentle unidirectional scraping and the 
suspensions of cells in the media were transferred into 15mL conical centrifuge tubes and pelleted 
by centrifugation (3000 rpm for 2 min). 50uL samples of supernatant and cell pellets flash-frozen 
on dry ice were placed in pre-weighed scintillation vials, weighed, and the radioactivity was 
measured using Pakard 5500 gamma counter (Perkin Elmer, CA). The background-corrected and 
decay-corrected radioactivity concentrations in individual cell pellets (cpm/g) was divided by 
corresponding cell culture media samples (cpm/g) to determine the fold increase of radiotracer 
accumulation in cells versus the cell culture media.  
Chemical Synthesis:  
Synthesis of ω-fluorinated acyl chains: 3-fluoropropionic acid was purchased from Santa 
Cruz Biotechnology (Dallas, TX) and used without further purification. 10-hydroxydecanoic acid, 
12-hydroxydodecanoic acid, and 16-hexadecanoichydroxyhexadecanoic acid were purchased 
from Sigma Aldrich (Milwaukee, WI) and used for synthesis of ω-fluorinated carboxylic acid 
chains. The n-hydroxycarboxylic acids were treated with molar excess of diethylaminosulfur 
trifluoride (DAST) at 0°C for 5-10 minutes. Immediately following, the reaction mixture was 
transferred dropwise to 5 ml of hexane resting on a small plug of silica gel primed with hexane to 
selectively hydrolyze the acetyl fluoride formed during the DAST reaction.  The compounds were 
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eluted from the silica using 50:50 ethyl acetate/hexane and they were used without further 
purification for formation of acetyl chloride and coupling to the lysine derivative.  
tert-Butyl (7-(3-fluoropropanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-
oxoheptan-2-yl)carbamate (5): 3-Fluoropropionic acid (61.7 mg, 0.66 mmol) was dissolved in 
acetonitrile with 1 equivalent of N,N'-dicyclohexylcarbodiimide (DCC) (155 mg) and a catalyst 
amount of 4-dimethylaminopyridine (DMAP) (few crystals). The mixture was stirred at 22°C 
under argon for 10 minutes. Subsequently, Boc-Lys-AMC (188 mg, 0.46 mmol) was dissolved in 
7 mL of dichloromethane (DCM) with 1 equivalent of triethylamine (TEA) and added dropwise 
to the reaction mixture. The reaction was stirred continuously at 22°C, under argon, for 12 hours. 
Following completion of the reaction, the solvent was evaporated and the compound was purified 
by column chromatography using a gradient of 0.5-2% methanol/dichloromethane for elution. The 
product was obtained in 85% yield as an off white powder. 1H NMR (400 MHz, CDCl3) δ 9.42 (s, 
1H), 7.68 (s, 1H), 7.47 (s, 1H), 7.38 (s, 1H), 7.26 (s, 1H), 6.20 (s, 1H), 6.14 (s, 1H), 5.54 (s, 1H), 
5.29 (s, 1H), 4.79 (t, J = 5.6 Hz, 1H), 4.67 (t, J = 5.6 Hz, 1H), 4.30 (s, 1H), 3.51 – 3.37 (m, 1H), 
3.35 – 3.16 (m, 1H), 2.60 (dd, J = 15.3, 9.7 Hz, 1H), 2.54 (t, J = 5.6 Hz, 1H), 2.38 (s, 2H), 1.45 (s, 
H), 1.94 – 1.88 (m, 2H), 1.82 – 1.62 (m, 2H), 1.57 (dd, J = 16.4, 11.8 Hz, 2H), 1.30 (dt, J = 17.4, 
13.0 Hz, 2H), 1.20 – 0.99 (m, 2H). 19F NMR (376 MHz, CDCl3) δ -217.96 (tt, J = 47.0, 27.5 Hz). 
HRMS (+ESI-TOF) m/z for C25H35N3O6 [M+Na]
+ calculated: 493.5802; found: 493.2097 
tert-Butyl (7-(6-fluorohexanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-
oxoheptan-2-yl)carbamate (6): 6-Bromoethylhexanoate (1 g) was dissolved in 10 mL of TBAF 
and stirred at 80°C for 3 hours. The resulting mixture was evaporated and purified by column 
chromatography using 10% ethyl acetate in hexane as the eluent. The ethyl protecting group was 
hydrolyzed by 100ul of 15wt% sodium methoxide in methanol. The following mixture was 
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evaporated and 2 mL of thionyl chloride (SOCl2) was added to the residue. The resulting mixture 
was stirred at 60°C, under reflux, for 3 hours. Following the reaction, all SOCl2 was evaporated 
and the product was washed with toluene before being evaporated once more. Boc-Lys-AMC 
(Bachem (92 mg, 0.24 mmol) was dissolved in 10 mL of dichloromethane with 1 equivalent of 
TEA.  The mixture was added dropwise to the flask containing the acetyl chloride residue, and the 
reaction was stirred continuously at 22°C, under argon, for 12 hours. Following completion of the 
reaction, the solvent was evaporated and the compound was purified by column chromatography 
using a gradient of 3-5% methanol/dichloromethane for elution. The product was obtained in 20% 
yield as an off white powder. 1H NMR (600 MHz, CDCl3) δ 11.20 (s, 1H), 9.40 (s, 1H), 7.68 (s, 
1H), 7.45 (s, 2H), 7.42 (s, 2H), 7.25 (d, 2H), 6.13 (s, 1H), 5.95 (s, 1H), 5.50 (s, 1H), 4.45 (t, J = 
5.9 Hz, 1H), 4.37 (t, J = 5.7 Hz, 1H), 4.28, 3.33 – 3.26 (m, 1H), 3.23 (dd, J = 13.3, 6.7 Hz, 1H), 
2.99 (d, J = 4.3 Hz, 1H), 2.55 (s, 2H), 2.37 (s, 2H), 2.18 (t, J = 7.4 Hz, 2H), 1.77 – 1.62 (m, 7H), 
1.57 (dd, J = 13.8, 6.9 Hz, 3H), 1.50 – 1.40 (m, 14H), 0.95 (t, J = 7.1 Hz, 2H). 13C NMR (151 
MHz, CDCl3) δ 173.2, 171.4, 161.1, 154.5, 152.3, 141.5, 125.0, 123.6, 115.8, 115.6, 113.2, 107.1, 
83.9 (d, J = 164.4 Hz), 80.4, 77.0 76.8, 60.0, 55.0, 52.2, 48.6, 38.3, 36.5, 31.2, 30.1 (d, J = 19.5 
Hz), 28.8, 28.3, 25.3, 25.1, 25.0, 24.9, 22.5, 20.1, 18.5, 13.5. 19F NMR (376 MHz, CDCl3) δ -
175.21 – -184.59 (m). HRMS (+ESI-TOF) m/z for C28H41N3O6 [M+Na]+ calculated: 535.66; 
found: 535.2642 
tert-Butyl (7-(10-fluorodecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-
oxoheptan-2-yl)carbamate (7): 10-Fluorodecanoic acid (45 mg, 0.24 mmol) was dissolved in 
excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours. Following the 
reaction, all SOCl2 was evaporated and the product was washed with toluene before being 
evaporated once more. Boc-Lys-AMC (96 mg, 0.24 mmol) was dissolved in 7 mL of 
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dichloromethane with 1 equivalent of TEA.  The mixture was added dropwise to the flask 
containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C, under 
argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and the 
compound purified by column chromatography using a gradient of 3-5% 
methanol/dichloromethane for elution. The product was obtained in 55% yield as an off white 
powder. 1H NMR (499 MHz, CDCl3) δ: 9.55 (s, 1H), 7.70 (s, 1H), 7.45 (s, 2H), 7.33 (s, 1H), 6.13 
(s, 1H), 5.94 (s, 1H), 5.59 (s, 1H), 4.47 (d, J = 12.1 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.02 (s, 1H), 
2.38 (s, 2H), 1.95 (s, 2H), 2.28 (t, J = 7.5 Hz, 1H), 2.16 (t, J = 7.6 Hz, 2H), 1.79 – 1.52 (m, 9H), 
1.46 (s, 9H), 1.26 (s, 10H). 13C NMR (126 MHz, CDCl3) δ 173.6, 171.6, 161.2, 156.5, 154.0, 
152.5, 141.6, 125.0, 115.7, 115.6, 113.1, 107.1, 84.2 (d, J = 163.9 Hz), 80.4, 64.3, 55.1, 38.5, 36.7, 
34.4, 31.6, 30.4, 30.3, 29.4, 29.31, 29.26, 29.2, 29.1, 29.0, 28.6, 28.4, 25.8, 25.7, 25.13, 25.08, 
25.0, 22.7, 18.5. 19F NMR (376 MHz, CDCl3) δ -217.73 – -218.25 (m). HRMS (+ESI-TOF) m/z 
for C32H49N3O6 [M+Na]
+ calculated: 614.3519, found M+Na: 614.3581 
tert-Butyl (7-(12-fluorododecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-
oxoheptan-2-yl)carbamate (8): 12-Fluorododecanoic acid (21 mg, 0.027 mmol) was dissolved 
in excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours.  Following the 
reaction, all SOCl2 was evaporated and the product was washed with toluene before being 
evaporated once more. Boc-Lys-AMC (36 mg, 0.09mmol) was dissolved in 7 mL of 
dichloromethane with 1 equivalent of triethylamine (TEA). The mixture was added dropwise to 
the flask containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C, 
under argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and 
the compound was purified by column chromatography using a gradient of 3-8% 
methanol/dichloromethane for elution. The product was obtained in 20% yield as an off white 
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powder. 1H NMR (500 MHz, CDCl3) δ: 9.55 (s, 1H), 7.70 (s, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.32 
(d, J = 7.5 Hz, 1H), 6.12 (s, 1H), 5.95 (s, 1H), 5.62 (d, J = 6.5 Hz, 1H), 4.41 (dt, J = 47.4, 6.2 Hz, 
2H), 3.34 – 3.16 (m, 2H), 2.36 (s, 3H), 2.15 (t, J = 7.7 Hz, 2H), 1.99 – 1.88 (m, 2H), 1.81 – 1.71 
(m, 2H), 1.72 – 1.51 (m, 8H), 1.44 (s, 9H), 1.39 – 1.32 (m, 4H), 1.23 (d, J = 5.6 Hz, 14H). 13C 
NMR (126 MHz, CDCl3) δ: 173.8, 171.8, 161.3, 156.6, 154.1, 152.6, 141.7, 125.1, 115.8, 115.7, 
113.2, 107.2, 84.3 (d, J = 163.8 Hz). 80.5, 55.3, 38.7, 36.9, 31.7, 30.6, 30.4, 29.6, 29.4, 29.3, 29.1, 
28.5, 25.9, 25.3, 25.2, 25.0, 22.8, 18.6. 19F NMR (376 MHz, CDCL3) δ -217.99 (dq, J = 47.4, 25.0 
Hz). HRMS (+ESI-TOF) m/z for C34H53N3O6 [M+Na]
+ calculated: 626.3415 found: 626.3395 
tert-Butyl (7-(14-decanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-oxoheptan-2-
yl)carbamate (9): Boc-Lys-AMC (100 mg, 0.25 mmol) was dissolved in 5 mL of 
dimethylformamide (DMF) with excess of N,N-diisopropylethylamine (DIPEA) (0.5 mL). 
Myristoyl chloride (92 mg, 0.37 mmol Sigma-Aldrich, Milwaukee, WI) was added dropwise to 
reaction at 0°C and subsequently stirred at 22°C under argon for 12 hours. The resulting mixture 
was evaporated and the residue was dissolved into ethyl acetate (EtOAc) and was washed 2 times 
with 2N aqueous hydrochloric acid solution. The organic layer was separated and dried for 2 hours 
on sodium sulfate, evaporated, and purified by using flash chromatography in an Alltech 900 mg 
silica cartridge (Fisher Scientific, Waltham, MA) with EtOAc as an eluent.  The compound was 
isolated as a white powder in 64% yield. 1H NMR (600 MHz, CDCl3) δ 9.62 (s, 1H), 7.71 (s, 1H), 
7.42 (d, J = 8.3 Hz, 1H), 7.29 (d, J = 7.7 Hz, 1H), 6.14 (s, 1H), 6.10 (s, 1H), 5.67 (d, J = 7.0 Hz, 
1H), 4.34 (d, J = 4.0 Hz, 1H), 3.33 – 3.15 (m, 2H), 2.35 (s, 3H), 2.16 (t, J = 7.6 Hz, 2H), 1.95 – 
1.87 (m, 1H), 1.79 – 1.69 (m, 1H), 1.61 – 1.53 (m, 4H), 1.44 (s, 9H), 1.31 – 1.15 (m, 26H), 0.85 
(t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.0, 171.8, 161.3, 156.6, 154.0, 152.7, 141.7, 
125.1, 115.8, 115.7, 113.2, 107.2, 80.5, 55.3, 38.8, 36.8, 32.0, 31.8, 29.8, 29.8, 29.7, 29.6, 29.5, 
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29.5, 29.1, 28.5, 26.0, 22.9, 22.8, 18.6, 14.2. HRMS (+ESI-TOF) m/z for C36H57N3O6 [M-
CH3+Na]
+ calculated: 636.3890 found: 636.3795. 
tert-Butyl (7-(16-fluorohexadecanamido)-1-((4-methyl-2-oxochroman-7-yl)amino)-1-
oxoheptan-2-yl)carbamate (10): 16-Fluorohexadecanoic acid (100 mg, 0.38 mmol) was 
dissolved in excess SOCl2 (1 mL, 1.3 mmol) and stirred at 60°C, under reflux, for 3 hours.  
Following the reaction, all SOCl2 was evaporated and the product was washed with toluene before 
being evaporated once more. Boc-Lys-AMC (100 mg, 0.25 mmol) was dissolved in 10 mL of 
dichloromethane with 1 equivalent of triethylamine (TEA). The mixture was added dropwise to 
the flask containing the acetyl chloride residue, and the reaction was stirred continuously at 22°C, 
under argon, for 12 hours. Following completion of the reaction, the solvent was evaporated and 
the compound was purified by column chromatography using a gradient of 3-8% 
methanol/dichloromethane for elution and isolated as a white powder in 20% yield. 1H NMR (500 
MHz, CDCl3) δ 9.27 (s, 1H), 7.69 (s, 1H), 7.50 (s, 2H), 6.19 (s, 1H), 5.76 – 5.67 (m, 1H), 5.40 (d, 
J = 7.7 Hz, 1H), 5.31 (s, 1H), 4.49 (t, J = 6.2 Hz, 1H), 4.39 (t, J = 6.2 Hz, 1H), 4.06 (t, J = 6.7 Hz, 
3H), 3.67 (d, J = 4.8 Hz, 3H), 3.65 (d, J = 4.7 Hz, 1H), 2.41 (s, 2H), 2.30 (dd, J = 15.0, 7.5 Hz, 
5H), 2.21 – 2.17 (m, 1H), 1.66 – 1.60 (m, 9H), 1.47 (s, 9H), 1.28 (d, J = 16.1 Hz, 28H). 19F NMR 
(376 MHz, CDCl3) δ -217.83 – -218.35 (m). HRMS (+ESI-TOF) m/z for C38H61N3O6 [M+Na]+ 
calculated: 698.4500, found: 698.4520 
Benzyl (6-amino-1-((1-((4-methyl-2-oxochroman-7-yl)amino)-1-oxo-6-
propionamidohexan-2-yl)amino)-1-oxohexan-2-yl)carbamate (11): Boc-Lys-AMC (232 mg, 
0.45mmol) was dissolved in trifluoroacetic acid (TFA) to remove the boc protecting group. The 
mixture was stirred for 30 minutes at 22°C and the TFA (2.5 mL) was evaporated. The resulting 
residue was dissolved in dichloromethane (DCM) and 1eq of TEA was added to neutralize the 
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product. The mixture was evaporated and the product was washed with water and dried to remove 
salts. The intermediate product was obtained as 138 mg of white powder.  This product was 
dissolved in DCM and 0.8 equivalents (85 mg) of Cbz-Lys-OH was added along with 1.5 eq. 1-
Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (67 mg) and Hydroxybenzotriazole 
(HOBT) (50 mg) and 3 eq. of DIPEA (0.12 mL). The mixture was stirred for 12 hours at 22°C 
under argon. The mixture was evaporated and dissolved in ethyl acetate and washed with saturated 
sodium carbonate solution. The organic layer dried over magnesium sulfate and evaporated. The 
residue was purified by column chromatography and the product was eluted with a gradient of 3-
5% MeOH/DCM. The product was obtained as an off white powder in 12% yield (40 mg). 1H 
NMR (600 MHz, DMSO-d6) δ 10.41 (s, 1H), 8.08 (d, J = 7.4 Hz, 1H), 7.75 (s, 1H),  7.68 (dd, J = 
10.8, 7.3 Hz, 2H), 7.46 (d, J = 8.5 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 7.32(s, 3H), 7.28 (dd, J = 7.3, 
2.8 Hz, 1H), 6.72 (t, J = 5.5 Hz, 1H), 6.24 (s, 1H), 5.00 (s, 2H), 4.34 (dd, J = 13.7, 7.7 Hz, 1H), 
3.98 (dd, J = 12.8, 8.3 Hz, 1H), 3.02 – 2.95 (m, 2H), 2.84 (dt, J = 12.7, 6.5 Hz, 2H), 2.37 (s, 3H), 
1.96 (t, J = 7.4 Hz, 2H), 1.75 – 1.65 (m, 1H), 1.65 – 1.53 (m, 2H), 1.48 (d, J = 9.4 Hz, 1H), 1.42 – 
1.34 (m, 3H), 1.33 (12H), 1.18 (s, 22H), 0.81 (t, J = 7.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ: 
174.2, 173.3, 170.9, 161.4, 157.0, 156.7, 154.1, 152.6, 141.7, 136.2, 128.6, 128.3, 128.1, 125.0, 
116.0, 113.3, 107.4, 79.4, 67.2, 55.7, 54.1, 50.8, 38.5, 36.9, 32.0, 30.9, 29.8, 29.7, 29.6, 29.5, 29.4, 
29.1, 28.5, 26.0, 25.4, 22.8, 22.6, 18.6, 14.2. HRMS (+ESI-TOF) m/z for C49H75N5O9 [M+Na]
+ 
calculated: 776.3913, found: 776.3911 
6-(12-Fluorododecanamido)-N-phenylhexanamide (12): 6-Amino-N-phenylhexanamide 
(AHA(Mukhopadhyay et al., 2006)) (0.10 g, 0.48 mmol) was dissolved in acetonitrile with 12-
fluorododecanoic acid, a catalyst amount of DMAP (few crystals), and 1 equivalent of DCC (275 
mg). The mixture was stirred under argon at 22°C for 12 hours. The solvent was evaporated and 
85 
 
the residue was purified by column chromatography. The product was eluted with 3% MeOH in 
DCM and subsequently purified by semi-preparative HPLC to improve the purity, eluted as a 
single peak at 8 minutes with 50% acetonitrile/water. The final compound was isolated in 10% 
yield. 1H NMR (400 MHz, DMSO-d6) δ 9.85 (s, 1H), 7.72 (s, 1H), 7.56 (d, J = 7.85Hz, 2H), 7.25 
(d, J = 1.8 Hz, 2H), 6.99 (t, J = 7.3 Hz, 1H), 4.44 (dt, J = 47.6 Hz, 2H), 2.99 (s, 2H), 2.25 (m, 2H), 
1.98 (m, 2H), 1.54 (m, 4H), 1.37 (m, 4H), 1.20 (s, 10H).19F NMR (376 MHz, DMSO-d6) δ -216.36 
– -216.88 (m). HRMS (+ESI-TOF) m/z for C24H40FN2O2 [M+Na]+ calculated 407.3074, found 
407.3083. 
6-(12-Bromododecanamido)-N-phenylhexanamide (13): DIPEA (0.13 mL, 0.73 mmol) 
was added to the mixture of 6-amino-N-phenylhexanamide (AHA) (prepared using previously 
published method(Mukhopadhyay et al., 2006)) (0.10 g, 0.48 mmol) and bromoundecanoic acid 
benzotriazole (0.21 g, 0.58 mmol) dissolved in DMF (5 mL), and left to stir at 22°C for 6 h. The 
solvent was then evaporated under reduced pressure; the crude was dissolved in DCM and washed 
with 2N hydrochloric acid. The organic layer was dried over sodium sulfate. Evaporation and 
purification with column chromatography (eluent - EtOAc) gave the desired precursor in 62% 
yield. 1H NMR (400 MHz, CDCl3) δ 8.25 (s, 1H), 7.55 (d, J = 7.9 Hz, 2H), 7.27 (t, J = 7.9 Hz, 
2H), 7.06 (t, J = 7.4 Hz, 1H), 5.96 (t, J = 5.2 Hz, 1H), 3.38 (t, J = 6.9 Hz, 2H), 3.22 (dd, J = 13.2, 
6.8 Hz, 2H), 2.35 (t, J = 7.4 Hz, 2H), 2.13 (t, J = 7.6 Hz, 2H), 1.88 – 1.77 (m, 2H), 1.76 – 1.66 (m, 
2H), 1.61 – 1.45 (m, 4H), 1.43 – 1.31 (m, 4H), 1.24 (s, 10H). 13C NMR (101 MHz, CDCl3) δ 173.6, 
171.8, 138.4, 128.9, 124.1, 119.9, 39.2, 37.3, 36.9, 34.2, 32.9, 29.6, 29.5, 29.5, 29.4, 29.4, 29.3, 
28.8, 28.2, 26.4, 25.9, 25.0. HRMS (+ESI-TOF) m/z for C24H40BrN2O2 [M+Na]
+ calculated 
467.2273, found 467.2283. 
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6-(12-Iodododecanamido)-N-phenylhexanamide (14): 6-(12-Bromododecanamido)-N-
phenylhexanamide (100 mg) was dissolved in acetone and 4 equivalents of NaI was added at 22°C 
and the mixture was stirred for 80 hours. The solution was evaporated and purified with column 
chromatography (eluent – EtOAc) to give the desired product in 73% yield (80 mg). 1H NMR (600 
MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 3H), 7.31 (t, J = 7.8 Hz, 2H), 7.09 (t, J = 7.4 Hz, 1H), 5.63 (s, 
1H), 3.26 (dd, J = 13.2, 6.7 Hz, 2H), 3.18 (t, J = 7.0 Hz, 2H), 2.37 (t, J = 7.3 Hz, 2H), 2.14 (t, J = 
7.6, 2H), 1.85 – 1.72 (m, 4H), 1.63 – 1.57 (m, 2H), 1.57 – 1.51 (m, 2H), 1.44 – 1.34 (m, 4H), 1.26 
(m, 12H). HRMS (+ESI-TOF) m/z for C24H40IN2O2 [M+Na]
+ calculated 515.2135, found 
515.2131. 
6-18F-(12-fluorododecanamido)-N-phenylhexanamide (15): The F-18 was obtained in 
kryptofix/K[18F] complex in acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne 
State University (Detroit, MI) and transferred into a crimped 2 mL V-vial for azeotropic drying. 
Acetonitrile (0.4 mL) was added to the mixture, which was dried under a stream of argon at 90-
100°C. A solution of 14 (2-3 mg) in dry acetonitrile (0.4 mL) was added to the dried kryptofix/ 
K[18F] and heated to 85-90°C under argon with stirring for 20 minutes. After cooling, the reaction 
mixture was passed through a 900 mg Altech silica gel cartridge (Fisher Scientific, Waltham, MA) 
and eluted with 2 mL of 10% methanol in dichloromethane (DCM). The solvent was evaporated 
under a stream of argon to remove DCM and to reduce the volume to 0.5 mL. The 15 was purified 
by semipreparative HPLC (40% ACN in water) by collecting the peak at 9 min. The decay 
corrected radiochemical yield was 12% and the compound purity was >95%, as assessed by 
analytical HPLC and co-elution with the non-radiolabeled reference standard 12.  
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4b. Continuing work 
  Preliminary dynamic PET/CT images acquired after i.v. administration of 12-[18F]-
DDAHA in normal and 9L tumor bearing rats have been done however significant defluorination 
is visible as soon as 5-10 minutes after injection of the radiotracer and increases with time post 
injection (Fig. 33). This is indicated by the abnormally high uptake of 18F into the bones of the 
animal and is increasing with time. As noted previously, this has been hypothesized based on 
studies performed with 16-[18F]-palmitic acid substrates, which demonstrated high rates of 
defluorination in rodents. It is possible that this problem would not persist in higher mammals and 
humans due to significantly lower circulating concentrations of enzymes, we have also begun work 
on a second generation of compounds aimed at reducing the likelihood of defluorination. 
It has been suggested that positioning the fluorine atom on the ω-3 position rather than on 
the terminal, ω-carbon, may reduce defluorination (Pandey et al., 2012). We have hypothesized 
that other midchain substitutions of a fluorine-18 atom may also prevent defluorination. From 
preliminary in silico studies it is plausible that these compounds would retain SIRT2 selectivity. 
In light of these observations, we have designed synthesis schemes for generating a second set of 
SIRT2 selective radiotracers based upon mid-chain fluorination of dodecanoyl or myristoyl acyl 
chains (Fig. 34). These synthesis schemes may provide means for constructing a more robust 
 
Figure 33. PET/CT images from a rat bearing a 9L brain tumor with 12[18F]-DDAHA 
demonstrating significant defluorination, as indicated by F-18 accumulation in the bone 
especially with increasing time post i.v. injection of the radiotracer.  
1 min 3 min 5 min                  15 min 25 min 35 min                  45 min
Time
1
0.3
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SIRT2-selective radiotracer to prevent against defluorination in rodents as well as higher 
mammals.  These schemes cover the chains fluorinated at the Ɣ-position, generating 4-
fluorododecanoyl and 4-flurotetradecanoyl, as well as 5-position to make 5-fluorododecanoyl and 
5-flurotetradecanoyl leaving groups which would be radiolabeled from the brominated-precursors. 
While these compounds place the fluorine atom in closer proximity to the carbonyl carbon, it 
should be far enough to limit interference with enzymatic activation and cleavage site. 
Additionally, we have developed schemes for radiolabeling the more terminal fluorines at ω-3 and 
ω-4 sites to generate 9-fluorododecanoyl or 11-fluorotetradecanoyl (ω-3) substituted chains and 
8-fluorododecanoyl or 10-fluorotetradecanoyl (ω-4) substituted chains with possible 
radiofluorination from the brominated precursors.  
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Fig. 34. Possible schemes for synthesis of alternative SIRT2-selective radiotracers that may be less 
susceptible to defluorination. A) Sample synthesis for 4-fluorododecanoyl or 4-fluorotetradecanoyl 
compounds with radiofluorination from the brominated precursor. B) Sample synthesis scheme for 
construction of 5-fluorododeconyl or 5-fluorotetradecanoyl compounds with radiofluorination 
from the brominated precursor. C) Sample synthesis for the ω-3 compounds, 9-fluorododecanoyl 
or 11-fluorotetradecanoyl substituted chains. D) Synthesis of ω-4 compounds 8-fluorododecanoyl 
or 10-fluorotetradecanoyl substituted chains with possible radiofluorination from the brominated 
precursors.  
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CHAPTER 5 DEVELOPMENT OF NOVEL PET IMAGING 
SUBSTRATES FOR SIRT1 
5a. Development of a novel substrate-type radiotracer, 2-[18F]PhAHA, for 
PET imaging of SIRT1-mediated epigenetic regulation  
Robin Bonomi, Vadim Popov, Maxwell Laws, David Gelovani, Anjoy Majhi, Amer M. 
Najjar, Aleksander Shavrin, Tong William Ping-Yiu, Nashaat Turkman, Xin Lu, Thomas 
Mangner, Juri G. Gelovani* 
Introduction 
Seven sub-types of SIRTs (SIRT 1-7) have been identified in humans (Haberland et al., 2009) 
and play a role in gene silencing, cell cycle regulation, metabolism, apoptosis, lifespan and 
circadian rhythms (Pan et al., 2011a). In particular, SIRT1  has been recognized for involvement 
in diabetes, cardiovascular disease and neurodegeneration (Haigis, 2010) through cleavage of an 
acetyl moiety from lysine residues of various proteins including PPARƔ, and NF-Kβ, and 
members of the p53 family. Furthermore, increased expression of SIRT1 has been correlated with 
poor prognosis in a variety of cancers such as pancreatic (Wauters et al., 2013), non-small cell 
lung carcinoma (Grbesa et al., 2015) and leukemias (Li et al., 2012) 
Due to the biological importance of SIRT1 (further reviewed in chapter two), many targeted 
therapies have been developed using small molecule therapeutics for activation or inhibition of 
SIRT1. Because of the notable link between resveratrol and SIRT1, clinical trials were conducted 
using resveratrol or a synthetic small molecule activator (i.e. SRT2104) to activate SIRT1-
mediated pathways for treatment of diabetes and obesity (Hoffmann et al., 2014; Poulsen et al., 
2013; Pulla et al., 2012). Additionally, the observation of SIRT1 overexpression in proliferative 
cancer cells has prompted investigation of the effects of SIRT1 inhibitors on progression of various 
cancers (Liu et al., 2009).  
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Several SIRT1 selective inhibitors have been developed and reported in literature, such as 
Selisistat (EX-527) (Napper et al., 2005; Solomon et al., 2006), Sirtinol (Grozinger et al., 2001), 
and Tenovin-6 (Lain et al., 2008). These compounds are gaining recognition for treatment of 
diseases through SIRT1-targeted pharmacomodulation. In vitro evidence has demonstrated a 
reduction in growth and proliferation of colon cancer and uveal melanoma cancer stem cells after 
treatment with SIRT1-selective inhibitors EX-527 and tenovin-6 (Dai et al., 2016; Suzuki et al., 
2009). Though these SIRT1 inhibitors have shown promise as anticancer drugs in vitro and in 
preliminary in vivo studies, few have been evaluated or approved for clinical trials (Park et al., 
2004). 
As noted, SIRT1 plays a pivotal role in many important cellular processes, however, the up- 
and downstream effects of SIRT1 are not fully understood. Therefore, the development of non-
invasive imaging approaches to monitoring SIRT1 expression and activity in vivo via PET imaging 
with a SIRT1-selective substrate radiotracer may aid in understanding disease progression and the 
development of novel SIRT1-targeted therapeutics.  
Recently, studies have demonstrated that SIRT1 is able to cleave other leaving groups outside 
of the acetyl moiety (Yao and Yang, 2011). In particular, Hirsch et al. demonstrated that SIRT1 
can dephenylacetylate a lysine residue (Hirsch and Zheng, 2011) (Fig. 35). Additionally, it has 
been implicated that other SIRT enzymes, namely SIRT2 and SIRT6, may contain the ability to 
cleave long acyl chains but may not be able to cleave an aromatic ring (Yao and Yang, 2011). 
Towards the development of a SIRT1-selective substrate radiotracer we developed a library of 
compounds investigating the relationship of substituted aromatic rings as leaving groups on SIRT1 
catalytic efficiency. In vitro assessment of these compounds using a fluorogenic assay indicated 
that the fluorinated phenyl ring leaving groups were cleaved more efficiently by SIRT1 than the 
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substituted benzyl ring leaving groups or aromatic rings with iodinated substitutions. For purposes 
of high-throughput screening, this library was developed with the carbazol-lysine-
aminomethylcoumarin backbone, however, this peptide mimetic is not well suited for use as an in 
vivo imaging agent, due to its high lipophilicity. Through fluoromeric screening, 2-fluorophenyl 
(2FPh) was identified as the lead leaving group to use for further development into a systemically 
viable radiotracer. Following this, 2-fluorophenylhexanoicanilide was developed using the 
aminohexanoicanilide backbone to form an analogous compound to the tested one, Cbz-
Lys(2FPh)-AMC, using providing increased systemic viability as seen in [18F]-TFAHA (Bonomi 
et al., 2015) and [18F]-FAHA (Yeh et al., 2013a). The resulting compound, 2-
fluorophenylaminohexanoicanilide (2-FPhAHA) was synthesized in the radiolabeled version 
[18F]-2-fluorophenylaminohexanoicanilide ([18F]-2FPhAHA) from the 2-nitrophenyl precursor. 
[18F]-2FPhAHA demonstrated efficacy as a viable imaging agent for SIRT1 expression-activity 
through in vitro and in vivo assessment. PET/CT images with [18F]-2FPhAHA in the rat model 
resulted in [18F]-2FPhAHA-derived accumulation in areas of the brain with higher SIRT1 activity 
were validated by the IHC and ISH data in literature (Ramadori et al., 2008; Zakhary et al., 2010) 
as well as by our own IHC and autoradiography data. Quantification of PET/CT images was 
performed using Logan plot analysis for specific regions of the brain to validate the differential 
washout of [18F]-2FPhAHA within the brain. 
The development of [18F]-2FPhAHA as a BBB permeable SIRT1-selective substrate type 
radiotracer with and subsequent characterization of SIRT1 expression-activity in vivo in the 
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absence of disease may further the study of SIRT1-mediated epigenetic regulation in various 
neuropathologies. 
Results: 
The library of compounds developed for in vitro assessment of SIRT1 catalytic activity 
utilized the carbazol-Lysine-aminomethylcoumarin backbone (Cbz-Lys-AMC) dervatized with 
fluorinated and iodinated phenyl and benzyl substituents (Fig. 36-37). The compounds (17-27) 
 
Figure 35. The unique SIRT1 mechanism for cleavage of a benzyl moiety (highlighted in red) from 
a lysine residue of a protein using NAD+ as a cofactor. 
 
Figure 36. Synthesis of control compound 17, Cbz-Lys(ac)-AMC.  
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were primarily synthesized from variations of existing methodologies for peptide mimetic 
synthesis, including acetyl-chloride coupling, in yields of 50-80% with >95% chemical purity as 
assessed by TLC, 1H, 13C, and 19F NMR and HRMS. 
The synthesis of 4-Fluorophenylaminohexanoicanilide (28) was accomplished through 
DCC-catalyzed coupling of the 4-fluorobenzoic acid with compound 1 in a yield of 77% and >95% 
purity (Fig. 38). The synthesis of small molecule compounds including, 2-[18F]ethyl benzoate (30), 
2-[18F]benzoic acid (31), and 2-[18F]benzaldehyde (34) with decay corrected radiochemical yields 
of 25% and 15%, respectively, was accomplished through radiofluorination of commercially 
available ortho-nitro compounds (29, 32) with high radiochemical purity (>95%) (Fig. 39). These 
compounds were assessed by analytical radio-HPLC for purity and verification of compound 
identification. 
 Synthesis of non-radiolabeled 2-
fluorophenylaminohexanoicanilide (35) was performed using 
in situ acetyl chloride formation to couple the commercially 
available 2-fluorobenzoic acid with N-aminophenylhexamide 
(prepared by previous methodology (Mukhopadhyay et al., 
2006)) in a 30% yield and high chemical purity, >95%, as 
 
Figure 38. Synthesis of 4-
fluorophenylaminohexanoic 
anilide (28). 
 
Figure 37. Synthesis of the focused library of SIRT1 substrates 
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assessed by TLC, 1H, 13C, and 19F NMR and HRMS. The synthesis of 2-
nitrophenylaminohexanoicanilide (36) was accomplished through coupling 2-nitrophenyl acetyl 
chloride with N-phenylhexamide in 70% yield with >95% chemical purity, as assessed by TLC, 
1H, 13C, and 19F NMR and HRMS. This compound was used for subsequent radiofluorination to 
produce [18F]-2FPhAHA (37) under novel radiofluorination conditions of 135°C in dry DMSO to 
produce the compound with high radiochemical purity >99% and a decay corrected RCY of 15% 
as assessed by radio-analytical HPLC (Fig. 40).  
Fluorogenic assay results screening compounds 18-27 from library in Fig. 37 indicate 
leaving groups containing a phenyl ring are cleaved more rapidly by SIRT1 than those with a 
benzyl moiety (Fig. 41). The aromatic ring leaving groups containing fluorine atoms are cleaved 
more rapidly than iodine-substituted rings. In particular, the fluorinated phenyl groups, especially 
in ortho- or meta-position, are the most efficiently cleaved substrates, with kcat/km values of 26.02 
(19) and 63.39 M-1, s-1 (20), respectively (Fig. 42). The ortho-fluorophenyl leaving group is 
cleaved 5-fold more efficiently by SIRT1 than any other SIRT or HDAC enzyme (Fig. 43). A 
reference, control, compound, 
BPS1, a p53 fragment (Arg-His-
Lys-Lys(ac)-AMC) was also 
analyzed for comparison 
purposes.  
The IC50 for the Cbz-
Lys(2FPh)-AMC is 12.60 uM as 
assessed by competitive 
A 
 
B 
 
Figure 39. A) Synthesis of 2-[18F]-ethylbenzoate (30) and 
corresponding benzoic acid (31) from the commercially available 2-
nitro-ethylbenzoate (29). B) Synthesis of 2-[18F]benzaldehyde (34) 
from 2-nitrobenzaldehyde (32). 
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inhibition assay with 
commercial SIRT1 
inhibitor, EX-527 (Fig. 
44).  
In vivo assessment 
of 2-[18F]PhAHA via 
dynamic PET/CT/MRI 
imaging in the normal rat 
displayed significant 
accumulation of 2-
[18F]PhAHA-derived radioactivity in specific areas of the brain, i.e. n.accumbens, dentate gyrus, 
hippocampus, lateral septal nucleus, caudate putamen and amygdala (Fig. 45-46). These areas of 
the brain correlate well with reported IHC data for SIRT1 expression within rodent brain (Fig. 47). 
Autoradiography preformed from these images demonstrated accumulated radioactivity in these 
areas of the brain as determined by alignment with brain atlas maps (Fig. 48).  
In vivo inhibitor studies demonstrate significant decrease in accumulation of 2-[18F]PhAHA-
derived radioactivity in areas of the brain after i.p. administration of EX-527 (5mg/kg), SIRT1-
selective inhibitor, 30 min prior to PET/CT imaging (Fig. 49).  
Assessment of radiolabeled 2-[18F]PhAHA metabolites by in vivo PET/CT imaging with i.v. 
administered 2-[18F]Ethylbenzoate (further metabolized to 2-[18F]Benzoic acid) and 2-
[18F]benzaldehyde was conducted to establish the potential contribution of metabolites to regional 
 
Figure 40. Synthesis of 2-nitrophenylaminohexanoicanilide (36) to 
be used as a precursor for radiolabeling with F-18 to form 2-
[18F]phenylaminohexanoicanilide (37). The non-radiolabeled 
standard 2-fluorophenylaminohexanoicanilide (35) was 
synthesized using similar methodology.  
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uptake of 2-[18F]PhAHA (Fig. 50). Furthermore, it is interesting to analyze the differences in 
radiotracer derived accumulation in each of these three compounds.  
 
Discussion: 
 
 
Figure 41. The catalytic efficiencies (kcat) for the library of compounds synthesized assayed 
against a panel of recombinant SIRT enzymes. A) Demonstrates the catalytic cleavage rat to be 
greatest for the 4FPh leaving group and the 2FPh leaving group. Statistical significance is 
denoted by stars as tested by ANOVA. B) Comparing the iodine vs fluorine substitutions on a 
phenyl or benzyl ring, 4IPh is cleaved significantly faster than the iodinated compounds, 
especially for SIRT1. C) Comparison of 2FBz vs 4FBz leaving groups, the 4FBz is cleaved more 
efficiently by SIRT1. 
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Towards the development of a novel substrate-type radiotracer for quantitative molecular 
imaging of SIRT1 expression and activity, we developed a focused library of substrates 
comprised of the Cbz-Lys-AMC backbone and various phenyl or benzyl leaving groups. This 
cap group has been widely used for SIRT substrates and is especially useful for preliminary 
screening due to the presence of a fluorescent moiety, 7-amino-4-methylcoumarin (AMC), with 
which high throughput fluorogenic assays can be used. Previously, it has been reported that in 
addition to the acetyl group, SIRT1 can also cleave a phenylacetylated lysine with 56% of the 
natural catalytic efficiency (Hirsch and Zheng, 2011) (Fig. 29). Similarly, other class III HDAC 
enzymes have been reported to cleave long acyl chains (myristoyl), glutaryl or succinyl moieties 
(Du et al., 2011; He et al., 2014; Heltweg et al., 2004; Hirsch and Zheng, 2011). However, there 
are no data on the effects of aromatic ring fluorine substitution or phenyl vs. benzyl moieties on 
SIRT1 catalytic efficiency. 
Current studies demonstrate that SIRT1 catalytic rate of cleavage (kcat) is greatest with either 
the 2FPh (19) leaving group or the 4FPh (21) leaving group (Fig. 36). Furthermore, these 
compounds display much greater rates of catalytic cleavage by SIRT1 than any of the other 
sirtuins. In testing the catalytic rate of cleavage for other types of leaving groups, including 
iodinated substrates (25, 26) and phenyl (18-21) and benzyl (22-24) moieties, it is clear that 2FPh 
(19), 3FPh (20), and 4FPh (21) are the strongest candidates for SIRT1 (Fig. 42). However, the 
rates of catalytic cleavage (kcat) are not always proportional to the catalytic efficiency (kcat/km), 
therefore further analysis was done to ensure the most efficient substrate leaving group was used 
for radiotracer development. Taking this into account, a full kinetic analysis was performed for a 
subset of the original library of compounds, to include only compounds 18-24. These results 
confirm that SIRT1 catalytic efficiency (kcat/km) is greatest with a phenyl ring leaving group as 
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opposed to a benzyl (phenylacetyl) moiety (Fig. 42). Interestingly, 21 was cleaved with a greater 
rate than 20 but is cleaved less efficiently when km is taken into account, making compounds 19 
and 20 the most efficient substrates for SIRT1(kcat/km = 26.02 and 63.39 M
-1, s-1) (Fig. 36).  
 
Figure 42. Evaluation of fluorine substituent positioning on both the phenyl and benzyl 
leaving groups on SIRT1 catalytic efficiency, as determined by fluorogenic (Fluor de Lys®) 
assay. The catalytic efficiency of SIRT1 is demonstrated by kcat/km and the error bars represent 
the standard deviation of the mean from N=3 experiments. The full kinetic parameters for 
SIRT1 with selected substrates are detailed in this table. The data represents the apparent 
Michelis-Menton kinetics as derived from initial steady-state reaction velocity. 
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Previously, SIRT1 has been 
reported to cleave a benzyl leaving 
group at 50% of its natural 
deacetylation rate, which is 
confirmed here, comparing 22 (21 
M-1, s-1) to BPS1 (65 M-1, s-1) (Fig. 
42), however, a fluorine 
substitution on the benzyl leaving 
group decreases the catalytic 
efficiency. Whereas, with a phenyl 
moiety, fluorine substitution 
actually increases catalytic 
efficiency. Compound 20, containing 3-fluorophenyl leaving group, is cleaved equally as 
efficiently as the acetylated standard, p53Lys382(ac) analogue (Arg-His-Lys-Lys(ac)-AMC, 
BPS1). (kcat/km = 65.29 M
-1, s-1) and compound 19 cleaved at 25% of the rate.  
Although, the 3-fluorophenyl (20) leaving group is cleaved moderately more efficiently by 
SIRT1 than the 2-fluorophenyl leaving group, compound 19 was chosen as the lead substrate for 
further development as an imaging agent. This decision was influenced by a significant increase 
in difficulty for radiofluorination and opportunity for in vivo defluorination by various esterase 
enzymes with a meta-fluorophenyl ring. However, current work is focused on development of 3-
[18F]fluorophenyl derived radiotracer for a SIRT1-selective imaging agent, as well. 
 
Figure 43. The catalytic efficiency for the lead compound 
Cbz-Lys (2FPh)-AMC (19) was assessed in a panel of 
recombinant HDACs for relative selectivity for SIRT1. 
The data were analyzed by one way ANOVA; statistically 
significant differences with P<0.05 were denoted by ****.  
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To establish selectivity of 19 for 
SIRT1 among other SIRT and HDAC 
proteins, compound 19 was screened 
against a panel of recombinant proteins 
including HDACs1-11 and SIRT1-7. 
Compound 19 demonstrated at least 3-
fold increase in relative rates of cleavage 
by SIRT1 over all HDACs based upon kcat 
values. HDAC 6 expressed the closest 
catalytic activity to SIRT1 of any other HDAC enzymes, with a relative kcat of 30% of SIRT1 (Fig. 
44 ), however HDAC6 has much lower expression in the brain, effectively increasing the SIRT1 
selectivity within the brain (Ramadori et 
al., 2008). Furthermore, to assess the 
effectiveness of lead substrate 19 against a 
potent, SIRT1-selective inhibitor, a 
competitive inhibition assay with EX-527 
(Selisistat) (Cui et al., 2014; Napper et al., 
2005) was performed using increasing 
concentrations of EX-527 and apparent km 
concentration of 19 for SIRT1 (239 μM). 
The observed inhibition for SIRT1 
cleavage of compound 19 with increasing 
concentrations of EX-527 can be used to 
 
Figure 45. HPLC analysis for catalytic rates of cleavage 
of 4-FPhAHA (28) with a panel of recombinant HDAC 
enzymes (HDACs 1-11 and SIRT1-5) demonstrating 
selective cleavage by SIRT1. 
 
Figure 44. IC50 curve for SIRT1 with 19 at its 
apparent km value obtained by competition assay 
with known potent SIRT1 selective inhibitor, EX-
527 at increasing concentrations on the log scale.  
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calculate an IC50  value of 
12.6 +/- 2.1 μM (Fig. 44). 
This value is significantly 
higher than previously 
reported IC50 value of 
0.098 μM obtained using 
fluorogenic oligo peptide-
acylated substrates of p53-
Lys382 (BPS1) (Napper et 
al., 2005). Using our 
system, we independently 
found a comparable IC50 of 
0.0103 +/- 0.0025 μM for BPS1 and SIRT1 with inhibitor EX-527. While the experimental IC50 
values for BPS1 and 19 vary significantly, the catalytic efficiency (kcat/km) differ much less and 
may be explainable, at least in part, due to the differences in cap groups (peptide vs blocking 
group). 
To create a more pharmacologically viable substrate radiotracer, compound 19 has been 
converted to an analogue using aminohexanoicanilide (AHA) backbone rather than the larger Cbz-
Lys-AMC group. The resulting radiotracer, 2-[18F]fluorophenylacetamidohexanoicanilide (2-
[18F]PhAHA, 37), was developed in both F-18 and F-19 versions (Fig. 40). Towards synthesis of 
this radiolabeled compound, there are no established methods for radiofluorination on a phenyl 
ring in the ortho position, thus we developed new methodology for radiosynthesis of 2-
[18F]PhAHA. Originally, both 2-nitrophenylaminohexanoicanilide (2-NO2PhAHA, 36) and 2-
Figure 46. Dynamic PET/CT images acquired using 2-
[18F]PhAHA demonstrating differential washout over time 
normalized to peak SUV values at 20 min.  
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trimethylamoniumsalt-phenylaminohexanoicanilide precursors were developed, however after 
testing radiofluorination conditions, only 2-NO2PhAHA proved to be successful. This finding 
contradicts the data for para- radiofluorination on a phenyl ring where the trimethylammonium 
salt precursor produces higher yields than the nitro leaving group.  
In vitro HPLC analysis of 4-FPhAHA demonstrates comparable cleavage rates (kcat) as 
compared to in vitro fluorogenic studies of 21 for SIRTs 1-5 (Fig. 45). This study confirms the 
 
Figure 47. Representative PET/CT images using 2-[18F]PhAHA aligned with rat brain atlas maps 
demonstrating the areas of high accumulation that align with areas of the brain such as 
hippocampus (CA1, CA2, CA3), dentate gyrus(DG), n. accumbens (Acb), caudate putamen (Cpu), 
and amygdala (amyg). 
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AHA backbone is sufficiently recognized 
and attached leaving group is cleaved by 
SIRT1 without appreciable loss in efficacy. 
The mechanism of substrate cleavage 
by SIRT enzymes allows for the radioactive 
leaving group to be transiently entrapped in 
a cell in a similar manner to other 
radiotracers such as 18F-FDG and 18F-FLT, 
by conversion of a tracer into a more polar 
molecule. Theoretically, as the result of ester 
linkage between the leaving group with O-
ADPR (Fig. 35), the leaving group is trapped 
inside the cell in form of the 18F-
fluorophenyl-O-ADPR product. Therefore, SIRT1-mediated cleavage of 18F-fluorophenyl group 
from 2-[18F]PhAHA with formation of 2-18F-fluorophenyl-O-
ADPR complex represents the rate-limiting step in the cellular 
entrapment of 2-[18F]PhAHA -derived radioactivity. The removal 
of an acetyl (or other) moiety from the O-ADPR group has been 
investigated and hypothesized that enzymes such as ARH3 may 
cleave an acetyl moiety from the O-AADPR (O-acetyl-ADP-
ribose) ring or possible methanolysis of acetyl into 1’O-
methyl’ADPR may occur. Additionally, a nucleophilic attack 
from lysine side chains of other proteins in close proximity may 
 
Figure 49. 
Autoradiography (left) 
aligned with 
corresponding 
PET/CT/MR image (right) 
for 2-[18F]PhAHA. 
 
Figure 48. IHC results demonstrating increased 
SIRT1-expression in the rat. A) Rat prefrontal 
cortex; B) Rat nucleus accumbens; C) Rat 
striatum; D) rat hippocampus. Data is from 
literature (Zakhary et al., 2010). The arrow 
indicates nuclear localization of the stain within 
neuronal fibers. 
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also de-acetylate the O-AADPR. However, little is known about the removal of a larger group 
such as a phenyl ring from ADP moiety, therefore further studies are needed to fully characterize 
the half-life of O-2-[18F]Ph-ADPR, and determine whether this intermediate is in fact stabile. 
These factors will contribute to the residence time for the possible radiotracer-derived metabolite, 
2-[18F]benzoic acid, within the cell. Characterizing the nature of this entrapment is important 
because this represents k4 in the molecular imaging equation and determines whether the 
circulating metabolite may contribute to radiotracer volume of distribution. 
Additionally, altered SIRT1 expression levels have been noted in many neurodegenerative 
diseases, such as Huntington’s, and have led to exploratory clinical trials with SIRT1 selective 
inhibitors, such as Selisistat (EX-527) (Smith et al., 2014), for treatment of the disease (Sussmuth 
et al., 2015). Though there is some debate in literature regarding the effectiveness of SIRT1 
activators vs. inhibitors for treatment of neurodegeneration (Naia and Rego, 2015). In fact, both 
SIRT1-activators and inhibitors are currently in clinical trials for treatments of different pathologic 
conditions. Therefore, non-invasive molecular imaging with PET using SIRT1-specific substrate-
type radiotracers may provide information about both location and magnitude for SIRT1-
expression and activity, which could help to determine the mechanistic, therapeutic and prognostic 
roles of SIRT1 in different pathological states. One area where this may be especially useful, is 
within the brain, where biopsies are not possible and SIRT1 plays very pleiotropic roles in both 
norm and neuropathological conditions.  
Dynamic PET/CT images of the brain, acquired in normal rats, using 2-[18F]PhAHA, have 
demonstrated significant differential tracer washout in areas of the brain with relatively higher 
SIRT1 expression, as correlated with ISH and IHC results in literature (Ramadori et al., 2008; 
Zakhary et al., 2010) (Fig. 46-48). The accumulation of 2-[18F]PhAHA- derived radioactivity in 
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areas of the brain is most predominant at 15-30 minutes post administration of the tracer. This is 
verified by both Logan plots and time activity curve quantification of PET/CT images with 2-
[18F]PhAHA (Fig. 46).  Alignment  of the brain regions to the corresponding brain atlas regions 
demonstrates high activity in hippocampus, caudate putamen, dentate gyrus, amygdala and n. 
accumbens (Fig. 47). While there is very little tracer-derived radioactivity accumulation in the 
brainstem region or the cerebellum. This observation, coupled with literature findings of little 
SIRT1 activity in these areas, allow us to use the brainstem as a reference tissue for quantification. 
 
 
Figure 50. Fluorescent microscopy staining for SIRT1 with an alexa-fluor 488 primary conjugated 
antibody (green), counter stained with DAPI as a nuclear marker (blue) at 10x magnification. The white 
box is magnified at 20x on bottom. 
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Furthermore, autoradiography was performed at 20 minutes post i.v. administration of 2-
[18F]PhAHA to capture the radioactivity 
accumulated at this time point, 
corresponding to the highest point of 
differential washout on the time activity 
curves (Fig. 49). The axial autoradiography 
images acquired with 2-[18F]PhAHA 
correlate well to the axial PET/CT images 
of the corresponding brain region. 
Fluorescent microscopy of brain 
slices stained for SIRT1 with DAPI counter 
stains demonstrates increased SIRT1 
expression in hippocampal regions, 
 
Figure 51. Fluorescent staining of SIRT1 expression in the hippocampus of a rat brain (green) counter 
stained with DAPI nuclear marker (blue).  
Figure 52. 20x magnification of hippocampal CA2 
region with SIRT1 fluorescent stain in green and DAPI, 
nuclear marker, in blue. 
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specifically in the CA2 region and nucleus accumbens (Fig. 50-52). The ventral and ventral-medial 
sides of the n. accumbens demonstrate the highest increase in SIRT1 expression. From the 
magnified image, it is possible to depict both nuclear and cytoplasmic localization for SIRT1. The 
hippocampal region also demonstrates significant increases in SIRT1 expression as seen on 
fluorescent images of the CA1, CA2 and CA3 region (Fig. 51). This correlates well with what is 
seen on PET/CT images with 2-[18F]PhAHA. It is evident from this image that the CA2 (lateral 
aspect of hippocampus) region has higher SIRT1 expression than CA1 (medial aspect of 
hippocampus).  The magnified view of CA2 shows heterogenous localization for SIRT1, both 
cytoplasmic as well as nuclear. Interestingly, the corpus collosum has no SIRT1 expression and 
only shows nuclear stains. Another key factor to note is the strong axonal staining evident within 
the hippocampus indicating strong SIRT1 localization and presence within the axonal cytoplasm. 
Within some cells of the image, it is possible to define the distinct axon radiating from the nucleus. 
The staining of SIRT1 in the hippocampus matches the more lateral accumulation of 2-
[18F]PhAHA within the hippocampus and lack of accumulation in the middle of the hippocampal 
region on coronal sections. Furthermore, these data correspond well to the published IHC and ISH 
data for SIRT1 in both mouse and rat brains (Ramadori et al., 2008; Zakhary et al., 2010). 
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To further test the responsiveness of novel SIRT1-selective radiotracer 2-[18F]PhAHA to an 
inhibitor in vivo, EX-527 was used at 5mg/kg dose i.p. 30 min prior to imaging to demonstrate 
differences in 2-[18F]PhAHA-derived radioactivity accumulation before and after inhibitor 
administration in the same animal, 24 hours apart. The significant decreases in 2-[18F]PhAHA-
derived radioactivity accumulation evident in dynamic PET/CT images after administration of 
inhibitor, specifically in regions of the brain of previously high radioactivity accumulation, 
validates the in vivo selectivity of this radiotracer for SIRT1. Quantitatively, these differences are 
demonstrated as differences in SUV at 22 min post radiotracer injection, for many regions of the 
brain, as well as muscle for reference (Fig. 53). As previously noted, the brainstem demonstrates 
little SIRT1 activity and accumulation of 2-[18F]PhAHA-derived radioactivity product, this is 
further validated through the lack of differences seen with and without inhibitor (Fig. 53). 
However, it should be noted that EX-527 may have limited BBB penetrability, thereby dampening 
the effects of the inhibitor within the brain. This is evidenced by other ongoing studies in rats 
Figure 53. A) PET/CT images acquired with 2-[18F]PhAHA (at 20 min post i.v. bolus injection) 
and without administration of  SIRT1 selective inhibitor EX-527 (5 mg/kg) given 30 min prior to 
radiotracer i.p.. B) Quantification of dynamic PET/CT images demonstrating a decrease in uptake 
of 2-[18F]PhAHA  in areas of high SIRT1-specific accumulation within the brain. 
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bearing brain tumors, with a broken BBB, where much greater differences in 2-[18F]PhAHA-
derived radioactivity accumulation are seen before and after inhibitor administration.  
Additional PET/CT images were acquired using radiolabeled metabolites of 2-[18F]PhAHA 
(37), including 2-[18F]Ethylbenzoate (30), 2-[18F]benzoic acid (31)  and 2-[18F]benzaldehyde (34) 
in both normal mice and rats (Fig. 54-55). It is possible that when 2-[18F]PhAHA is cleaved the 
phenyl ring leaving group may be attached to the -OADPR ring only briefly due to increased steric 
hindrance of a phenyl ring as compared to an acetyl moiety. While more in vitro studies are needed 
to understand this mechanism in full, imaging animals with possible radiolabeled metabolites 
provides information regarding the potential contribution of metabolites to the images acquired 
with 2-[18F]PhAHA. This study also helps to identify whether SIRT1 mediated cleavage is the 
primary source of cleavage for the parent compound or whether peripheral cleavage is occurring, 
leading to an increased fraction of free metabolites.  
 
Figure 54. A) PET/CT images of a mouse post i.v. administration of 2-[18F]Benzoic acid (31) B): PET/CT 
images of a mouse post i.v. administration of 2-[18F]ethylbenzoate (30) C) Overlay of A and B D) PET/CT 
images of a rat post i.v. administration of 2-[18F]Ethylbenzoate. All images taken at 25 min. post 
radiotracer injection. 
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2-[18F]Ethylbenzoate was  chosen as an attempt to create a more BBB permeable metabolite 
that would be cleaved to 2-[18F]benzoic acid (31) upon entering the brain by the abundant brain 
esterases. However, PET/CT images in mice at 20 min. post i.v. administration of 30 and 31 
demonstrated an increased BBB penetration of 31 over 30, which was surprising given the nature 
of the compounds’ polarity (Fig. 54). Furthermore, once inside the brain both of these compounds 
exhibited remarkable differences in accumulation patterns. Compound 31 accumulates 
preferentially in the median reticular nucleus (-2.0- -4.0), where as compound 30 accumulates 
much more in the hypothalamic and amygdala regions (-2.0) (Fig. 53-54). Also, interesting to note 
that imaging with compound 30 in a rat (Fig. 54D, Fig 55) does not demonstrate the same patterns 
as in a mouse and exhibits even lower BBB permeability. One possible reason for these differences 
could be due to changes in esterase activity between species. The reasoning behind reduced BBB 
penetrance with compound 30 is still 
yet unknown and warrants further 
investigation.  
In a rat, compounds 30 and 34 
were studied with the parent compound 
37. Compound 34 demonstrated 
significantly increased BBB 
permeability over compound 30 and 
strong accumulation in the brainstem 
(Fig. 54). 2-[18F]benzaldehyde exhibits 
remarkably different patterns of 
radioactivity accumulation within the 
 
Figure 55. PET/CT images with compound 30 
(bottom) and 31 (top) and corresponding brain 
histology and maps. 
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brain as compared to the 
parent compound, 2-
[18F]PhAHA. The biggest 
difference between the two 
is a great increase in 
accumulation of 2-
[18F]benzaldehyde-derived 
radioactivity within the 
brainstem, whereas 2-
[18F]PhAHA-derived 
radioactivity accumulation 
in this area is minimal. 
There are some regions 
within the brain of overlap, 
such as nucleus accumbens. 
The large variation in 
patterns of radioactivity 
accumulation between 
these three radiotracers 
within the brain highlights the results of using a substrate-type radiotracer. Within the brain, 
SIRT1-mediated cleavage of the parent compound causes cellular entrapment of the radiolabeled 
leaving group. Administration of the “pre-cleaved” metabolite (i.e. fluorobenzoic acid or 
fluorobenzaldehyde) does not allow enzyme-mediated entrapment to occur.  
 
Figure 56. Comparison between PET/CT images acquired 20 
min. post i.v. administration of three tracers, the parent compound 
2-[18F]PhAHA (37), and two possible metabolites: 2-
[18F]benzaldehyde (34) and 2-[18F]Ethylbenzoate (30) 
metabolized to 2-[18F]benzoic acid (31).  
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The pattern of accumulation of 2-[18F]-benzaldehyde (34) within specific regions of the brain 
has not yet been fully explained. However, it is known that benzaldehyde acts as a potent inhibitor 
of glutathione peroxidase (GSH-PX) (Tabatabaie and Floyd, 1996). Reportedly, 250 μM of 
benzaldehyde is sufficient to completely remove all residual GSH-PX activity and 2-
bromobenzaldehyde or 2-hydroxybenzaldehyde reduce GSH-PX activity by 80% at 250 μM 
(Tabatabaie and Floyd, 1996). These two compounds have similar chemical properties and size to 
2-fluorobenzaldehyde. Furthermore, areas within the brain demonstrating high levels of GSH-PX 
include structures within the brainstem (i.e. pons, medulla, mesencephalon) (Nisticò et al., 1992). 
These structures have almost a 2 fold increase in levels of active GSH-PX over other structures 
within the brain such as the cortex and hippocampus, particularly in adult rats (Nisticò et al., 1992). 
These findings may provide an explanation to the perceived selectivity for 2-[18F]-benzaldehyde 
(34) accumulation within structures of the brain, though more studies are needed for conclusive 
results. 
At this point, we can conclude that the metabolites may not be having a large influence on 
the distribution of 2-[18F]PhAHA seen in the brain. Even more importantly, there is a difference 
between SIRT1-mediated cleavage of 2-[18F]PhAHA and administering the pre-cleaved product, 
thus indirectly supporting the theory to the degree of radiolabeled metabolite entrapment within 
the cell. Further studies are also necessary to understand why the stark difference in BBB 
permeability between 30 and 31.  
The translation of 2-[18F]PhAHA to in vivo PET imaging may further the field of epigenetic 
regulation in both norm and disease and facilitate the development and clinical translation of 
SIRT1-targeted drugs. PET imaging with a substrate type radiotracer such as 2-[18F]PhAHA will 
allow for in vivo visualization and quantification of the enzyme expression-activity product. 
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Therefore, the accumulation of 2-[18F]PhAHA derived radioactivity is directly proportional to the 
amount of active enzyme in a tissue. The current approach to imaging SIRT1 activity using 
substrate-type radiotracers complements other methodologies for PET imaging of enzymes, 
including radiolabeled inhibitors. PET imaging with radiolabeled enzyme inhibitors is essentially 
similar to a receptor-ligand based imaging approach, where the amount of radiotracer-derived 
radioactivity accumulation is proportional to the amount of free (unoccupied) receptor or enzyme 
in a given tissue (J, 2000). The visualization of receptor or enzyme occupancy is especially 
important for determining the pharmacokinetics and bio-distribution of an inhibitor (i.e. drug or 
therapeutic agent). Successful inhibitor-type radiotracers have been developed specifically for 
HDAC class I, in the form of 11C-Martinostat (Hooker et al., 2009). However, imaging with an 
inhibitor does not provide information about the enzyme activity. In contrast, substrate-type 
radiotracers allow for assessment of the enzyme expression-activity and monitoring the 
pharmacodynamics of inhibitor at the target (enzyme) level. 
Conclusions 
Visualization and quantification of SIRT1 expression-activity non-invasively in vivo via PET 
imaging may help elucidate the role of SIRT1 in both norm and disease. This work includes the 
first ever PET/CT imaging with and characterization of SIRT1-selective radiotracer, 2-
[18F]PhAHA, in the brain and can be applied to many future studies of larger animals and 
pathologies such as cancers and neurodegenerative disorders. Additionally, this novel 
understanding of SIRT1 structure activity relationships may help in development of BBB 
permeable pharmacologic modulators. In summary, the development of a novel method for 
imaging SIRT1 expression-activity in the brain should help further the field of epigenetics and 
treatment of untreatable diseases. 
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 Experimental Section 
All solvents were purchased from Sigma-Aldrich Chemicals (Milwaukee, WI) and used 
without further purification. Boc-Lys(Ac)-AMC and Cbz-Lys-OH were purchased from Bachem 
(Bubendorf, Switzerland) and used without further purification. Preparation of 6-amino-
1hexanoicanilide (Mukhopadhyay et al., 2006) was synthesized using a previously published 
procedure (Yeh et al., 2013a). Thin layer chromatography (TLC) was performed on pre-coated 
Dynamic Absorbance F-254 silica gel, aluminum backed plates (Norcross, Georgia); flash 
chromatography was performed using silica gel pore size 60 Å, 230-400 mesh particle size (Sigma-
Aldrich, Milwaukee, WI). NMR spectra including 1H, 13C and 19F were performed on Mercury 
400 MHz, Varian 500 MHz or Agilent 600 MHz spectrometers. High-resolution mass spectra 
(HRMS) were obtained using Waters LCT Premier/XE spectrometer (Milford, MA) with an 
electrospray ionization (ESI) technique. The analytical high performance liquid chromatography 
(HPLC) system included: Ascentis RP-Amide 4.4x150 mm column (Supelco, Bellefonte, PA) 
connected to the 1100 series pump and UV detector (Agilent Technologies, Stuttgart, Germany), 
operated at 254 nm, and a radioactivity detector FC3200 (Eckert and Ziegler Radiopharma, Inc, 
Berlin, Germany). The semi-preparative HPLC system included: the Alltima 250x10mm C18 
column (Fisher Scientific, Waltham, MA) connected to the P4.1S pump, Azura 2.1S UV detector 
(Knauer, Berlin, Germany), operated at 254 nm, and a radioactivity detector FC-3500 (Eckert and 
Ziegler Radiopharma, Inc, Berlin, Germany). 
SIRT Enzyme Assay: Recombinant SIRT1-7 enzymes and BPS1 reference substrate for 
SIRT2, an oligopeptide corresponding to 379-382 of p53 (Arg-His-Lys-Lys(Ac)-AMC) were 
purchased from BPS Bioscience (San Diego, CA). 10 mM solutions of all newly synthesized 
compounds were prepared in pure DMSO and then diluted to 100 µM aliquots in DMSO for further 
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use. Enzyme assay reactions were performed in black, low binding 96-well microtiter plates (Nagle 
Nunc International, Rochester, NY). Endpoint assays were performed by incubation of the 
appropriate substrate, NAD, a SIRT enzyme, and inhibitor (if applicable) in enzyme assay buffer 
(50 µL final volume). Control wells without enzyme were included in each plate. After 40 min at 
37 °C, a developer mixture (50 µL) containing nicotinamide (2 mM) and trypsin (0.4 mg mL−1) 
was added, and the mixtures incubated for 30 min at 22°C. The intensity of cleaved 7-amino-
4methylcoumarin (AMC) fluorescence was measured using Synergy H1 microplate reader 
(Biotek, Winooski, VT) at 360 nm excitation and 450 nm emission wave lengths. Experiments for 
determination of enzyme kinetic parameters were performed by incubation of test compounds or 
BPS1 reference substrate at different concentrations with NAD+ and individual SIRT enzymes in 
an assay buffer (100 µL final volume) at 37°C for different periods of time (5, 10, 20, 30, and 60 
min), followed by in situ fluorophore cleavage by addition of a developer mixture (50 µL) 
containing nicotinamide (2 mM) and trypsin (0.4 mg mL−1). Fluorescence was measured as 
relative fluorescence units (RFU) at 22°C to determine the initial linear rate V0 (RFU min−1) for 
each concentration. The data were analyzed using GraphPad Prism v6.02 (GraphPad, La Jolla, 
CA) to afford km (µM) and Vmax (RFU min−1) values. The kcat values were calculated based on 
the RFU vs AMC concentration standard curve and the enzyme purities and concentrations 
provided by the manufacturer. 
  Fluorescent Staining: Perfused and fixed rat brains were sliced into 20 μm thick slices on 
a microtome for staining. The slices were mounted onto slides and stained with fluorescently 
conjugated primary SIRT1 antibody (Abcam) using 1:200 dilution. Following staining the slides 
were cover slipped using Vecashield mounting medium with DAPI included by placing 25 μL 
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drops of mounting media on each tissue slice. Images were taken using EVOS FL Auto Imaging 
System microscope (Thermo Fisher Scientific). 
MRI Procedure: Animals initially anesthetized with 5% isoflurane, and maintained 
between 2-3% for the remainder of the experiment. During the procedure each animal was placed 
on a heated re-circulating water platform in order to maintain body temperature.  The animals were 
held in position using a bite bar and a receive-only surface coil 2-element phased array for the rat 
brain) was placed dorsal to the head. Scans were acquired using a 7T ClinScan system (Bruker, 
UK) controlled by the Syngo software (Siemens, Knoxville, TN). A localizing scan was performed 
and adjustments to head position were made accordingly. T2 images were obtained (repetition time 
[TR] 3530 ms echo time, [TE] 38 ms, FOV 3.2 cm x 3.2 cm x 2.4 cm, resolution 125 µm x 125 
µm x 1 mm). Images were processed using ImageJ software (Bethesda, MD).   
PET Imaging Procedures in Animals: All studies performed under a protocol approved 
by the Institutional Animal Care and Use Committee of Wayne State University. Sprague-Dawley 
rats (200-250 g, N=3) were anesthetized with 3% isoflurane in oxygen and maintained at 2% 
isoflurane in oxygen throughout the imaging studies. The body temperature was maintained using 
electronically controlled heating pad (M2M Imaging, Cleveland, OH) set at 37oC. Anesthetized 
rats placed in the microPET R4 scanner (Siemens, Knoxville, TN) in the supine position with the 
long axis of the animal parallel to the long axis of the scanner with the brain positioned in the 
center of the field of view. Each radiotracer (300-500 µCi/animal) was administered in saline via 
the tail-vein injection in a total volume ≤1.25 ml.  Dynamic PET images were obtained over 60 
minutes, followed by 2 overlapping frames (5 min each) acquired to obtain a whole body images 
of radiotracer biodistribution in other organs and tissues. After PET imaging, the positioning bed 
with the affixed anesthetized animal was transferred to the Inveon SPECT/CT scanner (Siemens, 
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Knoxville, TN) and CT images and 4 overlapping frames (2 min each) were acquired covering the 
whole body using X-ray tube settings of 80 kV and 500 μA.  
Image Analysis and Quantification: PET images were reconstructed using ordered subset 
expectation–maximization (OSEM) method. PET image analysis was accomplished using the 
AMIDE software. Digital Rat Brain Atlas was used for alignment and identification of specific 
anatomical markers in the brain (Watson, 2006).  GraphPad Prism 6 (Graph Pad Software La Jolla, 
CA) and Excel 2010 (Microsoft, Redmond, WA) were used for image data analysis. Levels of 
accumulation of individual radiotracers in tissues were expressed as standard uptake values (SUV) 
that were calculated for the regions of interest (Ron S. Broide and Floyd E. Bloom) using the 
AMIDE software. The SUV is defined as the ratio of the tissue radioactivity concentration C (e.g. 
expressed as Bq/g tissue) at given time point post injection T, and the injected dose (e.g. in Bq, 
decay-corrected to the same time T), and normalized by the body weight in grams. Calculations 
for Logan plot analysis were performed as previously noted (Logan J, 1996). 
 Autoradiography: After PET imaging (or at certain time point after 300-500 µCi 
radiotracer injection i.v.), the animals were sacrificed, the brain was rapidly extracted, frozen, and 
embedded in the mounting medium M1 (Shandon-Lipshaw, Pittsburg, PA). Serial 20 µm thick 
coronal sections of frozen brain tissue were obtained at -13°C using a cryo-microtome CM3050S 
(Leica, Germany). Tissue sections were thaw-mounted on poly-A lysine coated glass slides and 
heat-fixed for 5 min at 65°C on a slide warmer (Fischer Scientific, PA). Tissue sections, mounted 
on slides, exposed to single-emulsion Carestream Kodak BioMax MR film (8”x10”, Sigma, 
Milwaukee, WI), without exposure to light, in cassettes for 12 hours. After tissue exposure, 
processing of the film used an automated system (Kodak X-Omat, Center for Molecular Medicine 
and Genetics, Wayne State University). 
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Chemical Synthesis: 
Method 1: For new substrate analogues, we primarily modified the protecting group on α-nitrogen 
and the acyl substituent on the ε-amino group. Benzyloxy carbonyl (Z, Cbz) was investigated as a 
protecting group within the cap moiety. Compounds were prepared following previously published 
methods (Heltweg et al., 2004; Heltweg et al., 2003) as shown in the synthetic Fig. 29-30 with 
minor modifications. Compounds 17-27 were synthesized from commercially available Cbz-Lys-
OH with formation of corresponding acetyl chloride following the published methods (Heltweg et 
al., 2004) which upon reaction with AMC (19) in presence of POCl3 and pyridine provide desired 
product in moderate to good yields.  
Synthesis of compound 16: Cbz-Lys (1 equiv.) was dissolved in a mixture of THF (5 mL) 
and water (5 mL). To this sodium bicarbonate (2 equiv.) and a solution of Boc2O (2.3 equiv.) in 
THF (5 mL). After stirring at room temperature overnight, the THF was removed under reduced 
pressure and the resulting aqueous solution was neutralized with 2N HCl. This was extracted with 
ethyl acetate and the combined organic layers were washed with brine. The organic layer was dried 
with sodium sulfate and concentrated to clear. The clear oil was used for further reaction without 
any purification with 2 in presence of NMM/isobutyl chloroformate (Fig 2). 
Benzyl (6-acetamido-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino-1oxohexan-2-
yl)carbamate (17): Compound 17 was prepared following previously published method 1, 
(Heltweg et al., 2004) as described in the synthetic Scheme 1 (Figure 1 and 2). Here we report MS 
(EI) and HRMS of the compound. MS (EI): m/z 478.4 [M-H]. High-resolution MS: Calculated for 
C26H29N3O6 (M+Na) 502.1954, found 502.1953. 
Benzyl (6-benzamido-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-oxohexan-2-
yl)carbamate (18): Compound 18 was synthesized by method 1 (Heltweg et al., 2004). The 
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resulting product was chromatograph with 5% methanol in dichloromethane. Yield: 63%, 1H NMR 
(CDCl3, 600 MHz): δ 9.38 (s, 1H), 7.76 (d, 2H, J = 7.8 Hz), 7.68 (s, 1H), 7.602-7.46 (m, 3H), 
7.39-7.34 (m, 7H), 6.18 (s, 1H), 595 (d, 1H, J = 7.2 Hz), 5.11 (m, 2H), 4.41 (s, 1H), 3.49 (m, 1H), 
2.40 (s, 3H), 2.07-2.05 (m, 1H), 1.88-1.80 (m, 1H), 1.70-1.64 (m, 2H), 1.56-1.50 (m, 2H). 13C 
NMR (CDCl3, 600 MHz): δ 171.00, 168.24, 161.26, 156.92, 154.07, 152.46, 141.47, 136.08, 
134.25, 134.23, 131.61, 128.61 (2C), 128.25, 128.02, 126.92 (2C), 125.10, 116.04, 115.84, 11.31, 
107.30, 67.28, 55.41, 38.73, 38.60, 31.24, 29.71, 28.75, 22.26, 18.56. MS (EI): m/z 542.6 [M+H]. 
High-resolution MS: Calculated for C31H31N3O6 (M+Na) 564.2111, found 564.2105. 
Benzyl (6-(2-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (19). Compound 19 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 3% methanol/dichloromethane and purified 
by combiflash with 5% methanol/dichloromethane. Yield: 69%, 1H NMR (DMSO-d6, 600 MHz): 
δ 10.51 (s, 1H), 8.29 (s, 1H), 7.77 (brs, 1H), 7.71 (d, 1H, J = 8.4 Hz), 7.65 (d, 1H, J = 7.8 Hz), 7.54 
(t, 1H, J = 7.2 Hz), 7.50-7.47 (m, 2H), 7.38-7.31 (m, 4H), 7.24-7.17 (m, 2H), 6.27 (s, 1H), 5.03 (s, 
2H), 4.16 (m, 1H), 3.24 (q, 2H, J = 6.6 Hz), 2.40 (s, 3H), 1.72-1.66 (m, 2H), 1.56-1.38 (m, 4H). 
13C NMR (DMSO-d6, 600 MHz): δ 172.49, 164.15, 160.59, 160.28, 158.63, 156.65, 154.09, 
153.68, 142.67, 137.39, 132.66, 130.42, 128.84 (2C), 128.32 (2C), 126.41, 124.85, 116.55, 116.40, 
115.77, 115.56, 112.75, 106.19, 65.98, 56.05, 39.33, 31.74, 29.04, 23.39, 18.45.19F (DMSO-d6, 
300 MHz): δ -114.49. MS (EI): m/z 560.6 [M+H]. High-resolution MS: Calculated for 
C31H30FN3O6 (M+Na) 582.2016, found 582.1989. 
Benzyl (6-(3-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (20). Compound 20 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and 
121 
 
purified by combiflash with 5% methanol/dichloromethane. Yield: 66%, 1H NMR (CDCl3): δ 9.19 
(brs, 1H), 7.67 (s, 1H), 7.55-7.49 (m, 4H), 7.46-7.351 (m, 6H), 7.20 (t, 1H, J = 7.8 Hz), 6.56 (brs, 
1H), 6.22 (s, 1H), 5.85 (brs, 1H), 5.14 (m, 2H), 4.40 (s, 1H), 3.51 (m, 2H), 2.43 (s, 3H), 2.07-2.06 
(m, 1H), 1.88-1.80 (m, 1H), 1.72-1.60 (m, 2H), 1.56-1.52 (m, 2H). 13C NMR (CDCl3): δ 170.56, 
166.86, 163.54, 161.18, 154.11, 152.21, 141.10, 136.00, 130.32, 128.59 (2C), 128.31, 128.06 (2C), 
125.14, 122.43, 118.66, 118.52, 116.15, 115.80, 114.41, 114.27, 113.41, 107.31, 67.36, 55.34, 
38.73, 30.95, 28.61, 22.16, 18.59. 19F (CDCl3, 300 MHz): δ -111.60. MS (EI): m/z 560.6 [M+H]. 
High-resolution MS: Calculated for C31H30FN3O6 (M+Na) 582.2016, found 582.1986. 
Benzyl (6-(4-fluorobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (21). Compound 21 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 72%, 1H NMR (CDCl3): δ 9.38 
(s, 1H), 7.78 (m, 2H), 7.66 (s, 1H), 7.51-7.45 (m, 2H), 7.39-7.33 (m, 5H), 6.99 (t, 2H, 6J), 6.65 (t, 
1H, J = 6 Hz)), 6.15 (s, 1H), 6.02 (d, 1H, J = 8 Hz)), 5.11 (s, 2H), 4.45 (brs, 1H), 3.49-3.46 (m, 
2H), 2.39 (s, 3H), 2.01-1.88 (m, 2H), 1.71-1.67 (m, 2H), 1.55-1.50 (m, 2H). 13C NMR (CDCl3): δ 
170.91, 167.16, 165.59, 161.17, 154.1, 152.36, 141.37, 136.00, 130.38 (2C), 129.31 (2C), 129.25, 
128.60 (2C), 128.32, 128.06, 125.13, 116.12, 115.80, 115.69, 115.54, 113.40, 107.30, 67.37, 
55.38, 38.66, 30.93, 28.69, 22.17, 18.57. 19F (CDCl3, 300 MHz): δ -107.70. MS (EI): m/z 560.6 
[M+H]. High-resolution MS: Calculated for C31H30FN3O6 (M+Na) 582.2016, found 582.1985. 
Benzyl (1-((4-methyl-2-oxo-2H-chromen-7-yl)amino-1-oxo-6-(2-
phenylacetamido)hexan-2-yl)carbamate (22). Compound 22 was prepared following previously 
published method 1 (Heltweg et al., 2004) as described in the synthetic Scheme 1. The resulting 
product was chromatograph with 3% methanol in dichloromethane and purified by combiflash 
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with 5% methanol/dichloromethane. Yield: 59%, This is known compound, so here we report MS 
(EI): m/z 554.6 [M-H]. High-resolution MS: Calculated for C32H33N3O6 (M+Na) 578.2267, found 
578.2269.   
Benzyl (6-(2-(2-fluorophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-
1-oxohexan-2-yl)carbamate (23). Compound 23 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 57%, 1H NMR (DMSO-d6): δ 
10.52 (s, 1H), 8.06 (t, 1H, J = 5.4 Hz), 7.78 (s, 1H),7.73-7.64 (m, 2H), 7.51 (s, 1H), 7.37-7.24 (m, 
7H), 7.12-7.09 (m, 2H), 6.27 (s, 1H), 5.04 (s, 2H), 4.13 (m, 1H), 3.04 (m, 2H), 2.40 (s, 3H), 1.68-
1.33 (m, 6H). 13C NMR (DMSO-d6): δ 172.10, 169.51, 167.22, 160.38, 156.18, 154.00, 153.68, 
142.69, 137.39, 132.19, 129.14, 129.01 (2C), 128.96, 128.85 (2C), 126.45, 124.60, 122.62, 115.79, 
115.57, 115.48, 112.76, 106.19, 65.99, 55.33, 38.98, 35.74, 31.17, 28.81, 22.85, 18.45. 19F 
(DMSO-d6, 300 MHz): δ -117.40. MS (EI): m/z 572.6 [M-H]. High-resolution MS: Calculated for 
C32H32FN3O6 (M+Na) 596.2173, found 596.2180.  
Benzyl (6-(2-(4-fluorophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-
1-oxohexan-2-yl)carbamate (24). Compound 24 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 60%, 1H NMR (MeOD): δ 7.78 
(s, 1H), 7.67 (d, 1H, J = 8.2 Hz), 7.46 (d, 1H, J = 2 Hz), 7.39-7.25 (m, 7H), 7.00-6.97 (m, 2H), 
6.22 (s, 1H), 5.12-5.11 (m, 2H), 4.26 (t, 1H, J = 5.3 Hz), 3.45 (s, 2H), 3.19 (t, 2H, J = 6.6 Hz), 2.45 
(s, 3H), 1.86-1.74 (m, 2H), 1.56-1.40 (m, 4H). 13C NMR (MeOD): δ 172.44, 172.36, 162.70, 
161.81, 161.08, 157.23, 153.91, 153.82, 141.94, 136.74, 131.58, 130.61, 130.40, 130.35, 128.09, 
127.66, 127.48, 125.27, 115.82, 115.79, 114.81, 114.76, 112.22, 106.66, 66.40, 55.83, 42.37, 
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38.79, 31.46, 28.58, 22.82, 17.12. 19F (MeOD, 300 MHz): δ -118.40. MS (EI): m/z 574.7 [M+H]. 
High-resolution MS: Calculated for C32H32FN3O6 (M+Na) 596.2173, found 596.2173. 
Benzyl (6-(4-iodobenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (25). Compound 25 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 60%, 1H NMR (CDCl3): δ 
9.17 (s, 1H), 7.69-7.66 (m, 3H), 7.54-7.46 (m, 4H), 7.42-7.34 (m, 5H), 6.21 (s, 1H), 5.86 (brs, 1H), 
5.12 (s, 2H), 4.38 (brs, 1H), 3.55-3.44 (m, 2H), 2.43 (s, 3H), 2.10-2.06 (m, 1H), 1.89-1.84 (m, 1H), 
1.71-1.68 (m, 2H), 1.57-1.50 (m, 2H). 13C NMR (MeOD): δ 171.50, 166.21, 160.30, 155.42, 
152.20, 135.86, 132.30 (2C), 126.97, 126.58 (2C), 126.15, 125.96, 123.76, 122.76, 120.18, 119.09, 
118.70, 116.95, 114.96, 114.32, 110.82, 105.17, 96.01, 64.87, 54.25, 37.45, 29.90, 27.00, 21.10, 
15.70. MS (EI): m/z 667.5 [M+]. High-resolution MS: Calculated for C31H30IN3O6 (M+Na) 
690.1077, found 690.1075. 
Benzyl (6-(2-(4-iodophenyl)acetamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-
1-oxohexan-2-yl)carbamate (26). Compound 26 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 3% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 72%, 1H NMR (MeOD): δ 8.11 
(brs, 1H), 7.88 (d, 1H, J = 8.4 Hz), 7.82 (s, 1H), 7.76-7.73 (m, 2H), 7.67 (d, 1H, J = 8.4 Hz), 7.61 
(d, 1H, J = 7.8 Hz), 7.54-7.48 (m, 2H), 7.40-7.31 (m, 2H), 7.09 (d, 1H, J = 7.8 Hz), 7.04 (d, 1H, J 
= 8.4 Hz), 6.26 (s, 1H), 5.13 (m, 2H), 4.25 (m, 1H), 3.43 (s, 2H), 3.21 (m, 2H), 2.48 (s, 3H), 1.89-
1.74 (m, 2H), 1.56-1.48 (m, 4H). 13C NMR (MeOD): δ 172.04, 171.92, 161.87, 154.00, 153.89, 
137.31 (2C), 137.23, 135.45, 131.20, 130.80 (2C), 128.09, 127.67, 127.50, 126.50, 125.35, 115.91, 
115.86, 112.26, 106.72, 91.30, 66.41, 55.80, 41.83, 38.53, 31.45, 28.53, 22.78, 17.15. MS (EI): 
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m/z 680.4 [M-H]. High-resolution MS: Calculated for C32H32IN3O6 (M+Na) 704.1233, found 
704.1231.   
Benzyl (6-(4-ethylbenzamido)-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (27). Compound 27 was synthesized by method 1 (Heltweg et al., 
2004). The resulting product was chromatograph with 5% methanol in dichloromethane and 
purified by combiflash with 5% methanol/dichloromethane. Yield: 77%, 1H NMR (CDCl3): δ 9.71 
(s, 1H), 7.68 (m, 3H), 7.44-7.39 (m, 2H), 7.38-7.30 (m, 4H), 7.12 (d, 2H, J = 7.8 Hz), 6.87 (s, 1H), 
6.26 (d, 1H, J = 7.8 Hz), 6.11 (s, 1H), 5.07 (s, 2H), 4.45 (brs, 1H), 3.42 (m, 2H), 2.62 (q, 2H, J = 
7.2 Hz), 2.44 (s, 3H), 1.98-1.82 (m, 2H), 1.67-1.48 (m, 4H), 1.19 (t, 3H, J = 7.2 Hz). 13C NMR 
(CDCl3): δ 171.55, 168.20, 161.40, 156.88, 153.89, 152.75, 148.11, 141.63, 136.17, 131.90, 
128.51 (2C), 128.13, 127.97 (2C), 127.89, 127.10 (3C), 125.05, 115.93, 115.84, 113.52, 107.21, 
67.14, 55.65, 39.09, 31.78, 28.89, 28.70, 22.55, 18.51, 15.27. MS (EI): m/z 570.7 [M+H]. High-
resolution MS: Calculated for C33H35N3O6 (M+Na) 592.2424, found 592.2433. 
Synthesis of 4-fluoro-phenylhexanoicanilide (28): 0.64 mmol of 4-fluorophenylacetic acid 
(purchased from Alfa-Aesar) was dissolved in ACN and 1 equivalent of DMAP was added with a 
catalyst amount of DCC. The mixture was stirred under argon for 10 minutes. Subsequently the 
amine, compound R1, (0.48 mmol) was dissolved in ACN and added to the mixture dropwise. The 
reaction was stirred under argon, at room temperature, overnight. The compound was purified 
using flash chromatography on a silica column and eluted with 3% MeOH in DCM. The compound 
was dried as white crystals in a yield of 77%. 1H NMR (499 MHz, CDCl3) δ 8.19(s, 1H), 8.12 (d, 
J = 7.9 Hz, 1H), 7.90 (t, J = 7.9 Hz, 1H), 7.85 (dd, J = 8.5, 5.4 Hz, 2H), 7.79 (dd, J = 8.4, 5.4 Hz, 
1H), 7.69 (t, J = 7.3 Hz, 1H), 7.59 (t, J = 8.7 Hz, 3H), 6.27 (s, 1H), 4.20 (s,3H), 4.10 (s, 1H), 3.99 
(t,2H, J = ), 3.82 (dd, J = 13.2, 6.8 Hz, 1H), 2.92 (t, J = 7.3 Hz, 1H), 2.50 (dd, J = 12.6, 3.2 Hz, 
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3H), 2.36 – 2.24 (m, 4H), 2.11 – 2.01 (m, 2H), 1.90 (d, J = 12.5, 8.9 Hz, 4H), 1.77 – 1.66 (m, 4H). 
13C NMR (126 MHz, CDCl3) δ 175.42, 171.36, 130.95, 128.95, 124.19, 119.80, 115.83 (d, J = 
21.3 Hz), 115.36 (d, J = 21.5 Hz), 77.27, 77.02, 76.76, 49.38, 42.80, 40.45, 39.29, 37.17, 33.70, 
28.87, 25.96, 25.51, 24.84, 24.68. 19F NMR (376 MHz, CDCl3) δ -115.86 (m).  
Radiosynthesis of 4-18F-phenylhexanoicanilide (28a): A solution of kryptofix/ K[18F] was 
received from the cyclotron and transferred into a crimped V-vial for drying.  Acetonitrile (0.4 
mL) was added to the mixture and it was dried under a stream of argon at 80°C.  4 mg of 4-nitro 
benzaldehyde in 0.4mL of DMF was added and stirred for 20 min at 120°C under Argon.  0.2mL 
of CHCl3 was then added to the mixture with 0.2mL of KOH/MeOH and stirred at -78°C for 10 
min.  The reaction mixture was evaporated under argon at room temperature to the DMF base.  
The resulting mixture was eluted through a cartridge with 10% MeOH/DCM and evaporated to 
dryness.  Subsequently, 0.4mL of t-Bu-OH was added with concentrated, 5M, NaOH and stirred 
for 5 min at room temperature. Borohydride (10mg) was added to the reaction mixture and stirred 
for 10 minutes at 50°C.  The resulting mixture was filtered and injected into semi-prep HPLC and 
purified with 35% ACN in H2O. The eluted mixture was coupled with compound 1 (10mg) using 
DCC and DMAP.  This was then purified for a yield of 180 uCi of pure compound (0.2% yield not 
decay corrected). 
2-Nitro-ethylbenzoate (29): Purchased from Alfa Aesar and used without further 
purification. 
2-F-ethylbenzoate (30a): Purchased from Alfa Aesar and used without further purification. 
2-18F-ethylbenzoate (30b): The F-18 was obtained in kryptofix/K[18F] complex in 
acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne State University (Detroit, MI) 
and transferred into a crimped 2 mL V-vial for azeotropic drying. Acetonitrile (0.4 mL) was added 
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to the mixture, which was dried under a stream of argon at 90-100°C. A solution of 29 (~2 mg) in 
dry DMSO (0.4 mL) was added to the dried kryptofix/ K[18F] and heated to 120°C under argon 
with stirring for 15 minutes. After cooling, the reaction mixture was passed through a 900 mg 
Altech silica gel cartridge (Fisher Scientific, Waltham, MA) and eluted with 2 mL of 10% 
methanol in dichloromethane (DCM). The solvent was evaporated under a stream of argon to 
remove DCM and to reduce the volume to 0.5 mL. 31 was purified by semipreparative HPLC 
(50% ACN in water) by collecting the peak at 15 min. The decay corrected radiochemical yield 
was 25% and the compound purity was >95%, as assessed by analytical HPLC and co-elution with 
the non-radiolabeled reference standard 32.  
2-18F-benzoic acid (31): Compound 30 was treated with 0.5mL of 1M NaOH at 80°C for 10 
minutes for hydrolysis of the ester group and form 31. Completion of the reaction was assessed by 
analytical HPLC. Subsequently, the solution was neutralized to pH of 7.5 with 0.5 mL of 1M HCl 
and the mixture was evaporated to dryness under a stream of argon. Compound 31 was redissolved 
in saline and prepared for animal injection.  
2-Nitro-benzaldehyde (32): Purchased from Alfa Aesar and used without further 
purification. 
2-Fluoro-benzaldehyde (33): Purchased from Sigma and used without further purification. 
2-18F-benzaldehyde (34): The F-18 was obtained in kryptofix/K[18F] complex in 
acetonitrile/water (1 mL) from the PET/Cyclotron Facility, Wayne State University (Detroit, MI) 
and transferred into a crimped 2 mL V-vial for azeotropic drying. Acetonitrile (0.4 mL) was added 
to the mixture, which was dried under a stream of argon at 90-100°C. A solution of 32 (~2 mg) in 
dry DMSO (0.4 mL) was added to the dried kryptofix/ K[18F] and heated to 130-140°C under 
argon with stirring for 12 minutes. After cooling, the reaction mixture was passed through a 900 
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mg Altech silica gel cartridge (Fisher Scientific, Waltham, MA) and eluted with 2 mL of 10% 
methanol in dichloromethane (DCM). The solvent was evaporated under a stream of argon to 
remove DCM and to reduce the volume to 0.5 mL. 34 was purified by semipreparative HPLC 
(50% ACN in water) by collecting the peak at 15 min. The decay corrected radiochemical yield 
was 15% and the compound purity was >95%, as assessed by analytical HPLC and co-elution with 
the non-radiolabeled reference standard 33.  
2-fluoro-phenylhexanoicanilide, 2-FPhAHA (35): Compound 1 (0.240g, 1.163 mmol) was 
dissolved in 5mL of dichloromethane and 0.5mL triethylamine. The 2-fluoro benzoylchloride (0.2 
mL, 1.696 mmol) was added dropwise at 0°C. The reaction was stirred at 0°C for 30 minutes then 
gradually warmed to RT and stirred under argon for 3 hours.  The mixture was washed with 
ethylacetate and 4N HCl solution.  The organic layer was dried over magnesium sulfate and then 
evaporated to dryness.  The resulting crude mixture was re-crystallized with diethyl-ether 
overnight and then filtered with vacuum filtration before being dried under high-vacuum.  Product 
35 (110mg) was made as a white solid in 28% yield. 1H NMR (400 MHz, cdcl3) δ 8.13 – 7.97 (m, 
1H), 7.81 (s, 1H), 7.53 (d, J = 7.8 Hz, 2H), 7.45 – 7.41 (m, 1H), 7.35 – 7.16 (m, 3H), 7.16 – 6.99 
(m, 2H), 6.80 (s, 1H), 3.46 (d, J = 5.9 Hz, 2H), 2.35 (t, J = 7.3 Hz, 2H), 1.82 – 1.69 (m, 2H), 1.69 
– 1.58 (m, 2H), 1.44 (d, J = 6.5 Hz, 2H). 13C NMR (101 MHz, cdcl3) δ 171.33, 163.47, 161.73, 
159.28, 138.18, 133.15 (d, J = 9.3 Hz), 131.82, 128.86, 124.75 (d, J = 3.1 Hz), 124.00, 121.21 (d, 
J = 11.3 Hz), 119.82, 115.98 (d, J = 24.8 Hz), 77.35, 77.03, 76.71, 39.74, 37.32, 29.17, 26.36, 
25.02. M/Z calculated: 329.1665; M/Z found : 329.1654 
2-Nitro-N-(6-oxo-6-(phenylamino)hexyl)benzamide: The solution of 2-nitrobenzoyl 
chloride (0.12 g, 0.62 mmol) in 0.5 mL of DCM was added dropwise to the mixture of 
phenylhexanamide (0.10 g, 0.48 mmol) and Hunig's base (0.13 mL, 0.73 mmol) in DMF (5 mL) 
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at 0°C and then left to stir at room temperature for 12 h. The solvent was then evaporated under 
reduced pressure; the crude was dissolved in EtOAc and washed with water. The organic layer 
was dried over sodium sulfate. Evaporation and purification with column chromatography 
(eluent - EtOAc) gave the desired precursor in 70-72% yield. 1H NMR (600 MHz, DMSO-d6) δ 
9.87 (s, 1H), 8.66 (t, J = 5.5 Hz, 1H), 8.02 (d, J = 8.1 Hz, 1H), 7.75 (t, J = 7.5 Hz, 1H), 7.67 (t, J 
= 7.8 Hz, 1H), 7.60 (d, J = 8.2 Hz, 2H), 7.57 (d, J = 7.5 Hz, 1H), 7.28 (t, J = 7.8 Hz, 2H), 7.01 (t, 
J = 7.3 Hz, 1H), 3.22 (dd, J = 12.9, 6.6 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.67 – 1.59 (m, 2H), 
1.58 – 1.50 (m, 2H), 1.42 – 1.33 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 171.2, 165.3, 147.0, 
139.4, 133.5, 132.8, 130.5, 129.0, 128.6, 124.0, 122.9, 119.0, 39.0, 36.4, 28.6, 26.1, 24.8. HRMS 
(+ESI-TOF) m/z for C19H21N3O4 [M+Na]
+ 356.1600; M/Z found : 356.1598 
Radiosynthesis of 2-18F-phenylhexanoicanilide 2-[18F]PhAHA (37): The F-18 was 
obtained in kryptofix/K[18F] complex in acetonitrile/water (1 mL) from the PET/Cyclotron 
Facility, Wayne State University (Detroit, MI) and transferred into a crimped 2 mL V-vial for 
azeotropic drying. Acetonitrile (0.4 mL) was added to the mixture, which was dried under a stream 
of argon at 90-100°C. A solution of 36 (~2 mg) in dry DMSO (0.4 mL) was added to the dried 
kryptofix/ K[18F] and heated to 130-140°C under argon with stirring for 12 minutes. After cooling, 
the reaction mixture was passed through a 900 mg Altech silica gel cartridge (Fisher Scientific, 
Waltham, MA) and eluted with 2 mL of 10% methanol in dichloromethane (DCM). The solvent 
was evaporated under a stream of argon to remove DCM and to reduce the volume to 0.5 mL. 37 
was purified by semi-preparative HPLC (65% ACN in water) by collecting the peak at 6 min. The 
decay corrected radiochemical yield was 10% and the compound purity was >95%, as assessed by 
analytical HPLC and co-elution with the non-radiolabeled reference standard 35.  
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5b. Continuing work 
The most aggressive and common form of brain cancer, gliomas, can originate from any 
glial cell within the brain but most commonly derive from astrocytes (astrocytoma, 70% of the 
cases) or oligodendrocytes (oligodendroglioma, 20-25% of the cases), while the remaining tumor 
types are formed from a mixture of astrocytes, oligodendrocytes and ependymal cells (Lino and 
Merlo, 2009). Glioblastomas or glioblastoma multiforme (GBM) tumors are generally termed as 
grade IV astrocytomas, based on the World Health Organization (WHO) classification scale.  
Glioblastomas are the most common, making up 50% of functional brain tissue tumors and 20% 
of intracranial tumors, as well as the most aggressive brain tumor type (median survival is 14.6 
months, 30% 2 year survival). While substantial progress has been made towards improving 
diagnosis of this disease, very little progress has been made in regards to treatment over the last 
decade.  
 Currently, GBM is treated primarily with surgery, when possible, followed by radiation 
and temozolomide (TMZ) treatment (Dubrow et al., 2013). Approval and increased usage of TMZ 
during the last decade has improved patient survival but there continues to be an unmet need for 
effective treatments of GBM. The standard of care therapy, even when successful, leaves patients 
with an average of only 6.9 months before recurrence (Stupp et al., 2005). Therefore, extensive 
research into biological mechanisms behind glioma tumor formation has been a primary area of 
focus for many researchers. Subsequently, the field of epigenetics and epigenetic regulators, have 
arisen as promising possible treatment targets for of this deadly disease. Epigenetic modifiers, such 
as HDAC enzymes, are responsible for manipulating gene transcription and may play a pivotal 
role in changing cellular phenotype from benign to malignant. In particular, SIRT1 (class III 
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HDAC) has emerged from the group of HDACs as a promising target within epigenetics for cancer 
therapy. 
SIRT1, as previously mentioned, plays a large role in metabolic regulation and oxidative 
stress. One primary complication for SIRT1 targeted therapy, is the pleiotropic role of SIRT1 in 
pathologic states and the role of SIRT1 as a strict tumor suppressor or promoter has yet to be fully 
uncovered and remains unclear at this time. For example, SIRT1 upregulation is correlated with 
disease progression and poor prognosis in breast and pancreatic cancers however the opposite has 
been observed in bladder and ovarian cancers (Mvunta et al., 2016; Sanchez-Carbayo et al., 2006). 
SIRT1-targeted small molecule activators (i.e. Resveratrol and SRT501) are currently in use in 
clinical trials for treatment of colon cancer and hepatocellular carcinoma (NCT00256334, 
NCT00920803), in these varieties of cancer, SIRT1 upregulation has been demonstrated to be 
beneficial. However, SIRT1 expression within one cancer type at different stages does not remain 
constant, implicating SIRT1 as a possible regulator of cancer prognosis.  
 One possible innovation for GBM that has been identified are SIRT1-targeted therapies 
due to its role in apoptotic pathways. Knockdown of SIRT1 in glioma cell lines demonstrated 
growth inhibition and increased apoptosis as compared to the wild type cancer cells, indicating 
that SIRT1 may play a role in the progression of GBM via PTEN/PI3K/AKT pathway (Qu et al., 
2012); a  pathway which is commonly over-activated in GBM (Narayan et al., 2013). Additional 
indications of SIRT1 in GBM pathology include glioblastoma cell lines with further adaptation to 
glucose dependence (Warburg effect) had increased levels NAD+ and SIRT1 expression .  
Due to the key regulatory role of SIRT1 in stress, apoptotic and metabolic responses within 
cells, SIRT1-directed therapies may provide a new route for treatment of gliomas. However, much 
is still unknown about the exact role of SIRT1 within cancers and especially gliomas. This work 
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should provide more evidence for treatment of glioma with SIRT1-directed therapies based on in 
vivo, non-invasive imaging studies with a SIRT1-selective imaging agent.  
To establish overexpression of SIRT1 in specific glioma cell lines, in vitro cellular uptake 
studies were performed using SRIT1-selective PET imaging agent termed 2-[18F]PhAHA. This 
study demonstrated increased radio-metabolite accumulation in U87 and C6 cells, expressing 
relatively higher expression of SIRT1, and decreased radio-metabolite accumulation in cells with 
relatively lower levels of expression of SIRT1 (i.e. MiaPaCa, MD-MB-231, MCF10DCIS). This 
work translated into in vivo imaging where glioma and gliosarcoma rat models were developed by 
intracranial injection of both U87 and 9L glioma cells. It should be noted that 9L and C6 cell lines 
represent a subset of grade IV astrocytomas, known as gliosarcomas, and are rat-derived tumor 
lines (Han et al., 2010). Many similarities between human glioma and rat derived gliosarcoma 
tumor types exist but there are also differences in the pathogenicity of the cells (Barth and Kaur, 
2009). Imaging both U87 as well as 9L derived tumors in vivo with 2-[18F]PhAHA will provide a 
better understanding and comparisons for the expression-activity of SIRT1 in two types of tumor.  
 Using 2-[18F]PhAHA for PET imaging it is possible to quantify and visualize changes in 
SIRT1 expression-activity as well as regional localization over time and tumor growth. For 
adequate tumor-co-registration and identification of brain regions, the PET/CT images were co-
aligned with T2 weighted MRI.  Quantification of images was performed using Logan analysis for 
further understanding of changes in radiotracer accumulation in the tumor and other areas of the 
brain with high SIRT1 activity. For further proof that 2-[18F]PhAHA is SIRT1-selective in tumor 
models, imaging studies using known SIRT1 inhibitor, EX-527, were performed. As expected, the 
accumulation of 2-[18F]PhAHA-derived radioactivity in the tumor and other areas of the brain with 
high SIRT1 expression was markedly decreased after administration of inhibitor.  
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These preliminary studies provide evidence that SIRT1 may play a role in progression of 
GBM and may be a possible undiscovered target for therapy. Furthermore, this new technology 
provides a route for non-invasive monitoring of therapy as well as designing individualized 
treatments based on enzyme expression levels within the tumor, which may vary patient to patient 
and even within a tumor of one patient.  
Results and Discussion:  
Towards improving treatments and diagnosis for patients with GBM, characterization of 
SIRT1-selective radiotracer, 2-[18F]PhAHA, was performed both in vitro and in vivo glioma and 
gliosarcoma tumor models. Development of PET imaging with 2-[18F]PhAHA in an animal glioma 
model is aimed at laying the foundation for future work to monitor the effects of SIRT1-targeted 
pharmacomodulation on tumor growth and progression. These studies demonstrate significant 
differences in SIRT1 expression-activity in tumor vs. normal brain tissue based on increased 
radioactive accumulation of 2-[18F]PhAHA-derived products.  
For this study, two different types of glioma models, human-derived glioblastoma and rat-
derived gliosarcoma, were developed in two types of rats, nude and Sprague Dawley (SD). Using 
the U87 lineage, a human-derived glioblastoma cell line in nude rats (Pontén, 1975), allowed for 
characterization in a more clinically relevant tumor as glioblastomas make up the majority of brain 
tumors. However, to better understand the fundamental role of SIRT1 in brain tumors, a Fischer 
rat-derived gliosarcoma SD rat model was also developed using 9L cell lines (Benda et al., 1971).  
Though gliosarcoma tumors make up a smaller percentage of clinically seen brain tumors, they 
represent a very severe and poorly understood group (Han et al., 2010). The 9L gliosarcoma is a 
well-established and widely used model for understanding tumor growth and biology (Stojiljkovic 
et al.). This model is especially appealing due to its immunogenicity in syngeneic hosts, such as 
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Fischer or SD rats, increasing success rates for tumor cell acceptance, post-injection. Additionally, 
the 9L cell line is a rapidly growing and more severe form of cancer than the U87  (Barth and 
Kaur, 2009).  
The noted increase in 9L tumor severity of may be due in part to a missense mutation in 
the DNA binding region of a key tumor suppressor protein, p53 (Asai et al., 1994). This mutation 
may disrupt the p53 interaction s-Myc and cause further progression of cell pathology (Asai et al., 
1994). However, the U87 cell line expresses wildtype p53 protein, but instead contains a 
pathogenic mutation in PTEN tumor suppressor gene (Haas-Kogan et al., 1998). These mutated 
proteins contribute significantly to the 
pathogenicity of the tumor but the effect on 
SIRT1 is involvement is yet unknown. 
Further study of the in vivo tumor models 
with SIRT1-selective radiotracer may help 
further this understanding. 
As indicated by in vitro cell uptake 
studies performed with 2-[18F]PhAHA, U87 
and 9L cell lines accumulate increased levels 
of radioactivity as opposed to other cell lines 
(i.e. MiaPaCa, MDA MB-231, MCF10AT1, 
and MCF10DCIS) (Fig. 57).  This correlates well with previous literature demonstrating an 
increase in levels of SIRT1 protein in glioma tissue using immunohistochemistry (IHC) with a 
staining intensity index for quantification (http://www.proteinatlas.org/ENSG0000009671-
SIRT1/cancer/tissue/glioma).  An example of literature SIRT1 IHC results in glioma tissue is 
 
Figure 57. Of the cell lines tested, U87 and C6 
glioma lines demonstrate the highest uptake of 
SIRT1-selective radiotracer 2-[18F]PhAHA 
derived radioactivity (P>0.05, One Way 
ANOVA).  
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displayed in Fig. 55 (Ma et al., 
2013). These panels indicate an 
increase in SIRT1 staining 
intensity in glioma tumor tissue 
as compared to normal brain 
tissue.  
Following in vitro 
characterization, tumors were 
grown in rats from i.c. injections 
of either 9L or U87 cell 
suspensions. For verification of 
tumor growth and location, T2-
weighted MR images of each animal were acquired between 10 and 14 days post i.c. tumor cell 
implantation. The SD rats developed 9L tumors successfully and underwent PET/CT and MR 
imaging sessions. The U87 cells, transfected with GFP, 
tumors were grown in nude rats and bioluminescence 
imaging was performed in addition to PET/CT and MRI.  
PET/CT imaging with 2-[18F]PhAHA were acquired 
shortly after the MR images to allow for accurate co-
registration and overlays of these images. From the 
dynamic PET/CT images, peak times for differential 
washout between areas of high levels and relatively lower 
 
Figure 58: IHC results for SIRT1 staining in different types 
of medulloblastoma cells. (Ma et al., 2013). 
Figure 59. H&E staining of axial 
section from brain of 9L tumor 
bearing rat aligned with 
corresponding PET/CT image at 30 
min post administration of 2-
[18F]PhAHA. Arrow indicates bregma 
(site of injection). 
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levels of  SIRT1 expression-activity within the brain, remained about 20 minutes as was the case 
in normal animals.  
Within some tumors, excellent co-registration exists between tumor and 2-[18F]PhAHA-
derived radioactivity accumulation, however, in others the areas of highest accumulation are in 
surrounding tumor tissue rather than centered within of the tumor itself. Fig. 59-60 displays a 9L 
tumor bearing rat with increased levels of 2-[18F]PhAHA-derived radioactivity accumulation in 
the tumor tissue. However, Fig. 61 displays PET/CT imaging using 2-[18F]PhAHA in a U87 tumor-
bearing rat and there is greater per-tumoral accumulation than central tumor accumulation. Yet, 
even in this animal, there are certain lesions with increased accumulation in the tumor. Both tumor 
types, 9L and U87, display great heterogeneity within the tumor tissue. Sample images of 2-
[18F]PhAHA-derived radioactivity accumulation in both 9L and U87 tumor bearing rats are 
displayed centered on the injection site at bregma (Fig. 59-60).  
To assess the effectiveness and growth localization of tumor tissue within the brain as well 
as confirmation that 
the cells are being 
expressed properly, 
bioluminescence 
imaging was 
performed with 
animals bearing U87 
tumors. This is only 
possible with the 
  
Figure 60. Coronal slices from dynamic PET/CT/MRI images of 9L 
tumor bearing rat at 30 min post 2-[18F]PhAHA administration centered 
at bregma. Top: MRI only; Middle: MRI/PET overlay; Bottom: 
PET/CT 
136 
 
U87 cell line, as it has been transfected with luciferase (Fig. 62).  
Following characterization of 2-[18F]PhAHA in both tumor models, U87 and 9L, it was 
interesting to compare the expression-activity of SIRT1 with HDACs class IIA, using 18F-TFAHA 
as a radiotracer for PET 
imaging. Figures 63-64 
display each tracer 
separately as well as the 
two overlaid in panels for 
U87 and 9L tumor 
models demonstrating 
the similarities and 
differences between 
HDAC and SIRT1 
expression within one animal, 24 hours apart.  These overlays effectively demonstrate the 
localization and differences in activity between 
HDACs class IIa and SIRT1 within regions of tumor 
and brain tissue.  
 
Figure 61. Coronal and axial slices from dynamic PET/CT/MRI 
images of U87 tumor bearing rat at 30 min post 2-[18F]PhAHA 
administration centered at bregma. Top: MRI only; Middle: 
MRI/PET overlay; Bottom: PET/CT 
 
Figure 62: Bioluminescence imaging of 
U87TdRLuc tumor in a rat demonstrating 
tumor localization within the brain. 
137 
 
Heterogeneity within the 9L tumors is clearly defined by differences in 2-[18F]PhAHA and 
18F-TFAHA accumulation. For example, tissue surrounding the needle track and infiltration in this 
area demonstrates increased accumulation of 2-[18F]PhAHA but not of 18F-TFAHA-derived 
radioactivity. Additionally, different lesions within this tumor have different levels of HDACs 
class IIa and SIRT1 expression-activity. 
 In U87 animals, one of the most striking differences is in the cerebellar lesion of the tumor 
at -4.0mm. This lesion demonstrates increased 18F-TFAHA-derived radioactivity accumulation as 
opposed to this same lesion imaged with 2-[18F]PhAHA, which demonstrates very little 
Figure 63. Coronal slices through bregma, injection site (0.0) and 1 mm steps to either side,  
for both tracers in the same 9L bearing tumor rat, 24 hours apart. Top, in red, are PET/CT 
images using 2-[18F]PhAHA at 20 min post i.v. administration. In green, are PET/CT images 
using 18F-TFAHA also at 20 min post i.v. administration of the tracer. The following line 
demonstrates overlay of the two tracers on CT followed by the tracer overlay on MRI. Lastly, 
MRI alone on bottom.   
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accumulation in this lesion (Fig. 64). In slices at -1.0 and -2.0 the accumulation of 2-[18F]PhAHA-
derived radioactivity is much more peripheral than that of 18F-TFAHA, located more centrally. In 
certain areas of the brain, the two classes of HDACs appear to complement each other in their 
activity levels. These observations will be further confirmed by IHC staining. 
Looking at the similarities and differences between 2-[18F]PhAHA – derived radioactivity 
accumulation within the two tumor models, it may be possible to conclude that there is higher 
SIRT1 expression-activity within the 9L tumor tissue (N = 6 animals) than the U87 tumor tissue 
(N = 3 animals) (Fig. 63). While, this is not conclusive, or statistically significant due to unequal 
numbers of animals, certainly more studies are needed to understand if this is a robust observation, 
or not. And if so, determining the mechanism causing these differences in SIRT1 expression levels 
will also be important. This difference is quantified by the differences in slopes between 9L 
(m=2.2) and U87 (m = 1.6) Logan plots when the brainstem is used as reference tissue, where the 
 
Fig. 64: Coronal slices through bregma, injection site (0.0) and 1 mm steps to either side, for 
both tracers in the same U87 bearing tumor rat, 24 hours apart. Top, in red, are PET/CT images 
using 2-[18F]PhAHA at 20 min post i.v. administration. In green, are PET/CT images using 
18F-TFAHA also at 20 min post i.v. administration of the tracer. The following line 
demonstrates overlay of the two tracers on CT followed by the tracer overlay on MRI. Lastly, 
MRI alone on bottom.   
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dotted lines represent 95% confidence intervals about the lines of best fit. The increase in slope in 
9L tumor animals demonstrates a higher distribution volume for the tracer in the tumor tissue 
relative to the U87 tumor animals. Therefore, 2-[18F]PhAHA is accumulating more effectively in 
9L tumors than U87 tumors (based on N = 6 for each group). Though, these results are still 
preliminary, as more studies are needed for full characterization of this finding. However, one 
possible reason for this may be due to afore mentioned p53 mutation within 9L gliosarcoma cell 
lines causing changes to SIRT1-p53 interactions (Asai et al., 1994). According to the current 
understanding, SIRT1 deacetylates p53 to promote cellular senescence and act as a co-tumor 
suppressor in many cases, however, this is complicated because SIRT1 does not fit the model of a 
true tumor suppressor (Brooks and Gu, 2011). Therefore, decreasing the effectiveness of p53 due 
to a mutation may or may not affect SIRT1 expression and activity within the cell. 
Quantification of the animals bearing 9L gliosarcoma and U87 glioma tumors demonstrate 
rapid accumulation and increase in 2-[18F]PhAHA-derived accumulation within the tumor almost 
immediately post administration of the tracer. Additional Logan plot analysis for 9L tumor bearing 
Figure. 65: Quantification of 2-[18F]PhAHA-derived accumulation in tumor tissue in both U87 
and 9L glioma models with brainstem as reference tissue for the Logan plot analysis. Dotted 
lines represent 95% confidence interval. 
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rats was performed using other areas of the brain including cortex, caudate putamen, n. 
accumbens, and hippocampus (Fig. 66) and the brainstem as reference tissue. Based on Logan 
analysis of the data, equilibrium was reached almost instantaneously as the y-intercept for each 
line (area of the brain, including tumor) was about zero. This is an important point for establishing 
and understanding the bio-availability of the radiotracer within the body. The Logan analysis also 
demonstrated significant differences, based on slopes of best-fit lines, for tumor tissue as compared 
to non-cancerous cortical tissue within the brain when normalized by the brainstem as a reference 
tissue (Fig. 65-66). Additionally, a significant difference in 2-[18F]PhAHA-derived accumulation 
between ipsilateral and contralateral regions of the brain, particularly in n. accumbens (Fig. 66). 
Interestingly, this is not true for all areas of the brain with high radio-metabolite accumulation, i.e. 
hippocampus, caudate putamen, as these regions display little differences between ipsi-and 
contralateral sides for N = 6 animals, based on 95% confidence intervals (Fig. 66). To understand 
completely if this is true difference in n. accumbens SIRT1 activity, more studies, including ex-
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vivo studies, are needed. It is possible that this an artifact due to partial volume effect as it is near 
the highly radioactive tumor tissue.  
Furthermore, due to the non-invasive method of imaging, this technology can be used for 
longitudinal studies and evaluation of SIRT1-targeted pharmacomodulation on tumor progression. 
Use of 2-[18F]PhAHA as a PET imaging agent has been successful for imaging the increase in 
SIRT1 expression-activity during progression of gliosarcoma (9L) tumor growth (Fig. 67). In this 
case, increases in 2-[18F]PhAHA-derived radioactivity correlate with tumor growth as displayed 
 
Figure 66. Logan plot quantification for areas of the brain with high SIRT1 expression-activity, 
including tumor lesions for animals bearing 9L tumors. All calculations were done using brainstem 
as reference tissue. Regression analysis was performed and demonstrated a significant difference 
between tumor and cortex tissue as well as a small significant difference for n. accumbens, i.l vs c.l. 
sides.  
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by MRI. The ability to track tumor progression in vivo using 2-[18F]PhAHA with PET/CT imaging 
may become an integral part of diagnosis and treatment for cancers of the brain.  
For further validation that 2-[18F]PhAHA-derived accumulation is accurately displaying 
increases in SIRT1 expression-activity, an in vivo blocking study with SIRT1-selective inhibitor, 
EX-527 was performed. The results of the study in rats bearing a 9L gliosarcoma tumor displayed 
significantly decreased activity within areas of 2-[18F]PhAHA-derived accumulation following 
intraperitoneal administration of SIRT1-selective inhibitor, EX-527 (5mg/kg 30 minutes prior to 
 
Figure 67. Coronal and axial sections in 1 mm steps through tumor of an animal at two different 
time points (7d and 15d) post i.c. 9L tumor cell injection. Using non-invasive SIRT1-targeted 
molecular imaging with 2-[18F]PhAHA we are able to track the changes in tumor growth and enzyme 
expression over time.  
 
 
Day 7
Day 15
Post i.c. 
tumor 
injection
Day 7
Day 15
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n
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administration of 2-[18F]PhAHA) (Fig. 68)  This is demonstrated both qualitatively (Fig. 68A) and 
quantitatively (Fig. 68B).  
Conclusions: 
 
Figure 68. A) PET/CT images of a rat bearing a 9L tumor acquired at 20 minutes post i.v. 
administration of 2-[18F]PhAHA scaled to the SUV values shown on the right. B) PET/CT images 
acquired at 20 minutes post i.v. administration of 2-[18F]PhAHA and 50 minutes post i.p 
administration of  5 mg/kg EX-527 (SIRT1-selective inhibitor) scaled to the same SUV values as 
figure A. C) The SUV curves for the tumor with and without blocking by EX-527 as determined by 
ROI drawn around the tumor based on PET/MRI images. Brainstem is shown for reference tissue, 
with relatively lower SIRT1 expression-activity and therefore lower uptake of 2-[18F]PhAHA. D) 
A quantitative representation for ROI’s derived from PET images with 2-[18F]PhAHA before 
(black) and after blocking with inhibitor (gray) for the tumor and other areas of high SIRT1 
expression-activity (i.e. N. Accumbens, Hippocampus, Caudate Putamen).  
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While further validation of SIRT1 localization is needed through immunohistochemistry, 
these results are promising indicators for use of 2-[18F]PhAHA with PET imaging in furthering the 
efficacy of diagnostics and therapies for GBM. In this work, it has been demonstrated that SIRT1-
selective radiotracer, 2-[18F]PhAHA, can be used for imaging SIRT1-expression-activity in two 
types of glioma models both at one time point and longitudinally. Furthermore, the imaging can 
be quantified to demonstrate significant differences of tracer accumulation in tissues. Most 
notably, this tracer can be used in complement with 18F-TFAHA to demonstrate differences in 
HDACs class IIa expression-activity and SIRT1 expression activity in glioma models. 
Methods: 
Cell cultures and in vitro Radiotracer Uptake Studies: The U87MG, MiaPaca, and 
MDA-MB-231, 9L, and C6 cell lines were obtained from the American Type Tissue Culture 
Collection (ATCC); the MCF10A cell line was obtained from the cell culture repository of the 
Karmanos Cancer Institute (Detroit, MI). Tumor cells were propagated in DMEM supplemented 
with 10% fetal calf serum (FCS), penicillin and streptomycin, at 37°C in a humidified atmosphere 
with 5% CO2. In vitro radiotracer uptake studies were performed as previously described (Yeh et 
al., 2013c). Briefly, prior to in vitro radiotracer uptake experiment, the cells were inspected for 
confluency and viability. Each of the four cell plates for a given cell line had the media removed 
by pipette aspiration, and fresh media (15 mL) containing the radiotracer (1-2 uCi/mL) was added 
to cells in the culture plates. The tumor cell monolayers were incubated with the radioactivity-
containing medium for 30 minutes. The cells were then harvested by gentle unidirectional scraping 
and the suspensions of cells in the media were transferred into 15mL conical centrifuge tubes and 
pelleted by centrifugation (3000 rpm for 2 min). 50uL samples of supernatant and cell pellets flash-
frozen on dry ice were placed in pre-weighed scintillation vials, weighed, and the radioactivity 
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was measured using Pakard 5500 gamma counter (Perkin Elmer, CA). The background-corrected 
and decay-corrected radioactivity concentrations in individual cell pellets (cpm/g) was divided by 
corresponding cell culture media samples (cpm/g) to determine the fold increase of radiotracer 
accumulation in cells versus the cell culture media.  
Bioluminescence Images: Animals were anesthetized using 2-3% isofluorane mixed with 
air and imaging was performed while animals were under anesthesia. Bioluminescence images 
(BLI) of gliomas were obtained after administration of luciferin (10 µl/g i.p.) using an InVivo 
Xtreme system (Bruker, UK) at 10 to 14 days post U87 cell implantation. 
MR Imaging: Animals initially anesthetized with 5% isoflurane, and maintained between 
2-3% for the remainder of the experiment. During the procedure each animal was placed on a 
heated re-circulating water platform in order to maintain body temperature.  The animals were held 
in position using a bite bar and a receive-only surface coil 2-element phased array for the rat brain) 
was placed dorsal to the head. Scans were acquired using a 7T ClinScan system (Bruker, UK) 
controlled by the Syngo software (Siemens, Knoxville, TN). A localizing scan was performed and 
adjustments to head position were made accordingly. T2 images were obtained (repetition time 
[TR] 3530 ms echo time, [TE] 38 ms, FOV 3.2 cm x 3.2 cm x 2.4 cm, resolution 125 µm x 125 
µm x 1 mm). Images were processed using ImageJ software (Bethesda, MD).   
Cell Suspension: (Maxwell Laws): The U87MG or 9L were obtained from ATCC, 
subsequently the U87 cells were transfected with luciferase lentiviral particles at MD Andersen 
Cancer Center and characterized at this location. The 9L cells were dislodged using Hank’s 
Balanced Salt solution (HBSS, 5 mL) for 1-2 minutes, centrifuged to obtain the cellular pellet, and 
resuspended in growth media sufficient enough to achieve 1x107 cells/mL or 1x104 cells/µL. 
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Injection Procedure: (Maxwell Laws): Rats were anesthetized via inhalation of 
isoflurane (3-5% in oxygen for induction, 1-3% for maintenance via nose cone). The rat was placed 
into a stereotaxic apparatus. An anterior/posterior incision was made to identify bregma, at which 
point a short-beveled 30-ga needle loaded with the cell suspension was placed relative to bregma; 
AP: -1.5, LAT: -4, DV: -6. A 5 µL tumor cell suspension was then injected slowly over 10 minutes, 
then the needle was slowly withdrawn 2 mM and the remaining 5 µL was injected slowly over 10 
minutes for a total of 1x105 cells in 10 µL.  
Nude rats were implanted via intracerebral injection (i.c.) with U87 glioma cells (1x105 
cells in 10 µL), that had been transfected to express a GFP-luciferase fusion reporter gene. 
Sprague-Dawley rats were given injected via i.c. injection with 9L gliosarcoma cells (1x105 cells 
in 10 µL) and grown for 7-14 days before the brains were harvested for ex-vivo studies. 
Radiosynthesis for 2-[18F]PhAHA : See previous chapter. 
Ongoing work: 
Currently, this study is undergoing completion through additional imaging of U87 and 9L 
tumor models as well as autoradiographical studies to complement the PET/CT imaging. 
Additional studies with EX-527 and 2-[18F]PhAHA will also be performed to increase statistical 
significance for the EX-527-dependent inhibition of SIRT1 as visualized by differences in 2-
[18F]PhAHA-derived accumulation. Lastly, IHC staining of brain slices will be performed using 
antibodies against both SIRT1 and phospho-SIRT1 to determine the exact localization of SIRT1 
and activated SIRT1 within the brain. With the addition of these studies, these results will provide 
valuable knowledge regarding the role of SIRT1 within glioma and gliosarcoma tumors. This data 
may then be applied to monitor the effects of SIRT1-targeted pharmacomodulation on tumor 
growth and progression.  
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CHAPTER 6 CONCLUSIONS AND FUTURE DIRECTIONS 
HDAC enzymes and epigenetic regulation demonstrate great potential for treatment of 
disease. Treating difficult diseases such as Alzheimer’s, cancer, and stress-related disorders may 
be aided greatly by the development of HDAC selective imaging substrates. The aim of this work 
was to develop isoform- and class-selective imaging agents for HDACs to gain understanding and 
visualization of HDAC expression-activity product. The use of radiolabeled substrates in PET 
imaging allows for non-invasive visualization and quantification of spatial and temporal dynamics 
of the HDACs in different organs and tissues. Through this work, selective, radiolabeled, imaging 
agents for HDAC class IIa, SIRT1, and SIRT2 have been established in vitro and in vivo. 
Furthermore, HDAC class IIa and SIRT1 imaging agents have been evaluated in a disease model, 
demonstrating effectiveness for imaging enzyme-mediated epigenetic regulation changes in 
cancer. These imaging agents can be applied to non-invasive monitoring of treatment and disease 
progression via PET imaging for many difficult diseases. The ability to use two complementary 
tracers for cancer imaging is especially important to identify areas of target responder vs non-
responder in a patient. Additionally, through the development of these tracers, many of the 
radiochemical syntheses developed in this work follow unprecedented steps and lay a strong 
foundation for future radiochemical synthesis of novel fluorinated compounds.  
The future work will be aimed at finishing in vitro characterization of these compounds and 
proceeding with in vivo studies for norm and disease. Studying the roles of the SIRTs and HDAC 
class IIa enzymes in stress related disorders and cancer could provide information for novel 
treatments and monitoring of disease. These studies are the first of their kind to demonstrate 
selective radiolabeled substrates for HDAC class IIa, SIRT1 and SIRT2. The synthesis of focused 
substrate libraries provides unprecedented information about the structure activity relationship for 
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these enzymes activity both in vitro and in vivo. This information may be instrumental in the 
development of future class- or isoform-selective activators or inhibitors for treatment of disease. 
The ability to non-invasively visualize HDAC enzyme expression-activity product in vivo 
through non-invasive imaging holds incredible promise for developing new treatments for disease.  
These imaging agents will enable non-invasive monitoring of pharmacodynamics of HDACs 
inhibitors on the target level. By opening the door to new methods of diagnosis and treatment for 
diseases such as cancer and stress-related disorders this research may lead to effective clinical 
trials and drug development. While more work is necessary to establish these compounds as 
imaging agents in vivo and in disease models, the work done and proposed lay the start to an 
exciting path of discovery for understanding the role of epigenetic regulation in the body.  
  
149 
 
REFERENCES 
Asai, A., Miyagi, Y., Sugiyama, A., Gamanuma, M., Hong, S.H., Takamoto, S., Nomura, K., 
Matsutani, M., Takakura, K., Kuchino, Y., 1994. Negative effects of wild-type p53 and s-
Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor 
suppressor genes for gene therapy. J Neurooncol 19, 259-268. 
Autiero, I., Costantini, S., Colonna, G., 2009. Human sirt-1: molecular modeling and structure-
function relationships of an unordered protein. PloS one 4, e7350. 
Barber, M.F., Michishita-Kioi, E., Xi, Y., Tasselli, L., Kioi, M., Moqtaderi, Z., Tennen, R.I., 
Paredes, S., Young, N.L., Chen, K., Struhl, K., Garcia, B.A., Gozani, O., Li, W., Chua, K.F., 
2012. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 
487, 114-118. 
Barth, R.F., Kaur, B., 2009. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, 
T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. Journal of neuro-oncology 94, 299-312. 
Beauharnois, J.M., Bolivar, B.E., Welch, J.T., 2013. Sirtuin 6: a review of biological effects and 
potential therapeutic properties. Molecular BioSystems 9, 1789-1806. 
Belanger, A.P., Pandey, M.K., DeGrado, T.R., 2011. Microwave-Assisted Radiosynthesis of 
[(18)F]Fluorinated Fatty Acid Analogs. Nuclear medicine and biology 38, 435-441. 
Benda, P., Someda, K., Messer, J., Sweet, W.H., 1971. Morphological and immunochemical 
studies of rat glial tumors and clonal strains propagated in culture. Journal of neurosurgery 
34, 310-323. 
Bharathi, S.S., Zhang, Y., Mohsen, A.-W., Uppala, R., Balasubramani, M., Schreiber, E., Uechi, 
G., Beck, M.E., Rardin, M.J., Vockley, J., Verdin, E., Gibson, B.W., Hirschey, M.D., 
150 
 
Goetzman, E.S., 2013. SIRT3 Regulates Long-chain Acyl-CoA Dehydrogenase by 
Deacetylating Conserved Lysines Near the Active Site. Journal of Biological Chemistry. 
Bheda, P., Jing, H., Wolberger, C., Lin, H., 2016. The Substrate Specificity of Sirtuins. Annu Rev 
Biochem. 
BioSolveIT, GmbH, LeadIT2.1.7, An der Ziegelei 79, 53757 St. Augustin, Germany. 
Blander, G., Guarente, L., 2004. The Sir2 family of protein deacetylases. Annual review of 
biochemistry 73, 417-435. 
Bonomi, R., Mukhopadhyay, U., Shavrin, A., Yeh, H.-H., Majhi, A., Dewage, S.W., Najjar, A., 
Lu, X., Cisneros, G.A., Tong, W.P., Alauddin, M.M., Liu, R.-S., Mangner, T.J., Turkman, N., 
Gelovani, J.G., 2015. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers 
for PET Imaging of Epigenetic Regulation in the Brain. PloS one 10, e0133512. 
Bordone, L., Guarente, L., 2005. Calorie restriction, SIRT1 and metabolism: understanding 
longevity. Nature reviews. Molecular cell biology 6, 298-305. 
Bottomley, M.J., Lo Surdo, P., Di Giovine, P., Cirillo, A., Scarpelli, R., Ferrigno, F., Jones, P., 
Neddermann, P., De Francesco, R., Steinkuhler, C., Gallinari, P., Carfi, A., 2008. Structural 
and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural 
zinc-binding domain. The Journal of biological chemistry 283, 26694-26704. 
Bouras, T., Fu, M., Sauve, A.A., Wang, F., Quong, A.A., Perkins, N.D., Hay, R.T., Gu, W., Pestell, 
R.G., 2005. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 
within the cell cycle regulatory domain 1. The Journal of biological chemistry 280, 10264-
10276. 
Brooks, C.L., Gu, W., 2009. How does SIRT1 affect metabolism, senescence and cancer? Nat Rev 
Cancer 9, 123-128. 
151 
 
Brooks, C.L., Gu, W., 2011. The impact of acetylation and deacetylation on the p53 pathway. 
Protein & cell 2, 456-462. 
Brownell, J., J. Zhou, T. Ranalli, R. Kobayashi, D. Edmondson, S. Roth, and, Allis, C.D., 1996. 
Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone 
acetylation to gene activation. Cell 84, 843-851. 
Chen, B., Cepko, C.L., 2009. HDAC4 regulates neuronal survival in normal and diseased retinas. 
Science 323, 256-259. 
Chen, V.B., Davis, I.W., Richardson, D.C., 2009. KING (Kinemage, Next Generation): a versatile 
interactive molecular and scientific visualization program. Protein science 18, 2403-2409. 
Chiang, Y.L., Lin, H., 2016. An improved fluorogenic assay for SIRT1, SIRT2, and SIRT3. 
Organic & biomolecular chemistry 14, 2186-2190. 
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., Chiu, C.-T., 2009. Multiple roles of HDAC 
inhibition in neurodegenerative conditions. Trends in neurosciences 32, 591-601. 
Claes, A., Idema, A.J., Wesseling, P., 2007. Diffuse glioma growth: a guerilla war. Acta 
neuropathologica 114, 443-458. 
Cohen, H.Y., Lavu, S., Bitterman, K.J., Hekking, B., Imahiyerobo, T.A., Miller, C., Frye, R., 
Ploegh, H., Kessler, B.M., Sinclair, D.A., 2004. Acetylation of the C terminus of Ku70 by 
CBP and PCAF controls Bax-mediated apoptosis. Molecular cell 13, 627-638. 
Cosgrove, M.S., Bever, K., Avalos, J.L., Muhammad, S., Zhang, X., Wolberger, C., 2006. The 
Structural Basis of Sirtuin Substrate Affinity†,‡. Biochemistry 45, 7511-7521. 
Cui, H., Kamal, Z., Ai, T., Xu, Y., More, S.S., Wilson, D.J., Chen, L., 2014. Discovery of potent 
and selective sirtuin 2 (SIRT2) inhibitors using a fragment-based approach. J Med Chem 57, 
8340-8357. 
152 
 
Dai, J.M., Wang, Z.Y., Sun, D.C., Lin, R.X., Wang, S.Q., 2007. SIRT1 interacts with p73 and 
suppresses p73-dependent transcriptional activity. Journal of cellular physiology 210, 161-
166. 
Dai, W., Zhou, J., Jin, B., Pan, J., 2016. Class III-specific HDAC inhibitor Tenovin-6 induces 
apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma. 
Scientific Reports 6, 22622. 
de Ruijter, A.J., van Gennip, A.H., Caron, H.N., Kemp, S., van Kuilenburg, A.B., 2003. Histone 
deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370, 737-
749. 
Dhordain, P., Lin, R.J., Quief, S., Lantoine, D., Kerckaert, J.P., Evans, R.M., Albagli, O., 1998. 
The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing 
complex to mediate transcriptional repression. Nucleic acids research 26, 4645-4651. 
Di Giovanni, S., Knights, C.D., Rao, M., Yakovlev, A., Beers, J., Catania, J., Avantaggiati, M.L., 
Faden, A.I., 2006. The tumor suppressor protein p53 is required for neurite outgrowth and 
axon regeneration. The EMBO journal 25, 4084-4096. 
Dillin, A., Kelly, J.W., 2007. Medicine. The yin-yang of sirtuins. Science (New York, N.Y 317, 
461-462. 
Donmez, G., Outeiro, T.F., 2013. SIRT1 and SIRT2: emerging targets in neurodegeneration. 
EMBO Molecular Medicine 5, 344-352. 
Dryden, S.C., Nahhas, F.A., Nowak, J.E., Goustin, A.S., Tainsky, M.A., 2003. Role for human 
SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. 
Molecular and cellular biology 23, 3173-3185. 
153 
 
Du, J., Zhou, Y., Su, X., Yu, J.J., Khan, S., Jiang, H., Kim, J., Woo, J., Kim, J.H., Choi, B.H., He, 
B., Chen, W., Zhang, S., Cerione, R.A., Auwerx, J., Hao, Q., Lin, H., 2011. Sirt5 is a NAD-
dependent protein lysine demalonylase and desuccinylase. Science (New York, N.Y.) 334, 
806-809. 
Dubrow, R., Darefsky, A.S., Jacobs, D.I., Park, L.S., Rose, M.G., Laurans, M.S., King, J.T., Jr., 
2013. Time trends in glioblastoma multiforme survival: the role of temozolomide. Neuro-
oncology 15, 1750-1761. 
Eagle, A.L., Fitzpatrick, C.J., Perrine, S.A., 2013a. Single prolonged stress impairs social and 
object novelty recognition in rats. Behavioural brain research 256, 
10.1016/j.bbr.2013.1009.1014. 
Eagle, A.L., Knox, D., Roberts, M.M., Mulo, K., Liberzon, I., Galloway, M.P., Perrine, S.A., 
2013b. Single prolonged stress enhances hippocampal glucocorticoid receptor and 
phosphorylated protein kinase B levels. Neuroscience research 75, 130-137. 
Fahie, K., Hu, P., Swatkoski, S., Cotter, R.J., Zhang, Y., Wolberger, C., 2009. Side chain 
specificity of ADP-ribosylation by a sirtuin. The FEBS journal 276, 7159-7176. 
Feldman, J.L., Baeza, J., Denu, J.M., 2013. Activation of the protein deacetylase SIRT6 by long-
chain fatty acids and widespread deacylation by mammalian sirtuins. The Journal of 
biological chemistry 288, 31350-31356. 
Feldman, J.L., Dittenhafer-Reed, K.E., Kudo, N., Thelen, J.N., Ito, A., Yoshida, M., Denu, J.M., 
2015. Kinetic and Structural Basis for Acyl-Group Selectivity and NAD(+) Dependence in 
Sirtuin-Catalyzed Deacylation. Biochemistry 54, 3037-3050. 
Finnin, M.S., Donigian, J.R., Pavletich, N.P., 2001. Structure of the histone deacetylase SIRT2. 
Nature structural biology 8, 621-625. 
154 
 
Ford, J., Ahmed, S., Allison, S., Jiang, M., Milner, J., 2008. JNK2-dependent regulation of SIRT1 
protein stability. Cell Cycle 7, 3091-3097. 
Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T., Repasky, M.P., 
Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P., Shenkin, P.S., 2004. Glide:  A 
New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of 
Docking Accuracy. Journal of Medicinal Chemistry 47, 1739-1749. 
Gao, L., Cueto, M.A., Asselbergs, F., Atadja, P., 2002. Cloning and Functional Characterization 
of HDAC11, a Novel Member of the Human Histone Deacetylase Family. Journal of 
Biological Chemistry 277, 25748-25755. 
Gao, Z., Zhang, J., Kheterpal, I., Kennedy, N., Davis, R.J., Ye, J., 2011. Sirtuin 1 (SIRT1) protein 
degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes 
to hepatic steatosis in obesity. Journal of Biological Chemistry 286, 22227-22234. 
Geng, Y.-Q., Li, T.-T., Liu, X.-Y., Li, Z.-H., Fu, Y.-C., 2011. SIRT1 and SIRT5 activity 
expression and behavioral responses to calorie restriction. Journal of Cellular Biochemistry 
112, 3755-3761. 
Gerhart-Hines, Z., Dominy, J.E., Blättler, S.M., Jedrychowski, M.P., Banks, A.S., Lim, J.-H., 
Chim, H., Gygi, S.P., Puigserver, P., 2011. The cAMP/PKA pathway rapidly activates SIRT1 
to promote fatty acid oxidation independently of changes in NAD+. Molecular cell 44, 851-
863. 
Grbesa, I., Pajares, M.J., Martinez-Terroba, E., Agorreta, J., Mikecin, A.M., Larrayoz, M., Idoate, 
M.A., Gall-Troselj, K., Pio, R., Montuenga, L.M., 2015. Expression of sirtuin 1 and 2 is 
associated with poor prognosis in non-small cell lung cancer patients. PloS one 10, e0124670. 
155 
 
Gregoretti, I.V., Lee, Y.M., Goodson, H.V., 2004. Molecular evolution of the histone deacetylase 
family: functional implications of phylogenetic analysis. J Mol Biol 338, 17-31. 
Grozinger, C.M., Chao, E.D., Blackwell, H.E., Moazed, D., Schreiber, S.L., 2001. Identification 
of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases 
by phenotypic screening. The Journal of biological chemistry 276, 38837-38843. 
Guo, H., Renaut, R.A., Chen, K., 2007. An input function estimation method for FDG-PET human 
brain studies.(Author abstract). Nuclear medicine and biology, 483. 
Guo, X., Williams, J.G., Schug, T.T., Li, X., 2010. DYRK1A and DYRK3 promote cell survival 
through phosphorylation and activation of SIRT1. Journal of Biological Chemistry 285, 
13223-13232. 
Haas-Kogan, D., Shalev, N., Wong, M., Mills, G., Yount, G., Stokoe, D., 1998. Protein kinase B 
(PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor 
PTEN/MMAC. Current Biology 8, 1195-S1191. 
Haberkorn U, B.B., Altmann A, Eisenhut M, Gelovani J, Mier W., 2007. Uptake and 
biodistribution of the histone deacetylase inhibitor SAHA in tumor bearing animals. European 
Journal of Nuclear Medicine and Molecular Imaging 34, S395-S395. 
Haberland, M., Montgomery, R.L., Olson, E.N., 2009. The many roles of histone deacetylases in 
development and physiology: implications for disease and therapy. Nat Rev Genet 10, 32-42. 
Haigis, M.C., Mostoslavsky, R., Haigis, K.M., Fahie, K., Christodoulou, D.C., Murphy, A.J., 
Valenzuela, D.M., Yancopoulos, G.D., Karow, M., Blander, G., Wolberger, C., Prolla, T.A., 
Weindruch, R., Alt, F.W., Guarente, L., 2006. SIRT4 inhibits glutamate dehydrogenase and 
opposes the effects of calorie restriction in pancreatic beta cells. Cell 126, 941-954. 
156 
 
Haigis, M.C.S., D. A. , 2010. Mammalian sirtuins: biological insights and disease relevance. Annu. 
Rev. Pathol 5, 253-295. 
Han, S.J., Yang, I., Tihan, T., Prados, M.D., Parsa, A.T., 2010. Primary gliosarcoma: key clinical 
and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. 
Journal of Neuro-Oncology 96, 313-320. 
He, B., Hu, J., Zhang, X., Lin, H., 2014. Thiomyristoyl peptides as cell-permeable Sirt6 inhibitors. 
Organic & biomolecular chemistry 12, 7498-7502. 
Heltweg, B., Brauch, C., Jung, M., Dequiedt, F., Marshall, B.L., Verdin, E., Yoshida, M., Nishino, 
N., 2004. Subtype selective substrates for histone deacetylases. Journal of Medicinal 
Chemistry 47, 5235-5243. 
Heltweg, B., Dequiedt, F., Verdin, E., Jung, M., 2003. Nonisotopic substrate for assaying both 
human zinc and NAD+-dependent histone deacetylases. Analytical biochemistry 319, 42-48. 
Hendricks, J.A., Keliher, E.J., Marinelli, B., Reiner, T., Weissleder, R., Mazitschek, R., 2011a. In 
vivo PET imaging of histone deacetylases by 18F- suberoylanilide hydroxamic acid ( 18F-
SAHA). Journal of Medicinal Chemistry 54, 5576-5582. 
Hendricks, J.A., Keliher, E.J., Marinelli, B., Reiner, T., Weissleder, R., Mazitschek, R., 2011b. In 
vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-
SAHA). J Med Chem 54, 5576-5582. 
Hiratsuka, M., Inoue, T., Toda, T., Kimura, N., Shirayoshi, Y., Kamitani, H., Watanabe, T., 
Ohama, E., Tahimic, C.G., Kurimasa, A., Oshimura, M., 2003. Proteomics-based 
identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 
gene. Biochemical and biophysical research communications 309, 558-566. 
157 
 
Hirsch, B.M., Zheng, W., 2011. Sirtuin mechanism and inhibition: explored with N(epsilon)-
acetyl-lysine analogs. Mol Biosyst 7, 16-28. 
Hoffmann, G., Breitenbücher, F., Schuler, M., Ehrenhofer-Murray, A.E., 2014. A novel sirtuin 2 
(SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer. 
Journal of Biological Chemistry 289, 5208-5216. 
Hooker, J.M., Kim, S.W., Alexoff, D., Xu, Y., Shea, C., Reid, A., Volkow, N., Fowler, J.S., 2009. 
Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic 
Studies of [11C]MS-275 using Positron Emission Tomography. ACS Chemical Neuroscience 
1, 65-73. 
Houtkooper, R.H., Pirinen, E., Auwerx, J., 2012. Sirtuins as regulators of metabolism and 
healthspan.(Report). Nature Reviews Molecular Cell Biology, 225. 
Hu, J., He, B., Bhargava, S., Lin, H., 2013. A fluorogenic assay for screening Sirt6 modulators. 
Organic & biomolecular chemistry 11, 5213-5216. 
Huhtiniemi, T., Salo, H.S., Suuronen, T., Poso, A., Salminen, A., Leppanen, J., Jarho, E., Lahtela-
Kakkonen, M., 2011. Structure-based design of pseudopeptidic inhibitors for SIRT1 and 
SIRT2. J Med Chem 54, 6456-6468. 
Imai, S., Armstrong, C.M., Kaeberlein, M., Guarente, L., 2000. Transcriptional silencing and 
longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800. 
Imaoka, N., Hiratsuka, M., Osaki, M., Kamitani, H., Kambe, A., Fukuoka, J., Kurimoto, M., Nagai, 
S., Okada, F., Watanabe, T., Ohama, E., Kato, S., Oshimura, M., 2012. Prognostic 
significance of sirtuin 2 protein nuclear localization in glioma: an immunohistochemical 
study. Oncology reports 28, 923-930. 
158 
 
Inoue, T., Hiratsuka, M., Osaki, M., Oshimura, M., 2007a. The molecular biology of mammalian 
SIRT proteins: SIRT2 in cell cycle regulation. Cell cycle (Georgetown, Tex 6, 1011-1018. 
Inoue, T., Hiratsuka, M., Osaki, M., Yamada, H., Kishimoto, I., Yamaguchi, S., Nakano, S., Katoh, 
M., Ito, H., Oshimura, M., 2007b. SIRT2, a tubulin deacetylase, acts to block the entry to 
chromosome condensation in response to mitotic stress. Oncogene 26, 945-957. 
Inoue, T., Hiratsuka, M., Osaki, M., Yamada, H., Kishimoto, I., Yamaguchi, S., Nakano, S., Katoh, 
M., Ito, H., Oshimura, M., 2007c. SIRT2, a tubulin deacetylase, acts to block the entry to 
chromosome condensation in response to mitotic stress. Oncogene 26, 945-957. 
Inoue, T., Nakayama, Y., Yamada, H., Li, Y.C., Yamaguchi, S., Osaki, M., Kurimasa, A., 
Hiratsuka, M., Katoh, M., Oshimura, M., 2009. SIRT2 downregulation confers resistance to 
microtubule inhibitors by prolonging chronic mitotic arrest. Cell cycle (Georgetown, Tex 8, 
1279-1291. 
J, L., 2000. Graphical analysis of PET data applied to reversible and irreversible tracers. Nuclear 
medicine and biology 27, 661-670. 
Jamonnak, N., Hirsch, B.M., Pang, Y., Zheng, W., 2010. Substrate specificity of SIRT1-catalyzed 
lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl-
lysine analogs. Bioorganic chemistry 38, 17-25. 
Jiang, H., Khan, S., Wang, Y., Charron, G., He, B., Sebastian, C., Du, J., Kim, R., Ge, E., 
Mostoslavsky, R., Hang, H.C., Hao, Q., Lin, H., 2013. SIRT6 regulates TNF-alpha secretion 
through hydrolysis of long-chain fatty acyl lysine. Nature 496, 110-113. 
Jin, L., Wei, W., Jiang, Y., Peng, H., Cai, J., Mao, C., Dai, H., Choy, W., Bemis, J.E., Jirousek, 
M.R., 2009. Crystal structures of human SIRT3 displaying substrate-induced conformational 
changes. Journal of Biological Chemistry 284, 24394-24405. 
159 
 
Jones, P., Altamura, S., De Francesco, R., Gallinari, P., Lahm, A., Neddermann, P., Rowley, M., 
Serafini, S., Steinkuhler, C., 2008. Probing the elusive catalytic activity of vertebrate class IIa 
histone deacetylases. Bioorg Med Chem Lett 18, 1814-1819. 
Khochbin, S., Verdel, A., Lemercier, C., Seigneurin-Berny, D., 2001. Functional significance of 
histone deacetylase diversity. Curr Opin Genet Dev 11, 162-166. 
Kim, M.S.e.a., 2012. An essential role for histone deacetylase 4 in synaptic plasticity and memory 
formation. Neuroscience 32, 10879-10886. 
Kim, S.W., Hooker, J.M., Otto, N., Win, K., Muench, L., Shea, C., Carter, P., King, P., Reid, A.E., 
Volkow, N.D., Fowler, J.S., 2013. Whole-body pharmacokinetics of HDAC inhibitor drugs, 
butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs 
by PET. Nuclear medicine and biology 40, 912-918. 
Knox, D., Perrine, S.A., George, S.A., Galloway, M.P., Liberzon, I., 2010. Single Prolonged Stress 
Decreases Glutamate, Glutamine, and Creatine Concentrations In The Rat Medial Prefrontal 
Cortex. Neuroscience letters 480, 16-20. 
Kokkonen, P., Rahnasto-Rilla, M., Kiviranta, P.H., Huhtiniemi, T., Laitinen, T., Poso, A., Jarho, 
E., Lahtela-Kakkonen, M., 2012. Peptides and Pseudopeptides as SIRT6 Deacetylation 
Inhibitors. ACS Medicinal Chemistry Letters 3, 969-974. 
Kokkonen, P., Rahnasto-Rilla, M., Mellini, P., Jarho, E., Lahtela-Kakkonen, M., Kokkola, T., 
2014. Studying SIRT6 regulation using H3K56 based substrate and small molecules. 
European journal of pharmaceutical sciences : official journal of the European Federation for 
Pharmaceutical Sciences 63, 71-76. 
Kwapis, J.L., Wood, M.A., 2014. Epigenetic mechanisms in fear conditioning: Implications for 
treating post-traumatic stress disorder. Trends in neurosciences 37, 706-720. 
160 
 
Laherty, C.D., Yang, W.M., Sun, J.M., Davie, J.R., Seto, E., Eisenman, R.N., 1997. Histone 
deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. 
Cell 89, 349-356. 
Lahm, A., Paolini, C., Pallaoro, M., Nardi, M.C., Jones, P., Neddermann, P., Sambucini, S., 
Bottomley, M.J., Lo Surdo, P., Carfi, A., Koch, U., De Francesco, R., Steinkuhler, C., 
Gallinari, P., 2007. Unraveling the hidden catalytic activity of vertebrate class IIa histone 
deacetylases. Proc Natl Acad Sci U S A 104, 17335-17340. 
Lain, S., Hollick, J.J., Campbell, J., Staples, O.D., Higgins, M., Aoubala, M., McCarthy, A., 
Appleyard, V., Murray, K.E., Baker, L., 2008. Discovery, in vivo activity, and mechanism of 
action of a small-molecule p53 activator. Cancer cell 13, 454-463. 
Lakshmaiah, K.C., Jacob, L.A., Aparna, S., Lokanatha, D., Saldanha, S.C., 2014. Epigenetic 
therapy of cancer with histone deacetylase inhibitors. Journal of cancer research and 
therapeutics 10, 469-478. 
Lange, G., Klein, R., Albrecht, J., Rarey, M., Reulecke, I., 2010. 
Lei Liu, C.P., Jessica Ginsberg, Jennifer Shih, Siddharth Arun, Gizem Donmez, 2015. Protective 
role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice 
model of Parkinson’s disease. Behavioural Brain Research 281, 215-221. 
Lennerz, V., Fatho, M., Gentilini, C., Frye, R.A., Lifke, A., Ferel, D., Wolfel, C., Huber, C., 
Wolfel, T., 2005. The response of autologous T cells to a human melanoma is dominated by 
mutated neoantigens. Proc Natl Acad Sci U S A 102, 16013-16018. 
Leskovac, V., 2003. Comprehensive enzyme kinetics. Kluwer Academic / Plenum Publishers, 
New York. 
161 
 
Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, Tessa L., Chen, W., Bhatia, 
R., 2012. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia 
Stem Cells in Combination with Imatinib. Cancer cell 21, 266-281. 
Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., Guarente, L., 2007. SIRT1 deacetylates and 
positively regulates the nuclear receptor LXR. Molecular cell 28, 91-106. 
Lim, J.-H., Gerhart-Hines, Z., Dominy, J.E., Lee, Y., Kim, S., Tabata, M., Xiang, Y.K., Puigserver, 
P., 2013. Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-
dependent activation of SIRT1-PGC1α complex. Journal of Biological Chemistry 288, 7117-
7126. 
Lin, Z.F., Xu, H.B., Wang, J.Y., Lin, Q., Ruan, Z., Liu, F.B., Jin, W., Huang, H.H., Chen, X., 
2013. SIRT5 desuccinylates and activates SOD1 to eliminate ROS. Biochemical and 
biophysical research communications 441, 191-195. 
Lino, M., Merlo, A., 2009. Translating biology into clinic: the case of glioblastoma. Curr Opin 
Cell Biol 21. 
Liu, P.Y., Xu, N., Malyukova, A., Scarlett, C.J., Sun, Y.T., Zhang, X.D., Ling, D., Su, S.P., Nelson, 
C., Chang, D.K., Koach, J., Tee, A.E., Haber, M., Norris, M.D., Toon, C., Rooman, I., Xue, 
C., Cheung, B.B., Kumar, S., Marshall, G.M., Biankin, A.V., Liu, T., 2013. The histone 
deacetylase SIRT2 stabilizes Myc oncoproteins. Cell death and differentiation 20, 503-514. 
Liu, T., Liu, P.Y., Marshall, G.M., 2009. The Critical Role of the Class III Histone Deacetylase 
SIRT1 in Cancer. Cancer research 69, 1702-1705. 
Logan J, F.J., Volkow ND, Wang GJ, Ding YS, Alexoff DL, 1996. Distribution volume ratios 
without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16, 
834-840. 
162 
 
Logan J, F.J., Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, 
Bendriem B, Gatley SJ, Christman DR, Graphical analysis of reversible radioligand binding 
from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in 
human subjects. J Cereb Blood Flow Metab 10, 740-747. 
Lombardi, P.M., Cole, K.E., Dowling, D.P., Christianson, D.W., 2011. Structure, mechanism, and 
inhibition of histone deacetylases and related metalloenzymes. Current opinion in structural 
biology 21, 735-743. 
Luo, J., Nikolaev, A.Y., Imai, S., Chen, D., Su, F., Shiloh, A., Guarente, L., Gu, W., 2001. 
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107, 137-148. 
Ma, J.-X., Li, H., Chen, X.-M., Yang, X.-H., Wang, Q., Wu, M.-L., Kong, Q.-Y., Li, Z.-X., Liu, 
J., 2013. Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in 
vivo and in vitro. Neuropathology 33, 7-16. 
Majdzadeh, N., Morrison, B.E., D'Mello, S.R., 2008. Class IIA HDACs in the regulation of 
neurodegeneration. Front Biosci 13, 1072-1082. 
Marcotte, P.A., Richardson, P.R., Guo, J., Barrett, L.W., Xu, N., Gunasekera, A., Glaser, K.B., 
2004. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate 
and a secondary trypsin reaction. Analytical biochemistry 332, 90-99. 
Mashimo, M., Kato, J., Moss, J., 2014. Structure and function of the ARH family of ADP-ribose-
acceptor hydrolases. DNA repair 0, 88-94. 
Mathias, R.A., Greco, T.M., Oberstein, A., Budayeva, H.G., Chakrabarti, R., Rowland, E.A., 
Kang, Y., Shenk, T., Cristea, I.M., 2014. Sirtuin 4 Is a Lipoamidase Regulating Pyruvate 
Dehydrogenase Complex Activity. Cell 159, 1615-1625. 
163 
 
Matsushima, S., Sadoshima, J., 2015. The role of sirtuins in cardiac disease. American journal of 
physiology. Heart and circulatory physiology 309, H1375-1389. 
McGlynn, L.M., Zino, S., MacDonald, A.I., Curle, J., Reilly, J.E., Mohammed, Z.M., McMillan, 
D.C., Mallon, E., Payne, A.P., Edwards, J., Shiels, P.G., 2014. SIRT2: tumour suppressor or 
tumour promoter in operable breast cancer? European journal of cancer (Oxford, England : 
1990) 50, 290-301. 
Meng, Q., Li, F., Jiang, S., Li, Z., 2013. Novel (64)Cu-Labeled CUDC-101 for in Vivo PET 
Imaging of Histone Deacetylases. ACS Med Chem Lett 4, 858-862. 
Michan, S., Sinclair, D., 2007. Sirtuins in mammals: insights into their biological function. The 
Biochemical journal 404, 1-13. 
Mock, B.H., Brown-Proctor, C., Green, M.A., Steele, B., Glick-Wilson, B.E., Zheng, Q.-H., 2011. 
An automated SPE-based high-yield synthesis of [11C]acetate and [11C]palmitate: no liquid–
liquid extraction, solvent evaporation or distillation required. Nuclear medicine and biology 
38, 1135-1142. 
Moniot, S., Steegborn, C., Schutkowski, M., 2013. Crystal structure analysis of human Sirt2 and 
its ADP-ribose complex. Journal of Structural Biology 182, 136-143. 
Morris, M.J., Monteggia, L.M., 2013. Unique functional roles for class I and class II histone 
deacetylases in central nervous system development and function. Int J Dev Neurosci 31, 370-
381. 
Mukhopadhyay, U., Tong, W.P., Gelovani, J.G., Alauddin, M.M., 2006. Radiosynthesis of 6-
([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA) for PET imaging of histone 
deacetylase (HDAC). Journal of Labelled Compounds and Radiopharmaceuticals 49, 997-
1006. 
164 
 
Mukhopadhyay U, T.W., Gelovani J, Alauddin M., 2006a. Radiosynthesis of 6-
([18F]fluoroacetamido)-1-hexanoicanilide ([18F]FAHA) for PET imaging of histone 
deacetylase (HDAC). J Label Comp Radiopharm. 49, 997–1006. 
Mukhopadhyay U, T.W., Gelovani J, Alauddin MM, 2006b. Radiosynthesis of 6-(18F-
fluoroacetamido)-1-hexanoicanilide (18F-FAHA) for PET Imaging of histone deacetylase 
(HDAC). J Labelled Comp Radiopharm 49, 997-1006. 
Muth, V., Nadaud, S., Grummt, I., Voit, R., 2001. Acetylation of TAF(I)68, a subunit of TIF-
IB/SL1, activates RNA polymerase I transcription. The EMBO journal 20, 1353-1362. 
Mvunta, D.H., Miyamoto, T., Asaka, R., Yamada, Y., Ando, H., Higuchi, S., Ida, K., Kashima, 
H., Shiozawa, T., 2016. Overexpression of SIRT1 is Associated With Poor Outcomes in 
Patients With Ovarian Carcinoma. Applied immunohistochemistry & molecular morphology 
: AIMM / official publication of the Society for Applied Immunohistochemistry. 
Naia, L., Rego, A.C., 2015. Sirtuins: double players in Huntington's disease. Biochimica et 
biophysica acta 1852, 2183-2194. 
Napper, A.D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.-F., Barker, J., Yau, W.T., Amouzegh, 
P., Flegg, A., Hamelin, E., Thomas, R.J., Kates, M., Jones, S., Navia, M.A., Saunders, J.O., 
DiStefano, P.S., Curtis, R., 2005. Discovery of Indoles as Potent and Selective Inhibitors of 
the Deacetylase SIRT1. Journal of Medicinal Chemistry 48, 8045-8054. 
Narayan, R.S., Fedrigo, C.A., Stalpers, L.J., Baumert, B.G., Sminia, P., 2013. Targeting the Akt-
pathway to improve radiosensitivity in glioblastoma. Curr Pharm Des 19, 951-957. 
Nishii R, M.U., Yeh H, Sohomonyan S, Volgin A, Alauddin M, Tong W, Gelovani J., 2007. PET 
imaging of histone deacetylase activity in rat brain using 6-([18F]fluoroacetamide)-1-
hexanoicanilide ([18F]FAHA). J Nucl Med 48, 336. 
165 
 
Nishina, S., Kosaki, R., Yagihashi, T., Azuma, N., Okamoto, N., Hatsukawa, Y., Kurosawa, K., 
Yamane, T., Mizuno, S., Tsuzuki, K., Kosaki, K., 2012. Ophthalmic features of CHARGE 
syndrome with CHD7 mutations. Am J Med Genet A 158a, 514-518. 
Nisticò, G., Ciriolo, M.R., Fiskin, K., Iannone, M., de Martino, A., Rotilio, G., 1992. NGF restores 
decrease in catalase activity and increases superoxide dismutase and glutathione peroxidase 
activity in the brain of aged rats. Free Radical Biology and Medicine 12, 177-181. 
North, B.J., Verdin, E., 2004. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome 
Biol 5, 224. 
North, B.J., Verdin, E., 2007a. Interphase Nucleo-Cytoplasmic Shuttling and Localization of 
SIRT2 during Mitosis. PloS one 2, e784. 
North, B.J., Verdin, E., 2007b. Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-
dependent phosphorylation. J Biol Chem 282, 19546-19555. 
Oberdoerffer, P., Michan, S., McVay, M., Mostoslavsky, R., Vann, J., Park, S.K., Hartlerode, A., 
Stegmuller, J., Hafner, A., Loerch, P., Wright, S.M., Mills, K.D., Bonni, A., Yankner, B.A., 
Scully, R., Prolla, T.A., Alt, F.W., Sinclair, D.A., 2008. SIRT1 redistribution on chromatin 
promotes genomic stability but alters gene expression during aging. Cell 135, 907-918. 
Outeiro, T.F., Kontopoulos, E., Altmann, S.M., Kufareva, I., Strathearn, K.E., Amore, A.M., Volk, 
C.B., Maxwell, M.M., Rochet, J.C., McLean, P.J., Young, A.B., Abagyan, R., Feany, M.B., 
Hyman, B.T., Kazantsev, A.G., 2007. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated 
toxicity in models of Parkinson's disease. Science (New York, N.Y 317, 516-519. 
Outeiro, T.F., Marques, O., Kazantsev, A., 2008. Therapeutic role of sirtuins in neurodegenerative 
disease. Biochimica et biophysica acta 1782, 363-369. 
166 
 
Ozden, O., Park, S.-H., Wagner, B.A., Song, H.Y., Zhu, Y., Vassilopoulos, A., Jung, B., Buettner, 
G.R., Gius, D., 2014. SIRT3 deacetylates and increases pyruvate dehydrogenase activity in 
cancer cells. Free Radical Biology and Medicine 76, 163-172. 
Pan, P.W., Feldman, J.L., Devries, M.K., Dong, A., Edwards, A.M., Denu, J.M., 2011a. Structure 
and biochemical functions of SIRT6. Journal of Biological Chemistry 286, 14575-14587. 
Pan, P.W., Feldman, J.L., Devries, M.K., Dong, A., Edwards, A.M., Denu, J.M., 2011b. Structure 
and biochemical functions of SIRT6. The Journal of biological chemistry 286, 14575-14587. 
Pandey, M.K., Belanger, A.P., Wang, S., DeGrado, T.R., 2012. Structure Dependence of Long-
Chain [(18)F]Fluorothia Fatty Acids as Myocardial Fatty Acid Oxidation Probes. Journal of 
medicinal chemistry 55, 10674-10684. 
Pandithage, R., Lilischkis, R., Harting, K., Wolf, A., Jedamzik, B., Luscher-Firzlaff, J., Vervoorts, 
J., Lasonder, E., Kremmer, E., Knoll, B., Luscher, B., 2008. The regulation of SIRT2 function 
by cyclin-dependent kinases affects cell motility. The Journal of cell biology 180, 915-929. 
Paredes, S., Villanova, L., Chua, K.F., 2014. Molecular Pathways: Emerging Roles of Mammalian 
Sirtuin SIRT7 in Cancer. Clinical Cancer Research 20, 1741-1746. 
Park, J.H., Jung, Y., Kim, T.Y., Kim, S.G., Jong, H.S., Lee, J.W., Kim, D.K., Lee, J.S., Kim, N.K., 
Kim, T.Y., Bang, Y.J., 2004. Class I histone deacetylase-selective novel synthetic inhibitors 
potently inhibit human tumor proliferation. Clinical cancer research : an official journal of the 
American Association for Cancer Research 10, 5271-5281. 
Paxinos, G., and Charles Watson, 2006. The rat brain in stereotaxic coordinates. 
Peng, C., Lu, Z., Xie, Z., Cheng, Z., Chen, Y., Tan, M., Luo, H., Zhang, Y., He, W., Yang, K., 
Zwaans, B.M., Tishkoff, D., Ho, L., Lombard, D., He, T.C., Dai, J., Verdin, E., Ye, Y., Zhao, 
167 
 
Y., 2011. The first identification of lysine malonylation substrates and its regulatory enzyme. 
Molecular & cellular proteomics : MCP 10, M111.012658. 
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, 
T.E., 2004. UCSF Chimera--a visualization system for exploratory research and analysis. 
Journal of computational chemistry 25, 1605-1612. 
Picard, F., Kurtev, M., Chung, N., Topark-Ngarm, A., Senawong, T., Machado De Oliveira, R., 
Leid, M., McBurney, M.W., Guarente, L., 2004. Sirt1 promotes fat mobilization in white 
adipocytes by repressing PPAR-gamma. Nature 429, 771-776. 
Pontén, J., 1975. Neoplastic human glia cells in culture, Human tumor cells in vitro. Springer, pp. 
175-206. 
Poulsen, M.M., Vestergaard, P.F., Clasen, B.F., Radko, Y., Christensen, L.P., Stødkilde-
Jørgensen, H., Møller, N., Jessen, N., Pedersen, S.B., Jørgensen, J.O.L., 2013. High-Dose 
Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-
Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body 
Composition. Diabetes 62, 1186-1195. 
Price, V., Wang, L., D'Mello, S.R., 2013. Conditional deletion of histone deacetylase-4 in the 
central nervous system has no major effect on brain architecture or neuronal viability. J 
Neurosci Res 91, 407-415. 
Pulla, V.K., Battu, M.B., Alvala, M., Sriram, D., Yogeeswari, P., 2012. Can targeting SIRT-1 to 
treat type 2 diabetes be a good strategy? A review. Expert Opinion on Therapeutic Targets 
16, 819-832. 
Qu, Y., Zhang, J., Wu, S., Li, B., Liu, S., Cheng, J., 2012. SIRT1 promotes proliferation and 
inhibits apoptosis of human malignant glioma cell lines. Neuroscience letters 525, 168-172. 
168 
 
Rahman, S., Islam, R., 2011. Mammalian Sirt1: insights on its biological functions. Cell 
Communication and Signaling. 
Ramadori, G., Lee, C.E., Bookout, A.L., Lee, S., Williams, K.W., Anderson, J., Elmquist, J.K., 
Coppari, R., 2008. Brain SIRT1: anatomical distribution and regulation by energy availability. 
The Journal of Neuroscience 28, 9989-9996. 
Rarey, M., Kramer, B., Lengauer, T., Klebe, G., 1996. A Fast Flexible Docking Method using an 
Incremental Construction Algorithm. Journal of Molecular Biology 261, 470-489. 
Reid, A.E., Hooker, J., Shumay, E., Logan, J., Shea, C., Kim, S.W., Collins, S., Xu, Y., Volkow, 
N., Fowler, J.S., 2009a. Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET 
imaging of histone deacetylase in the baboon brain. Nuclear medicine and biology 36, 247-
258. 
Reid, A.E., Hooker, J., Shumay, E., Logan, J., Shea, C., Kim, S.W., Collins, S., Xu, Y., Volkow, 
N., Fowler, J.S., 2009b. Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET 
imaging of histone deacetylase in the baboon brain. Nucl Med Biol 36, 247-258. 
Renthal, W., Maze, I., Krishnan, V., Covington, H.E., 3rd, Xiao, G., Kumar, A., Russo, S.J., 
Graham, A., Tsankova, N., Kippin, T.E., Kerstetter, K.A., Neve, R.L., Haggarty, S.J., 
McKinsey, T.A., Bassel-Duby, R., Olson, E.N., Nestler, E.J., 2007. Histone deacetylase 5 
epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 56, 517-
529. 
Riester, D., Hildmann, C., Grunewald, S., Beckers, T., Schwienhorst, A., 2007. Factors affecting 
the substrate specificity of histone deacetylases. Biochem Biophys Res Commun 357, 439-
445. 
169 
 
Riester, D., Wegener, D., Hildmann, C., Schwienhorst, A., 2004. Members of the histone 
deacetylase superfamily differ in substrate specificity towards small synthetic substrates. 
Biochemical and biophysical research communications 324, 1116-1123. 
Roessler, C., Nowak, T., Pannek, M., Gertz, M., Nguyen, G.T., Scharfe, M., Born, I., Sippl, W., 
Steegborn, C., Schutkowski, M., 2014. Chemical probing of the human sirtuin 5 active site 
reveals its substrate acyl specificity and Peptide-based inhibitors. Angewandte Chemie 
(International ed. in English) 53, 10728-10732. 
Ron S. Broide, J.M.R., Najla Aftahi, Warren Young,, Floyd E. Bloom, a.C.J.W., 2006. Distribution 
of Histone Deacetylases 1–11 in the Rat Brain. Journal of Molecular Neuroscience 07, 47-58. 
Rumpf, T., Schiedel, M., Karaman, B., Roessler, C., North, B.J., Lehotzky, A., Oláh, J., Ladwein, 
K.I., Schmidtkunz, K., Gajer, M., Pannek, M., Steegborn, C., Sinclair, D.A., Gerhardt, S., 
Ovádi, J., Schutkowski, M., Sippl, W., Einsle, O., Jung, M., 2015. Selective Sirt2 inhibition 
by ligand-induced rearrangement of the active site. Nat Commun 6. 
Runkle, A.C., Shao, X., Tluczek, L.J., Henderson, B.D., Hockley, B.G., Scott, P.J., 2011. 
Automated production of [11C]acetate and [11C]palmitate using a modified GE Tracerlab 
FX(C-Pro). Applied radiation and isotopes : including data, instrumentation and methods for 
use in agriculture, industry and medicine 69, 691-698. 
Sakkiah, S., Arooj, M., Cao, G.P., Lee, K.W., 2013. Insight the C-Site Pocket Conformational 
Changes Responsible for Sirtuin 2 Activity Using Molecular Dynamics Simulations. PloS one 
8, e59278. 
Sali, A., Blundell, T.L., 1993. Comparative protein modelling by satisfaction of spatial restraints. 
J Mol Biol 234, 779-815. 
170 
 
Sanabria S, F.H., Riffel K, Williams M, Gibson R, Gelovani JG, Cook J, Hostetler E., 2008. 
Quantification of HDAC inhibition by F-SAHA in rhesus monkey brain using the PET tracer 
[18F]FAHA. NeuroImage 41, T15. 
Sanchez-Carbayo, M., Socci, N.D., Lozano, J., Saint, F., Cordon-Cardo, C., 2006. Defining 
molecular profiles of poor outcome in patients with invasive bladder cancer using 
oligonucleotide microarrays. J Clin Oncol 24, 778-789. 
Sankaranarayanapillai, M., Tong, W.P., Maxwell, D.S., Pal, A., Pang, J., Bornmann, W.G., 
Gelovani, J.G., Ronen, S.M., 2006. Detection of histone deacetylase inhibition by noninvasive 
magnetic resonance spectroscopy. Molecular cancer therapeutics 5, 1325-1334. 
Sankaranarayanapillai, M., Tong, W.P., Yuan, Q., Bankson, J.A., Dafni, H., Bornmann, W.G., 
Soghomonyan, S., Pal, A., Ramirez, M.S., Webb, D., Kaluarachchi, K., Gelovani, J.G., 
Ronen, S.M., 2008. Monitoring histone deacetylase inhibition in vivo: noninvasive magnetic 
resonance spectroscopy method. Mol Imaging 7, 92-100. 
Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R., Sherman, W., 2013. Protein and ligand 
preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput 
Aided Mol Des 27, 221-234. 
Sauve, A.A., 2010. Sirtuin chemical mechanisms. Biochimica et biophysica acta 1804, 1591-1603. 
Sauve, A.A., Wolberger, C., Schramm, V.L., Boeke, J.D., 2006. The Biochemistry of Sirtuins. 
Annual Review of Biochemistry 75, 435-465. 
Schlicker, C., Gertz, M., Papatheodorou, P., Kachholz, B., Becker, C.F., Steegborn, C., 2008a. 
Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. 
Journal of molecular biology 382, 790-801. 
171 
 
Schlicker, C., Gertz, M., Papatheodorou, P., Kachholz, B., Becker, C.F., Steegborn, C., 2008b. 
Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J 
Mol Biol 382, 790-801. 
Schneider, N., Lange, G., Hindle, S., Klein, R., Rarey, M., 2013. A consistent description of 
Hydrogen bond and Dehydration energies in protein–ligand complexes: methods behind the 
HYDE scoring function. J Comput Aided Mol Des 27, 15-29. 
Schuster, S., Roessler, C., Meleshin, M., Zimmermann, P., Simic, Z., Kambach, C., Schiene-
Fischer, C., Steegborn, C., Hottiger, M.O., Schutkowski, M., 2016. A continuous sirtuin 
activity assay without any coupling to enzymatic or chemical reactions. Sci Rep 6, 22643. 
Schwer, B., Verdin, E., 2008. Conserved metabolic regulatory functions of sirtuins. Cell 
metabolism 7, 104-112. 
Seo, Y.J., Muench, L., Reid, A., Chen, J., Kang, Y., Hooker, J.M., Volkow, N.D., Fowler, J.S., 
Kim, S.W., 2013. Radionuclide labeling and evaluation of candidate radioligands for PET 
imaging of histone deacetylase in the brain. Bioorganic & medicinal chemistry letters 23, 
6700-6705. 
Shelley, J.C., Cholleti, A., Frye, L.L., Greenwood, J.R., Timlin, M.R., Uchimaya, M., 2007. Epik: 
a software program for pK a prediction and protonation state generation for drug-like 
molecules. J Comput Aided Mol Des 21, 681-691. 
Singh, S., Kumar, P.U., Thakur, S., Kiran, S., Sen, B., Sharma, S., Rao, V.V., Poongothai, A.R., 
Ramakrishna, G., 2015. Expression/localization patterns of sirtuins (SIRT1, SIRT2, and 
SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of 
cervical cancer cells. Tumour biology : the journal of the International Society for 
Oncodevelopmental Biology and Medicine 36, 6159-6171. 
172 
 
Smith, B.C., Settles, B., Hallows, W.C., Craven, M.W., Denu, J.M., 2011. SIRT3 Substrate 
Specificity Determined by Peptide Arrays and Machine Learning. ACS chemical biology 6, 
146-157. 
Smith, M.R., Syed, A., Lukacsovich, T., Purcell, J., Barbaro, B.A., Worthge, S.A., Wei, S.R., 
Pollio, G., Magnoni, L., Scali, C., Massai, L., Franceschini, D., Camarri, M., Gianfriddo, M., 
Diodato, E., Thomas, R., Gokce, O., Tabrizi, S.J., Caricasole, A., Landwehrmeyer, B., 
Menalled, L., Murphy, C., Ramboz, S., Luthi-Carter, R., Westerberg, G., Marsh, J.L., 2014. 
A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell 
models of Huntington's disease. Human molecular genetics 23, 2995-3007. 
Solomon, J.M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P.S., Huber, L.J., 
2006. Inhibition of SIRT1 Catalytic Activity Increases p53 Acetylation but Does Not Alter 
Cell Survival following DNA Damage. Molecular and Cellular Biology 26, 28-38. 
Stojiljkovic, M., Piperski, V., Dacevic, M., Rakic, L., Ruzdijic, S., Kanazir, S., Characterization 
of 9L Glioma Model of the Wistar Rat. Journal of Neuro-Oncology 63, 1-7. 
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., 
Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, 
T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., Mirimanoff, R.O., 2005. 
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New 
England journal of medicine 352, 987-996. 
Sussmuth, S.D., Haider, S., Landwehrmeyer, G.B., Farmer, R., Frost, C., Tripepi, G., Andersen, 
C.A., Di Bacco, M., Lamanna, C., Diodato, E., Massai, L., Diamanti, D., Mori, E., Magnoni, 
L., Dreyhaupt, J., Schiefele, K., Craufurd, D., Saft, C., Rudzinska, M., Ryglewicz, D., Orth, 
M., Brzozy, S., Baran, A., Pollio, G., Andre, R., Tabrizi, S.J., Darpo, B., Westerberg, G., 
173 
 
2015. An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, 
in patients with Huntington's disease. British journal of clinical pharmacology 79, 465-476. 
Suzuki, K., Koike, T., 2007. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of 
resistance to axonal degeneration in slow Wallerian degeneration mice: a crucial role of 
tubulin deacetylation. Neuroscience 147, 599-612. 
Suzuki, T., Asaba, T., Imai, E., Tsumoto, H., Nakagawa, H., Miyata, N., 2009. Identification of a 
cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorganic & 
medicinal chemistry letters 19, 5670-5672. 
Tabatabaie, T., Floyd, R.A., 1996. Inactivation of Glutathione Peroxidase by Benzaldehyde. 
Toxicology and Applied Pharmacology 141, 389-393. 
Tan, M., Peng, C., Anderson, Kristin A., Chhoy, P., Xie, Z., Dai, L., Park, J., Chen, Y., Huang, 
H., Zhang, Y., Ro, J., Wagner, Gregory R., Green, Michelle F., Madsen, Andreas S., 
Schmiesing, J., Peterson, Brett S., Xu, G., Ilkayeva, Olga R., Muehlbauer, Michael J., 
Braulke, T., Mühlhausen, C., Backos, Donald S., Olsen, Christian A., McGuire, Peter J., 
Pletcher, Scott D., Lombard, David B., Hirschey, Matthew D., Zhao, Y., 2014. Lysine 
Glutarylation Is a Protein Posttranslational Modification Regulated by SIRT5. Cell 
metabolism 19, 605-617. 
Tang, B.L., Chua, C.E., 2008. SIRT2, tubulin deacetylation, and oligodendroglia differentiation. 
Cell motility and the cytoskeleton 65, 179-182. 
Tang, W., Kuruvilla, S.A., Galitovskiy, V., Pan, M.L., Grando, S.A., Mukherjee, J., 2014. 
Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT 
imaging of NNK-treated A/J mice model. Am J Nucl Med Mol Imaging 4, 324-332. 
174 
 
Tarantino, G., Finelli, C., Scopacasa, F., Pasanisi, F., Contaldo, F., Capone, D., Savastano, S., 
2014. Circulating Levels of Sirtuin 4, a Potential Marker of Oxidative Metabolism, Related 
to Coronary Artery Disease in Obese Patients Suffering from NAFLD, with Normal or 
Slightly Increased Liver Enzymes. Oxidative medicine and cellular longevity 2014, 10. 
Taunton, J., C. A. Hassig, and S. L. Schreiber, 1996. A mammalian histone deacetylase related to 
the yeast transcriptional regulator Rpd3p. Science (New York, N.Y.) 272, 408-411. 
Taylor, D.M., Maxwell, M.M., Luthi-Carter, R., Kazantsev, A.G., 2008. Biological and potential 
therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 65, 4000-4018. 
Tedeschi, A., Di Giovanni, S., 2009. The non-apoptotic role of p53 in neuronal biology: 
enlightening the dark side of the moon. EMBO reports 10, 576-583. 
Thomas, E.A., 2009. Focal nature of neurological disorders necessitates isotype-selective histone 
deacetylase (HDAC) inhibitors. Mol Neurobiol 40, 33-45. 
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., Reinberg, D., 2004a. 
Human SirT1 interacts with histone H1 and promotes formation of facultative 
heterochromatin. Molecular cell 16, 93-105. 
Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P., Reinberg, D., 2004b. 
Human SirT1 Interacts with Histone H1 and Promotes Formation of Facultative 
Heterochromatin. Molecular cell 16, 93-105. 
Vaziri, H., Dessain, S.K., Ng Eaton, E., Imai, S.I., Frye, R.A., Pandita, T.K., Guarente, L., 
Weinberg, R.A., 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 
107, 149-159. 
175 
 
Venza, I., Visalli, M., Oteri, R., Cucinotta, M., Teti, D., Venza, M., 2013. Class II-specific histone 
deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma 
cells. Pigment cell & melanoma research 26, 193-204. 
Volmar, C.-H., Wahlestedt, C., 2015. Histone deacetylases (HDACs) and brain function. 
Neuroepigenetics 1, 20-27. 
Wang, C., Schroeder, F.A., Wey, H.Y., Borra, R., Wagner, F.F., Reis, S., Kim, S.W., Holson, E.B., 
Haggarty, S.J., Hooker, J.M., 2014. In vivo imaging of histone deacetylases (HDACs) in the 
central nervous system and major peripheral organs. J Med Chem 57, 7999-8009. 
Wang, F., Nguyen, M., Qin, F.X., Tong, Q., 2007. SIRT2 deacetylates FOXO3a in response to 
oxidative stress and caloric restriction. Aging cell 6, 505-514. 
Wang, F., Tong, Q., 2009. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 
and enhancing FOXO1's repressive interaction with PPARgamma. Molecular biology of the 
cell 20, 801-808. 
Wang, J., Yu, J.-T., Tan, M.-S., Jiang, T., Tan, L., 2013. Epigenetic mechanisms in Alzheimer's 
disease: Implications for pathogenesis and therapy. Ageing Research Reviews 12, 1024-1041. 
Wang, R.H., Sengupta, K., Li, C., Kim, H.S., Cao, L., Xiao, C., Kim, S., Xu, X., Zheng, Y., 
Chilton, B., Jia, R., Zheng, Z.M., Appella, E., Wang, X.W., Ried, T., Deng, C.X., 2008. 
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant 
mice. Cancer cell 14, 312-323. 
Watson, G.P.C., 2006. The Rat Brain in Stereotaxic Coordinates. Academic Press. 
Wauters, E., Lobo, V.J.S.-A., Pinho, A.V., Mawson, A., Herranz, D., Wu, J., Cowley, M.J., Colvin, 
E.K., Njicop, E.N., Sutherland, R.L., 2013. Sirtuin-1 regulates acinar-to-ductal metaplasia and 
supports cancer cell viability in pancreatic cancer. Cancer research 73, 2357-2367. 
176 
 
Wey, H.Y., Wang, C., Schroeder, F.A., Logan, J., Price, J.C., Hooker, J.M., 2015. Kinetic Analysis 
and Quantification of [(1)(1)C]Martinostat for in Vivo HDAC Imaging of the Brain. ACS 
Chem Neurosci 6, 708-715. 
Williams, S.R.e.a., 2010. Haploinsufficiency of HDAC4 causes brachydactyly mental retardation 
syndrome, with brachydactyly type E, developmental delays, and behavioral problems. 
American Journal of Human Genetics 87. 
Wolffe, A.P., and D. Pruss, 1996. Targeting chromatin disruption: transcription regulators that 
acetylate histones. Cell 84, 817-819. 
Yang, X.-J., Grégoire, S., 2005. Class II Histone Deacetylases: from Sequence to Function, 
Regulation, and Clinical Implication. Molecular and Cellular Biology 25, 2873-2884. 
Yang, X., Seto, E., 2007. HATs and HDACs: from structure, function and regulation to novel 
strategies for therapy and prevention. Oncogene 26, 5310-5318. 
Yao, Y.-L., Yang, W.-M., 2011. Beyond Histone and Deacetylase: An Overview of Cytoplasmic 
Histone Deacetylases and Their Nonhistone Substrates. Journal of Biomedicine and 
Biotechnology 2011, 146493. 
Yeh, H.-H., Tian, M., Hinz, R., Young, D., Shavrin, A., Mukhapadhyay, U., Flores, L.G., Balatoni, 
J., Soghomonyan, S., Jeong, H.J., Pal, A., Uthamanthil, R., Jackson, J.N., Nishii, R., Mizuma, 
H., Onoe, H., Kagawa, S., Higashi, T., Fukumitsu, N., Alauddin, M., Tong, W., Herholz, K., 
Gelovani, J.G., 2013a. Imaging epigenetic regulation by histone deacetylases in the brain 
using PET/MRI with 18F-FAHA. NeuroImage 64, 630-639. 
Yeh, H.H., Young, D., Gelovani, J.G., Robinson, A., Davidson, Y., Herholz, K., Mann, D.M., 
2013b. Histone deacetylase class II and acetylated core histone immunohistochemistry in 
human brains with Huntington's disease. Brain Res 1504, 16-24. 
177 
 
Yeh, S.H.-H., Lin, C.-F., Kong, F.-L., Wang, H.-E., Hsieh, Y.-J., Gelovani, J.G., Liu, R.-S., 2013c. 
Molecular Imaging of Nonsmall Cell Lung Carcinomas Expressing Active Mutant EGFR 
Kinase Using PET with [(124)I]-Morpholino-IPQA. BioMed Research International 2013, 
549359. 
Zakhary, S.M., Ayubcha, D., Dileo, J.N., Jose, R., Leheste, J.R., Horowitz, J.M., Torres, G., 2010. 
Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. The 
Anatomical Record 293, 1024-1032. 
Zeglis, B.M., Pillarsetty, N., Divilov, V., Blasberg, R.A., Lewis, J.S., 2011. The synthesis and 
evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-
FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression 
in cancer. Nucl Med Biol 38, 683-696. 
Zhang, J., Chen, X., 2007. DeltaNp73 modulates nerve growth factor-mediated neuronal 
differentiation through repression of TrkA. Molecular and cellular biology 27, 3868-3880. 
Zhao, K., Harshaw, R., Chai, X., Marmorstein, R., 2004. Structural basis for nicotinamide cleavage 
and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. Proc Natl 
Acad Sci U S A 101, 8563-8568. 
Zhu, K., Borrelli, K.W., Greenwood, J.R., Day, T., Abel, R., Farid, R.S., Harder, E., 2014. Docking 
Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring. Journal of 
Chemical Information and Modeling 54, 1932-1940. 
Zovkic, I.B., Meadows, J.P., Kaas, G.A., Sweatt, J.D., 2013. Interindividual variability in stress 
susceptibility: A role for epigenetic mechanisms in PTSD. Frontiers in Psychiatry 4. 
  
178 
 
ABSTRACT 
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Over the past two decades, epigenetic regulation has become a rapidly growing, highly 
innovative and influential field of biology and medicine. Protein acetylation and deacetylation, 
two key epigenetic regulatory mechanisms, are mediated by histone acetylase transferases (HATs) 
and histone deacetylases (HDACs), respectively. To date, the vast majority of studies on epigenetic 
regulation have been conducted in cell cultures and tissue samples using conventional 
methodologies of molecular and cellular biology, which contain inherent limitations for 
monitoring therapy and disease. Therefore, there is a growing need for novel, advanced 
methodologies that allow for non-invasive detection and monitoring of HDAC–mediated 
epigenetic regulatory processes in different organs and tissues. One such methodology is molecular 
imaging with positron emission tomography (PET), which allows for non-invasive visualization 
and quantification of spatial and temporal dynamics of expression-activity of various receptors 
and enzymes in different organs and tissues in norm and disease. The availability of selective 
substrates to various classes and isoforms of HDACs would enable the development of 
radiolabeled imaging agents for non-invasive in vivo PET imaging. Therefore, the aim of this work 
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is to develop class- and/or isoform-selective radiolabeled substrates of HDACs, with particular 
emphasis on class III (sirtuins, SIRTs).   
Herein, HDAC class IIa, SIRT1 and SIRT2-selective radiotracers have been developed and 
validated through in vitro and in vivo characterization. Two of these tracers, 18F-TFAHA for 
HDAC class IIa and and 2-[18F]PhAHA for SIRT1, have also been validated in a disease model 
demonstrating their utility in understanding epigenetic regulation in an aggressive form of brain 
cancer. The development of these targeted imaging agents may help develop new therapies for 
disease as well as methodologies for monitoring treatment effectiveness and disease progression. 
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